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ABSTRACT
The aim of this thesis is to advance our understanding of the mechanisms controlling
nerve degeneration, by examining the molecular interactions of the Wlcf gene and its
chimeric protein product. Wallerian degeneration is normally complete within
twenty-four to forty-eight hours of axotomy, but in the mouse mutant C57B1/Wlds
the process is delayed by up to three weeks. The Wlcf mutation comprises an 85Kb
tandem triplication of genomic region containing the complete sequence for Rbp7
(retinoid binding protein 7), Nmnatl (nicotinamide mononucleotide
adenyltransferase) and the N-70 amino acids of Ube4b (a ubiquitin ligase). At the
boundaries of this in frame tandem triplication, a chimeric "fusion" gene is formed
comprising the N-70 Ube4b linked to Nmnat. The protein product localises to nuclei.
Transgenic expression of the chimeric gene has previously been shown to be
sufficient to reproduce the Wlcf nerve-degeneration phenotype in both mice and rats.
The main objectives in my research were; 1. To develop a rapid and effective method
for determining the copy number of Wlcf alleles in mutant and transgenic Wlcf
mouse lines. 2. To map the regional distribution and sub cellular localisation of the
Wlcf chimeric protein product within the nervous system. 3. To test the hypothesis
that the expression of the constituent components of the Wlcf chimeric gene is
sufficient to alter mRNA levels of other genes that may themselves be downstream
effectors of the Wlcf neuroprotective phenotype.
1. A rapid and cost effective method for genotyping was developed using
quantitative real time PCR on genomic DNA from the spontaneous Wlcf mutant
mouse and transgenic lines. This method allows the determination of Wlcf copy
number (specifically a region of the N10-Ube4b portion of the Wlcf gene) for
genotyping and calculating insertion number in transgenic lines.
2. A highly specific antibody generated against the Wld-18 peptide confirms that the
Wlcf protein product is localised to neuronal nuclei. Mapping of the Wlcf protein
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product in the CNS showed that the neuronal distribution is not uniform either in the
spontaneous mutant or the transgenic models. The intranuclear distribution varied
between and within cell types; some neurones showed intense, particulate staining,
others showed fine speckling, while others had large nuclear inclusions that varied in
shape. Cerebellar granule cells in the Wlds mouse have a consistent expression
pattern, with about 90% of cells containing at least one large nuclear inclusion of
Wlds protein. The expression of Wlds - containing inclusions in these cells increased
with postnatal age in vivo and also in vitro in primary cultures and cell lines. The
inclusions persist, evidently without detriment to the animals as they mature. Co-
immunostaining and/or co-transfection studies in the HEK293 cell lines suggested
that the Wlds protein co-localises with certain transcription factors including
HDAC5; and members of the SMRT family; and a member of the ubiquitin
proteasome system, VCP.
3. Microarray analysis and quantitative real time PCR of Wlds compared with wild-
type C57B16 mouse cerebellar mRNA indicated differences in expression levels for
at least 11 genes outside the Wlds locus. Some of these genes were down-regulated,
but others were up-regulated. The greatest differences were strong down-regulation
of Pttgl and strong up-regulation of a homologue of Edrl. Transfection of human
(HEK293) cells with a Wlcf-eGFP construct mimicked changes shown in Wlds
mouse mRNA levels. The sub-cellular distribution of Wlds protein is dependent on
both the Nmnat-1 and Ube4b regions of the protein and both are required to target
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Wld protein to discrete intranuclear foci. The induced changes in Pttgl mRNA
levels, but not the Edrl-like transcript, were partly mimicked by transfecting
HEK293 cells with the Nmnat-1 component of the chimeric gene, or by exogenous
administration of NAD at a concentration of ImM. This effect was blocked by
sirtenol, an inhibitor of the nuclear transcription factor Sirtl. Transfection with the
N10-Ube4b component of the Wlds gene partly mimicked up-regulation of the Edrl-
like transcript but had no effect on expression levels of Pttg-1 mRNA. WZ</-positive
cerebellar granule cells show a protective phenotype, but Pttgl-KO peripheral nerves
do not.
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Together, these studies suggest that the Wlds gene product functions as a
bidirectional regulator of gene expression, driving up and down the transcription of
several specific genes via more than one intra-nuclear signalling pathway. The
summed effects of these variations in mRNA levels may be required for full
expression of the Wlds neuroprotective phenotype. Identification of the genes and
proteins ultimately responsible may open up new possibilities for understanding and
treatment of the consequences of injury to the nervous system, whether induced by
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"There are only two ways of coming to know a machine: one is that the master who
made it should show us its artifice; the other is to dismantle it and examine its most
minute parts separately and as a combined unit...." (Descartes, 1664).
The nervous system could be viewed in accordance with Descartes' mechanistic
viewpoint, as a machine. An intricate machine, but still a machine. In order that we may
understand how it works we must arguably dismantle and examine its component parts
and their interactions. Simplistically, the nervous system comprises central (CNS) and
peripheral (PNS) components (as they are currently labelled, the classification is
obviously man made, not an inherent property of an integrated mechanism). These
components may then be simplified further to a grouping of different cell types. The
cells can be subclassified further as a collection of organelles and supporting material,
made up of all the macromolecules now customarily associated with them.
The advent of molecular biology allows us to decompile processes within these cells and
their organelles even further. In many respects, the field of modern molecular biology
was spawned from the field of Mendelian genetics. Mendel carried out experiments that
required extraordinary patience, and without which (and taking into account the work of
others at the time including Koreuter and Gartner), it is impossible to guess where the
field of modern molecular biology would now stand. Mendel observed that phenotypic
traits are determined by factors passed from parents to progeny, and that these factors
are unchanged as they are inherited from generation to generation. Mendel's first
(segregation) and second laws (independent assortment) explain to us his observed
patterns of inheritance (Mendel, 1865). What Mendel did not know at this time, was that
the factors he was describing are genes.
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Molecular biology advanced at a prodigious rate following the publication of a seminal
paper by Hershey and Chase (1952). Up to that point it was thought that protein was the
genetic material of the cell, despite an earlier demonstration that DNA, not protein was
responsible for the genetic transformation of rough bacteria to smooth. The scientific
community remained unconvinced of the findings by Avery, McLeod and McCarty
(1944) until Hershey and Chase firmly established DNA as the prime candidate
containing the genetic information within organisms. This finding was followed quickly
by elucidation of the structure of DNA by Watson and Crick in 1953. In the next major
breakthrough of 1955, Arthur Kornberg demonstrated DNA replication in vitro. He
found that he could do this using DNA fragments, dNTP's (nucleotides) and E. coli cell
lysate. Eventually he purified a single enzyme and was able to achieve DNA replication
in vitro with only DNA fragments, dNTP's, Mg++ ions and the Kornberg enzyme, now
called DNA polymerase I (Kornberg 1959). In 1958, Meselson & Stahl demonstrated
that DNA replication is semi-conservative by labelling (bacterial) parental DNA with
15N and allowing the labelled strains to undergo a round of growth and therefore a
round of DNA replication (Meselson & Stahl, 1958). The central dogma of molecular
biology was first suggested by Crick in 1958. "The central dogma of molecular biology
deals with the detailed residue-by-residue transfer of sequential information, such
information cannot be transferred from protein to either protein or nucleic acid" (Crick
1958). Thus, once information is encoded as protein (DNA to RNA to protein) it cannot
be returned to nucleic acid. There are currently no known exceptions to the central
dogma, correctly stated. Once again Crick was ahead of his time and questioned how
this flow of information ever began. In 1968 he suggested (what would later be termed
the RNA world hypothesis in a 1986 article by Harvard molecular biologist Walter
Gilbert), "that RNA must have been the first genetic molecule, further suggesting that
RNA, besides acting as a template, might also act as an enzyme and, in so doing,
catalyze its own self-replication". The fact that some RNA may also be able to act as
enzymes was not actually shown until the 1980s by Thomas R. Cech. By the 1970, the
genetic code and the processes of transcription and translation had been elucidated and
reverse transcriptase has been discovered (Temin & Mizutani 1970).
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"You, your joys and your sorrows, your memories and your ambitions, your sense of
personal identity andfree will, are in fact no more than the behaviour ofa vast assembly
of nerve cells..." (Crick 1994). The ability to deconstruct the nervous system down to
the molecular level has now allowed us to observe the consequences of various injuries
and diseases that affect it. For example, molecular techniques have been critically
important for studying the role of the aberrant accumulation of protein in neurones
associated with Alzheimer's dementia, ischaemic death of cells following stroke and cell
damage following head injury. Employing molecular biology techniques to further
uncover general mechanisms of cell death and cell survival in the nervous system will
therefore be of vital importance in order to develop suitable therapeutic strategies for a
wide range of neurodegenerative disorders.
In this thesis I have used molecular biological techniques to further our understanding of
how a spontaneous mutation (Wlcf) retards the consequences of one form of traumatic
injury: a specific form of axonal degradation known as Wallerian degeneration.
1.1.0. What is Wallerian degeneration?
Wallerian degeneration is a process that results from injury and/or diseases that affect
axons. It can be defined as the degeneration of the distal segment of a nerve fibre/axon
that has been severed/separated from its cell body (Figure 1.1). The process of Wallerian
degeneration was most famously described in 1850 by Augustus Waller. Waller carried
out experiments on frog hypoglossal and glossopharyngeal nerves to investigate the
effects of nerve lesions. Post lesion, he noted a loss of muscle contraction, and
described the axon as appearing "discontinuous, fragmented and granulated" (see Stoll
et al. 2002 & Gillingwater 2001). Wallerian degeneration has been well studied and is
an elegant and reliable model system, which can be used to study the patho-physiology
of traumatic injury as well as diseases of the nervous system (Raff et al., 2002; Coleman
& Perry, 2002).
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Although Waller did his pioneering work on amphibians, the main biological resources
for studying this phenomenon in more recent times have been rodents. Generally,
injured axons degenerate within three days of a nerve lesion in rats and mice (Coleman
& Ribchester, 2004), by a sequence of events that are very similar across most species.
However, there are exceptions to this in time scale. For example, in giant squid, crayfish
and fish, isolated axons may be preserved for months rather than days.
One of the earliest morphological changes seen with Wallerian degeneration is the
breakdown of the axonal cytoskeleton (Crawford et al. 1995). It has now been shown
through electron microscopy that major early changes (within one to three days)
following nerve transection include fragmentation of the endoplasmic reticulum, and
disintegration of neurofilaments and microtubules (Glass & Griffin, 1991). Another
distinctive degenerative marker is the swelling and lysis of mitochondria. Following this,
breakdown and removal of the myelin sheath is initiated by phagocytosing macrophages
(for review see Gillingwater & Ribchester, 2001). Macrophages and Schwann cells were
shown to be important in Wallerian degeneration because myelin contains molecules
that inhibit axonal growth and retard regeneration, whereas macrophages aid in the
removal of these molecules, so the removal of myelin is conventionally thought to be a
desirable end result of Wallerian degeneration (Be'eri et al. 1998, Lawson et al. 1994).
Another marker, or possible measure of degeneration is an increase in the number of
non-neuronal nuclei in the transected distal stump, which arise from proliferation of
dedifferentiated Schwann cells and invading myleomonocytic cells (Brown et al. 1992).
"Digestive chambers" are formed from enlarged nodal spaces as the myelin sheath
retracts from the nodes of Ranvier. These chambers are where the complete breakdown
of axonal material proceeds inexorably to its conclusion. However, axonal debris and
myelin may persist within the central nervous system for weeks or months (Lawson et
al. 1994). The digestive chambers are removed by macrophages and phagocytosing
Schwann cells, which simultaneously proliferate, and eventually join up end to end to
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form "bands of Bungner". These structures are thought to play a role in guiding the
regenerating proximal nerve stump to denervated sites (see Gillingwater & Ribchester,
2001). In explant systems in which macrophages have been excluded, the axons retain
their structure for a much longer period of time, and in animals with depleted
macrophage populations a similar result is seen (Ludwin and Bisby 1991). In the
peripheral nervous system, basal lamina tubing ensheathing the nerve may retain
dividing Schwann cells (columns of Schwann cells surrounded by basal lamina are
commonly known as endoneural tubes). There is also evidence that Schwann cells
actively promote regeneration by means of secreted factors (Lunn et al. 1989).
1.1.1. Differences between Wallerian degeneration in the CNS and PNS
There are temporal differences in the rate of Wallerian degeneration between the central
and peripheral nervous systems (CNS and PNS respectively). It has been thought
previously that this may be due to increased time delay in the activation of the
mononuclear response (Lawson et al. 1994) and an inability of macrophages to
adequately infiltrate the more densely packed regions of the brain. It is also said that the
activation of the mononuclear phagocytes "occurs in response to Wallerian degeneration
of axons rather than loss of electrical activity per se" (Lawson et al. 1994).
During Wallerian degeneration, lesioned axons in the CNS collapse and disintegrate at
roughly the same time as in the PNS, however, the removal of myelin debris containing
growth inhibitors is slowed considerably, i.e. it takes place over a time course of months
(Stoll et al. 2002). Recruitment of macrophages could be dependent on loss of an
inhibitory factor normally expressed by an intact nerve, or by the production of a
chemotactic factor expressed by the injured nerve itself (Ludwin and Bisby 1991).
Increased knowledge of the mechanism and progression of Wallerian degeneration may
be important in understanding axonal death, in a number of debilitating diseases such as
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amyotrophic lateral sclerosis and multiple sclerosis, as well as a number of peripheral
neuropathies (Coleman and Ribchester 2004).
1.1.2. What initiates Wallerian degeneration?
Theories about what initiates Wallerian degeneration include loss of trophic support
from the cell body and activation of calpain by calcium influx. Interestingly, however,
several groups have compared Wallerian degeneration to an active process similar to
apoptosis (Buckmaster et al. 1995, Ribchester et al. 1995).
Calcium ions appear to be required to seal the damaged axon, and possibly to aid with
the activation of later degenerative mechanisms. There are mechanisms within the
neuron to help maintain the ion balance such as sequestration of calcium ions by
mitochondria (Tsao et al. 1999, Xue et al. 2002). Buckmaster et al. (1995) also showed
that increased cytoplasmic calcium levels could increase cell survival. However, calcium
ions could be debilitating to the neuron after lesioning. Changes have been seen
indicating Na+-K+-ATPase inhibition. For example, intact membranes exclude Na+,
while K+ would continue to leak through open ion channels, along with CF following
passively to maintain the gradient. With the K+ gradient dissipated, Na+ can now enter
the axon allowing Ca2+ entry through Na+/ Ca2+ exchange, or through the failure of other
mechanisms for Ca2+ extrusion or sequestration. Ca2+ could then enter the cell to the
point where degradative enzymes are activated.
Importantly, Wallerian degeneration is known to begin at distal synapses. In the rat,
recordings of action potentials over muscle membrane following sciatic nerve section
show that all electrical activity declines by 24-36 hours (Miledi & Slater 1970), and it is
after this that neuromuscular junctions begin to visibly degenerate. Complete disruption
of the endplate takes between 3 and 5 hours (Miledi & Slater 1968).
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Injury to an axon also has immediate effects on the Schwann cells surrounding it,
including a considerable decrease in myelin protein mRNA expression (Ludwin and
Bisby 1991). Inuiguez and Alvarez (1999) hypothesise that differentiated Schwann cells
repress the sprouting programme of injured axons, and that on dedifferentiation
Schwann cells lose their ability to repress the sprouting programme. They propose that
this programme is then expressed by injured axons until they receive a signal that
instructs them otherwise. However, degeneration and not regeneration is the focus of
this thesis, and the biological tool I have used to study this is the Wlct mouse.
1.2. The Wlct mutant mouse
The Wlct mouse occurred as the result of a spontaneous natural mutation in the C57B1/6J
line of mice. This mutation has a surprising, but covert, effect on the degeneration of
axons and synapses (Perry et al. 1990, Andressen et al. 2001). The C57BlAVlds (C57B1/
Wallerian degeneration, slow) mutant mouse was first discovered in the course of
experiments in which the authors were attempting to manipulate macrophage influx to
damaged peripheral nerves, and by chance noted that these nerves showed delayed
Wallerian degeneration (Lunn et al. 1989).
1.2.1. What are the effects of Wlct on Wallerian degeneration?
Wallerian degeneration is normally complete within twenty-four to forty-eight hours of
axotomy, but in the Wlct mouse (initially named C57Bl/01a) the process is delayed by
up to three weeks (Lunn et al. 1989). That is, axons are still capable of conducting a
compound action potential (CAP), and for this to be possible, the plasma membrane and
associated trans-membrane voltage-gated channels must retain their integrity and
maintain a balance of the normal intracellular ion levels.
In an ultrastructural study by Ludwin and Bisby (1991), a marked delay in Wallerian
degeneration was seen most clearly at all stages up to four weeks post injury when
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comparing Wlct to wild-type. After this, the differences became indistinguishable from
the wild type. Although the morphology of nerves is preserved up to 4 weeks after nerve
lesion, physiological signs suggest an earlier deterioration in the ability to conduct action
potentials (Gillingwater & Ribchester 2001).
The obvious differences in the degeneration rates of the nerves between Wlct and wild-
type mice, suggest that the Wlct mutation is of great potential value in furthering our
knowledge/understanding of mechanisms underlying nerve degeneration. Studies to
elucidate the mechanism by which this mouse inherits its slow Wallerian degeneration
phenotype could therefore aid in our understanding of diseases that have a primarily
axonal pathology (Perry et al. 1989).
All of the above information relates to axonal protection. There is, however, also a
synaptic protection component to the Wlct phenotype. Normally, following separation of
the axon from the cell body, the axon and the synapse are seen to degenerate. In Wlct
mice however, there appears to be a withdrawal of synapses rather than degeneration.
This withdrawal has been said to be reminiscent of neonatal synapse elimination
observed during development (Gillingwater & Ribchester 2001, Gillingwater et al.
2002/2003).
The majority of the studies carried out on Wlct protection have been conducted on
peripheral tissue (Gillingwater & Ribchester 2001, Gillingwater et al. 2002). With
regards the study of central nervous tissue, there have been few in vivo (Gillingwater et
al. 2004, Ferri et al. 2003, Gillingwater et al. submitted), studies of protection, and those
in vitro studies have been limited to tissue easily accessible for culture (i.e. cerebellum,
cortex and hippocampus (Buckmaster et al. 1995, Deckwerth & Johnson 1994, Araki et
al. 2005, Wishart et al. submitted, Gillingwater et al. submitted).
Mice with the Wlcf gene are developmentally normal, that is they have normal numbers
of axons and undergo synapse elimination as normal. In 1997, Parson et al. carried out a
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study on elimination of motor nerve terminals. The conclusions of this study were three
fold; first, that the Wlds gene does not have a direct effect on the normal rate of synapse
elimination in post natal mice; second, that muscle fibres can sustain polyneuronal
synaptic inputs even after motor axons are separated from their cell bodies, and third,
and perhaps most importantly, synapse elimination and Wallerian degeneration do not
occur by the same mechanism.
1.2.2. The Wlct phenotvpe is age dependent
Perry et al. 1992 were the first to suggest that the effectiveness of the gene that slows the
rate of Wallerian degeneration in C57BL/Wlds mice declines with age. In four-week-old
mice they showed that action potentials could still be evoked up to five days after sciatic
nerve section and that compound action potentials could be evoked up to three weeks
after section in the distal nerve stump. They contrasted this with one-year-old Wlds mice,
where they saw no action potentials five days after nerve section. They also showed that
there was no difference in the extent of axon decline between heterozygous and
homozygous Wlds mice. It was also noted that normally in C57BL/J6 mice there is a
slowing in the degeneration of nerves with increasing age. However this can probably be
attributed in part to a decline in immune response and by the general slowing down of
other metabolic processes.
Tsao et al. (1999) stated that the rate of CNS Wallerian degeneration in Wlds mice also
accelerates with the advancing age of the animal. They speculate that the protein product
of the Wlds mutation, involved with generating the Wlds phenotype, is associated with
particular changes in energy status and metabolism of the cell involved, but not however
through the generation of a "detectable novel metabolite". They conclude that tolerance
to Wallerian degeneration does not correspond with an increased energy status of the
resting state of the cell.
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In contrast to both of these studies, Crawford et al. (1995) presented data suggesting that
the C57BL/Wlds phenotype of prolonged survival of transected nerves was unaffected
by age. A study by Gillingwater et al. (2002) agreed with the axonal findings of
Crawford and colleagues, but in addition clearly demonstrated that both structure and
function of motor nerve terminals following nerve injury are related to the age of the
individual Wlct mouse. Thus, mice older than three months lose functional transmission
after nerve section much faster than a younger mouse.
In neuromuscular junctions observed by Ribchester et al. (1995) & Gillingwater et al.
(2002), two features were noted; 1) The centre of the synaptic boutons showed an
accumulation of neurofilaments, and so called "giant" synaptic vesicles. They postulate
that as Wlds mice mature, the axotomy induced synaptic response changes from
withdrawal to degeneration. 2) It has been found that it is not the age of the animal that
affects degeneration in the Wlct mouse per se, but the age of the axon. A newly
regenerated axon in an older animal behaves as an axon in a younger Witt mouse. This
was found by Gillingwater et al. (2002) through the use of a conditioning lesion to
regenerate axons in old Wlct mice, and following a second lesion the regenerated axons
and synapses degenerate similar to that found in the young Wlct mice. Therefore, it is
likely that it is the age of the synapse rather than the age of the tissue surrounding it
which determines the degenerative mechanism.
Thus it appears that Wlct has a selective effect on neurones, protecting axons from
degeneration, but not cell bodies, and providing an age related protection of synapses
which is dependent on the maturity of the neuronal tissue examined, not the
chronological age of the animal (Gillingwater and Ribchester, 2001, Gillingwater et al.
2002).
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1.2.3. What has been learnt from studying the Wlct mouse?
Given the need for more detailed information of how Wallerian degeneration progresses,
it is therefore of interest to study aspects of this process in Wltf mice where Wallerian
degeneration is considerably slowed. The study of the Wlds mutation allows us to glean
information not only on how Wallerian degeneration proceeds, but also how it may be
possible to intervene. The following experimental information could not have been
obtained in wild-type nerves where Wallerian degeneration would proceed too quickly
for an in-depth examination.
In 1990 it was suggested by Perry et al. that the gene product responsible for slow
Wallerian degeneration in the PNS also affects the CNS. In the same paper they also
ruled out Schwann cells as being the essential cell involved in the prolongation of axon
survival (Perry et al. 1990). Schwann cells have however been shown (in trembler mice)
to affect the local modulation of neurofilament, and therefore local cytoskeletal
architecture (Tsao et al. 1994). The mutation responsible for the altered Wallerian
degeneration phenotype was initially thought to act by slowing macrophage infiltration
to a damaged nerve. This was later discounted due to an elegant series of experiments in
which sciatic nerve chimeras were generated through transplanting sections of nerves
from wild type mice and Wldt mice and then allowing subsequent regeneration of host
axons through the grafts containing the donor Schwann cells. These experiments
demonstrate that fast or slow degeneration is a property conferred by the host and cannot
be ascribed to the Schwann cells (Glass et al. 1993).
In 1991 Ludwin and Bisby presented evidence that once the actual process of
degeneration has begun, the cellular mechanisms that are involved look the same as
those in the normal animal but proceed at a slower rate. The Wld" mouse has also been
used to study movement of cytoskeletal proteins following transection (Glass and Griffin
1991). Nerves were examined at various intervals following transection. No evidence
was found to suggest proximal to distal emptying as would be expected if anterograde
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transport was predominating, instead gradual redistribution of neurofilament towards
severed ends could be seen, with a higher concentration towards the proximal end of the
distal stump. The authors suggest that this points towards an ability for bi-directional
transport of neurofilament in transected fibres. In 1994 Tsao et al. state that up to
fourteen days post transection, bi-directional transport of neurofilaments have been
shown to continue. They suggest that this shows that axonal transport systems also
remain intact, and that the mutation does not affect the ability of proteases, once they are
activated, to proceed with protein degradation within the axon. IL-6 has also been shown
to be up regulated 1 day after nerve injury. Given that axonal transport can continue for
up to 2 weeks after axotomy, the increased levels of IL-6 may continue to be
transported. Interestingly, mice lacking IL-6 show smaller action potentials and, after
injury, they show slower regeneration of sensory nerves. However, motor nerve
terminals are shown to regenerate normally. These findings are similar to what Brown et
al. have shown in 1992 (b). But, where Wlds mice showed delayed macrophage influx to
the injured area, the IL-6 deficient mice showed no difference in macrophage numbers
(Stoll et al. 2002).
In 1994 Deckwerth and Johnson argued that if in programmed death, the neurites and
soma are not linked and degenerate autonomously, then in the Wlct mouse, when the cell
body dies the neurites should remain viable. This is exactly what they saw in a very
simple and elegant experiment reproducing the Wlct phenotype in vitro with primary
explant cultures of dorsal root and superior cervical ganglion. The cells put out neurites
in the presence of nerve growth factor. Deckwerth and Johnson (1994) showed that
neurites would remain viable even after removal of NGF and apoptosis of the neuronal
soma. Glass et al. (1993) also showed that survival of transected Wlct dorsal root ganglia
(DRG) in explant cultures survived longer than transected wild type DRG in explant. In
1995, Buckmaster et al. carried out similar experiments, showing extended neurite
survival in culture and Raff et al. (2002) also showed that localised dying back occurs in
sympathetic neurones. If the distal part of an axon is locally deprived of NGF, that part
of the axon will degenerate leaving the rest of the axon and cell intact. This phenotype
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can even be seen when neurons are plated as single cells without Schwann cells arguing
that the Wlct phenotype is a property of the axon/neurite in question, and not the
surrounding support cells.
Ribchester et al. (1995) suggested that the rate of degeneration of terminals and some of
the physiological characteristics of degenerating motor terminals in Wlct mice are
similar to those in muscles kept at a much lower ambient temperature than normal.
Ribchester et al. (1995) also state that the time course of degeneration depends on the
length of the distal nerve stump (about 48 hours per extra centimetre).
In 1999, Tsao et al. suggested that there are three distinct stages of Wallerian
degeneration, and that this was revealed through the use of temperature modulation. The
effect of lowering temperature on slowing the rate of Wallerian degeneration could be
attributed to alterations of degradative enzyme activity and/or rates of axoplasmic
transport. They found that 100% of compound action potential was preserved if the
nerve was cooled from 37 to 25 degrees after axotomy. This suggests that there is a
critical period after the initial injury and before Wallerian degeneration effects manifest
themselves, during which the sequence of events leading to axonal destruction may have
started but are not yet evident. The three stages of Wallerian degeneration elucidated by
Tsao et al. (1999) through the use of the Wlct mouse are as follows: 1) The initial
response occurs during the first 12 hours after axotomy. This latency can be prolonged
by lowering ambient temperatures. Events taking place in this stage appear to initiate
processes giving rise to Wallerian degeneration, 2) 12 to 24 hours post axotomy,
morphology is normal, CAP remains close to 100% (until 24 hours), but cooling cannot
prolong this stage, and finally, 3) Rapid degeneration of the axon during the period 24-
48 hours, and corresponds with the rapid enzymatic digestion of axonal components. It
is suggested that catastrophic Ca2+ entry marks the transition from stage 1) to 2), which
enables Ca2+ influx, and stage 3), resulting from protease and lipase activation due to
Ca2+ influx. This suggests that the slower rate of Wallerian degeneration is an intrinsic
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property of the axons, rather than, for example, a property of supporting glial cells
(Ribchester et al. 1995, Glass et al. 1993).
The degradation of axons by Wallerian degeneration and its selective protection by the
Wlds gene has motivated the hypothesis that the cell body, axon and synapses are
separate compartments with regards mechanisms of degeneration (Figure 1.1). The slow
Wallerian degeneration phenotype has been of great importance in unmasking for
example, synaptic withdrawal in response to axotomy, which is similar in both rate and
appearance to neonatal synapse elimination (Gillingwater and Ribchester 2001). As
mentioned previously, this is experimental data it would not have been possible to obtain
from a wild-type animal, as axonal degeneration proceeds at such a rate as to make it
impossible to see potential differences in synaptic degeneration.
1.3.0. What is known about the Wlds mutation?
Mice carrying the Wlds mutation are indistinguishable from their C57BL/6J strain mates
in their appearance, behavior, histocompatibility and genotyping of more than 50
microsatellite markers and restriction fragment length polymorphisms (RFLPs, Coleman
et al. 1998, Mi et al. 2002/2003).
The mutation responsible for the delay in Wallerian degeneration was identified by
positional cloning and gene sequencing (Figure 1.2). The mutation maps to the distal
portion of mouse chromosome four, homologous with the human chromosomal region
Ip34-lp36 (Lyon et al. 1993). Perry et al. (1990) showed that the gene behaved as a
single autosomal dominant gene, with heterozygotes slightly less affected than
homozygotes. Lyon et al. (1993) mapped the locus (Wlds) of the gene believed to be
responsible for the Wlds phenotype, and they showed that crossing did not impair the
expression of the mutant phenotype with their linkage testing stocks. In the course of
this investigation the mutant phenotype was found to vary with age (Perry et al. 1992).
Ribchester et al. (1995) also commented that the capacity of motor nerve terminals to
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withstand nerve injury is related to the age of the individual mouse, they showed that
mice over three months of age lost functional transmission much more rapidly after
nerve section than younger adult mice. Thus, a reduced "gene dose" (in heterozygotes)
and aging (in homozygotes) appear to weaken the Wlcf phenotype (Figure 1.3).
Coleman et al. (1998) carried out the fine mapping of the gene responsible for the Wlcf
phenotype through the generation of a 1.4Mb bacterial artificial chromosome (BAC),
and contig mapping. They found that the Wlcf mutation comprises three genes, which
are themselves arranged within a tandem triplication of about eighty-five kilobases (Kb)
in size (Conforti et al. 2000, Coleman et al. 1998, Lyon et al. 1993, Figure 1.2).
1.3.1. How did this mutation arise?
Although the Wlcf mutation involves a spontaneous triplication of an 85 kb region, in
some cases duplication was noted. Coleman et al. 1998 suggested that this could indicate
some instability in the repeat copy number, which also suggests that the triplication
arose from a duplication by unequal crossing over. The predominant genotype appears to
have been the triplication for a number of years now. The duplication has only been
observed post mortem, so it would be of interest to know how duplication affects
phenotype. Mi et al. (2002) after examining 128 chromosomes from Wlcf mice using
PFGE (pulse field gel electrophoresis), suggested that they can examine the instability of
the triplication at the chromosomal level. They were all found to contain the triplication.
This indicated the duplications may have been an original mutation rather that a partial
reversion. They have also pronounced the triplication to be a stable mutation.
Coleman et al. (1998) also pointed out the presence of a mini-satellite array of eight
bases (5'-GCCCCCAC-3\ guanine and cytosine rich) at both the distal and proximal
boundaries of each repeat unit, which they believe suggests recombination between short
homologous sequences, either by "illegitimate" or "non-homologous" recombination.
There is the possibility that this mutation arose from viral origin. A small viral sequence
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would present the possibility of doing a pathogenicity island (PAI) study on gene
compression if the viral sequence is actually linked to the gene. This has not been
mentioned in any publications on Wlds to date. The repeat sequence is present at the
proximal boundary and also makes up part of a minisatellite repeat of twenty-two base
pairs at the distal end. This eight base pair repeat should not, statistically be present by
chance at each boundary. Statistically it should only appear in sequence once every
sixty-four kilobases. There are of course, always exceptions. There was also an
endogenous retroviral sequence found, 40-46 Kb from the proximal end of the repeat
unit
Three genes are encoded within the eighty-five Kb tandem triplication. These include
firstly, Rbp7; a novel member of the cellular retinoid binding protein family, and it is
highly expressed in white adipose and mammary tissue. It was previously suggested that
it was undetectable by Northern blot of Wlds brain (Conforti et al. 2000, but see results
chapter 5). It is likely to function in retinol storage and release. Given that retinoic acid
can induce neuronal differentiation it was thought during the early characterisation of
the Wlds mutation that Rbp7 may be involved in neuroprotection in the Wlds mouse.
However, the possibility that Rbp7 may play a critical role in the generation of the Wlds
phenotype was discounted by the demonstration that transgenic lines which express only
the chimeric portion of the mutation (i.e. the N-70 Ube4b/Nmnatl C-303 chimera) is
sufficient to recapitulate the Wlds phenotype (Adalbert et al. 2005; Mack et al. 2001). As
Rbp7 is not over expressed in these transgenic lines and the phenotype is expressed it is
considerably unlikely to contribute to the phenotype. There has however been no direct
test of the effects of Rbp7 overexpression in a model system. Secondly, D4Colele\ has
since been shown to code for nicotanamide mononucleotide adenyltransferase (Nmnatl)
that was previously undescribed. Nmnatl is involved in the regulation of NAD+ levels.
This will be discussed below in more detail. Finally, Ufd2, ubiquitin fusion degradation
protein, shown to have high homology with the N-terminal fragment of the
ubiquitination factor E4B (Ube4b). Ube4b is a part of the ubiquitin proteasome system,
which will also be discussed in more detail below. Both Nmnatl and Ube4b lie in the
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same orientation and when brought together form the Wldt chimeric gene. The chimeric
mRNA is strongly expressed in the nervous system and codes for a fusion protein (in
frame) that is made up of the N-terminal seventy amino acids of Ube4b (which are
normally not expressed in Ufd2 in yeast) and the C-terminal three hundred and two
amino acids of Nmnatl, and an aspartic acid formed at the junction (Conforti et al. 2000,
Figure 1.2). There are also two more potential exons spliced to the 5' end of the exon
noted using a 3'-RACE (rapid amplification of cDNA ends) and RT-PCR, identified by
Conforti et al. (2000) through exon trapping, which are not present in the expressed
sequence tag (EST) database. The authors also did not give a sequence or any additional
information about them. It is not known whether or not these potential exons have any
significance.
The chimeric gene has been shown to be responsible for the slow Wallerian
degeneration phenotype through the use of a viral vector to transform DRG (dorsal root
ganglion) cells and induce a protective phenotype against toxic neuropathy in the
peripheral nervous system (Wang et al. 2001) as well as by studying various transgenic
lines (Mack et al. 2001, Adalbert et al. 2005) demonstrating that transgenic expression
of the chimeric protein in rats and mice is sufficient to fully reproduce the gene dose
dependent protective phenotype. Until this point the possibility remained, however
unlikely, that the causative gene did not lie within the triplication, but may be subject to
a positional effect (Conforti et al. 2000). There is a wide expression of the transcript,
which is consistent with the observation that Ube4b (whose promoter is thought to drive
the expression) has an EST in a wide variety of tissues, with particularly high expression
in the brain (Conforti et al. 2000). The fusion protein has been shown to give a dose-
dependent block of Wallerian degeneration (Mack et al. 2001, Figure 1.3), conferring
protection of both the motor and sensory axons in the C57B1/Wlds and transgenic mice
containing the same gene (Mack et al. 2001). I will now refer to the protein product of
the gene (Ube4b/Nmnatl) as "Wlds protein". Coleman et al. 1998 suggested that an
increased dosage of the gene may cause an increase in its rate of transcription, and
therefore a steady increase in the amount of protein product (Figure 1.3). All exons
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within the fusion protein are in the same chromosomal orientation (5' proximal, 3'
distal).
1.4.0. How might Wlct work?
The exact mechanism by which the Wlct mutation is protecting axons is unknown.
However, every experiment undertaken leads us one step closer to an understanding.
Lunn et al. (1989) suggested that failure to recruit macrophages and polymorphonuclear
cells were the reason for the resulting slow rate of Wallerian degeneration. They blocked
recruitment with an antibody, and found that a reduction in myelomonocytic recruitment
helped preserve a rapidly degenerating nerve for at least five days. Ribchester et al.
(1995) suggests that nerve section normally activates cellular components or processes
already present, but which are latent in axons and motor nerve endings. Could it be that
in Wlct mice, either the trigger or the cellular response is abnormal?
There is evidence suggesting that the phenotype is not due to the surrounding glia (Glass
et al. 1993). However, examining axon-glia signalling with respect to CNTF (ciliary
neurotrophic factor) that is a potential maintenance factor, in wild type animals
following axotomy, the CNTF protein and mRNA levels decline rapidly, whilst in the
Wlct mice both CNFT protein and mRNA levels remain constant for at least four days
following axotomy before declining slowly to be equal with wild-type levels at ten days
(Subang et al. 1997).
Wallerian degeneration appears to occur via mechanisms distinct from those responsible
for degeneration of the cell body, since over-expression of bcl-2 which inhibits somatic
apoptosis, appears not to affect its rate and that the degeneration appears to occur in a
caspase independent manner suggesting a non-apoptotic mechanism (Ikegami & Koike
2003, Ferri et al. 2003). It is also known that caspase-3, which is important for apoptosis
in neurones (Xue et al. 2001), is not activated in Wallerian degeneration indicating that
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the mechanism of Wallerian degeneration is distinct from the caspase dependent
apoptosis required for cell body apoptosis. Caspase inhibitors do not alter the
progression of this type of degeneration and in cultures of sensory Wlct neurones,
removal of NGF will cause the cell body to undergo apoptosis immediately whilst axons
may remain in culture for a following five days plus (Buckmaster et al. 1995, Deckwerth
& Johnson 1994).
Buckmaster et al. (1995) showed that the rate of degradation could be slowed by
increased time in culture before cutting or withdrawal reaching a maximum by about
seven days. This suggests that the mechanism responsible for the protective phenotype
requires time to activate in culture, i.e. the Wlds protein is present in the adult cerebellar
granule cells, but is not visible at the age (P4) from which the cultured cells were taken
from (see chapter 4). So in this case, the delay in the onset of protection in culture could
represent the time taken for the activation of the protective phenotype (further
explanation will be given in chapter 4). Following culture of sympathetic neurones DRG
and SCG, Buckmaster et al. (1995) observed the effect of removing NGF (nerve growth
factor) as an initiator of SCG death (Edwards et al. 1991) from the culture media. Raised
potassium in the media in conjunction with NGF withdrawal was found to extend cell
survival by up to 3 times. In this case it was seen that cell bodies die first and that
neurites would remain for some time. This indicates that neurite degradation is
controlled by the neurites themselves (as suggested in section 1.2.3), or that the
degradation of neurites is continuously inhibited by a signal from the cell body, and
when this is removed the neurites begin to break down. With cerebellar granule cells,
which were the authors CNS cells of choice for culture, after three days in culture
neurites were cut, Wlct cells survived for 3-4 days but wild type cells survived only 18-
20 hours. After seven days in culture, the axotomised Wlcf neurites survived for up to
and more than five days and the wild-type only survived for about 36 hours after section.
This study formed the basis of an assay I will use to measure Wlct phenotype in vitro
(described in chapter 4).
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It has been shown that the chimeric Wlds protein is localised almost exclusively to
neuronal nuclei, and is therefore not present in large amounts in axonal or synaptic
compartments (Mack et al. 2001; Fang et al. 2005, Wishart et al. submitted). I will also
demonstrate that Wlds protein co-localises with transcriptional regulators such as
HDAC5 and SMRT, as well as part of the UPS (VCP, see chapter 4). This suggests that
Wldt is not capable of directly protecting axons and synapses, but rather that downstream
effector targets, present in non-somatic neuronal compartments, are required to generate
the neuroprotective phenotype (Coleman & Ribchester, 2004). Several lines of
investigation appear to lend support to the hypothesis that gene expression patterns
could be regulated by Wlds (Gillingwater and Ribchester 2001, Araki et al. 2004, Fang et
al. 2005).
In protecting axons that have been severed, the fusion protein localised to the nucleus in
areas of the nervous system showing a protective phenotype (Mack et al. 2001, Fang et
al. 2005, Wishart et al. submitted) is protecting a part of a neuron that has effectively
been disconnected from the cell body and nucleus. This, importantly, suggests an
indirect mechanism of neuroprotection.
1.5.0. Dissecting the molecular mechanism of Wldt-induced axon protection
I have described how the Wlds gene is an amalgamation of three genes in the
spontaneous mutant: Nmnatl (Nicotanamide mononucleotide adenyltransferase 1), Rbp7
(Retinoid binding protein 7) and Ube4b (Ubiquitination factor E4b). I have also stated
that the portion of the mutation sufficient to reproduce the Wlds neuroprotective
phenotype is the N70-Ube4b-Nmnatl-C303 chimera. The sequestration of the Wlds
chimeric protein to neuronal nuclei suggests that it is incorrectly located to have a direct
effect on axonal and synaptic protection following disease and injury.
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Three strong hypotheses concerning the mechanism of action are therefore;
1. Over expression of Nmnatl\ Over expression of this protein within nuclei may
lead to high local concentrations of Nmnatl, which if functional could affect
neuronal survival through the NAD pathway via several routes.
2. Dominant negative effect of Ube4b\ Ube4b is a component of the ubiquitin
proteasome pathway. One speculated mode of action is that because the Wlct
mutation only incorporates the N70 amino acids of Ube4b, it may act by
interfering with native Ube4b. It could also be a case that a large amount of
"foreign" protein within the nucleus leads to sequestration of the majority of the
cells chaperone system, resulting in an alteration of the ubiquitin proteasome
system.
3. Gene regulation by either or both Ube4b/Nmnatl; Both Nmnatl and Ube4b have
been shown to be capable of affecting transcriptional regulation, either directly
or indirectly.
These possibilities will be explored in more detail below.
1.5.1. Nmnatl INAD hypothesis
In humans the nuclear enzyme Nmnatl catalyses an important step in the NAD (NADP)
biosynthetic pathway (Raffaelli et al. 2002, Figure 1.4) and therefore also plays an
important role in the oxido-reducatse pathway in mitochondria. It has been demonstrated
that in yeast and C.elegans, life span can be extended through manipulation of the NAD+
pathway. This is through the activation of the NAD+ dependent histone deacetylase
Sirt2p. It has been shown that an increase in NPT1, which encodes a nicotinate
phosphoribotransferase critical for the NAD+ salvaging pathway, increases Sir2
dependent silencing, stabilising the rDNA locus (which would otherwise give rise to
circular forms of rDNA termed extrachromosomal rDNA circles that replicate, but do
not segregate to daughter cells and eventually kill cells, by titrating essential
transcription factors and replication factors once the numbers exceed 1000 copies) and
can extend yeast life span by up to 60% (Anderson et al. 2002). Both Nptl and SIR2
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have been demonstrated to provide resistance against heat shock suggesting that they
can also act in a more general manner, which can promote cell survival.
A recent publication by Araki et al. (2004) suggested that it is an increase in nuclear
NAD biosynthesis that prevents axonal degeneration in the Wldt mouse. This was based
on the effects of adding exogenous NAD to DRG cultures before insult, to show that this
was sufficient for protection. Although the protection demonstrated was not as strong as
that seen in the Wlcf mouse, it was an improvement on the situation normally seen in the
wild-type mouse. Furthermore, Araki et al. also suggested that this protection was
mediated through a Sirtl dependent pathway. The evidence for this was that when
cultures incubated with exogenous NAD were exposed to sirtinol, an inhibitor of Sirtl,
the cultured neurones no longer displayed a neuroprotective phenotype. This study has
generated a controversy within the field of Wldt research, mainly because generation of
transgenic lines which over express Nmnatl were previously thought to have no
neuroprotective phenotype (Coleman and Perry 2002). Until recently, no one has
published confirmation of the work published by Araki et al. (2004). A recent paper
presents results which did not completely agree with all of Araki's findings (Wang et al.
2005). At the time of writing this thesis, Coleman et al. were preparing a paper for
publication (M.P.Coleman, personal communtication) showing that several transgenic
lines over-expressing Nmnatl fail to show the neuroprotective phenotype described by
Araki et al. (2004). This highlights the importance of validating work carried out in
vitro, in vivo models when investigating phenotype.
Wang et al. (2005) are the first group to publish data relating to the Araki study. The
suggestion by Wang et al. that NAD is important in regulating neuroprotection supports
some of the findings of the Araki et al. paper. Moreover, Wang et al. suggest that there
is a Sirtl independent local pathway which could be involved in the NAD dependent
protection. That is, local bioenergetics pathways may be important as suggested by the
ability of lOmM methyl-pyruvate (a membrane permeable version of the glycolytic end
point, pyruvate) to prevent a decrease in axonal ATP levels and protect against axonal
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degeneration. It was also shown that inhibition of the Sirtl pathway did not affect
neuroprotection in their model system. This also is not consistent with the observations
reported by Araki et al. (2004) and suggests that the action of NAD in a Sirtl dependant
fashion is not sufficient to fully reproduce the Wlds neuroprotective phenotype in vitro.
Thus, the role of NAD levels in conferring the Wlct phenotype still remains unclear.
1.5.2, Ube4b and the ubiquitin proteasome hypothesis
Proteasome inhibitors have been demonstrated to block Wallerian degeneration both in
vitro and in vivo, and for this reason, until the publication of the study by Araki et al.
(2004), the Ube4b portion of the Wirt gene has been considered the most likely
candidate for neuroprotective regulation in Wlct (Zhai et al. 2003).
Ubiquitin is a highly conserved 76 amino acid protein. This protein acts as a tag, and the
length of this tag is very important in its recognition. The ubiquitin proteasome is "a
complex macromolecular tube whose inner aspect is lined with proteases" (Grey, 2001).
The ubiquitin proteasome system and ubiquitin, until relatively recently, were thought to
only be involved in preventing protein misfolding and removal of proteins which have
become so misfolded that this cannot be prevented. I discuss in more depth below, the
emerging view that ubiquitination is a very versatile process, whose complexity should
be considered to rival that of the phosphorylation signalling system. Monoubiquitination
has been shown to be involved in various activities ranging from histone regulation and
transcriptional regulation to endocytosis and budding of retroviruses from the plasma
membrane in yeast (Hicke, 2001). The most important point to note is that there is a
mechanism for determining ubiquitin chain length, and that the ubiquitin proteasome
system has a threshold length of four ubiquitin subunits before the chain and attached
protein cargo are directed to the proteasome for degradation.
In yeast, members of the E4 family ubiquitination factor proteins (of which Ube4b is a
member) are involved in multiubiquitin chain assembly, and their activity is linked with
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cell survival under stress conditions. This suggests that eukaryotic cells may use E4
dependent proteolysis pathways for many cellular functions (Kogel et al. 1999, Figure
1.5). See below.
Substrates of the ubiquitin/proteasome pathway can be "recognised" by the ubiquitin
conjugation system and are then signalled for degradation by the addition of ubiquitin
molecules (Kogel et al. 1999, Figure 1.5). For ubiquitin molecules to be added to a
protein, several events must take place which utilise combinations of several different
interacting proteins;
1) El-Ubiquitin activating enzymes. Els hydrolyse ATP to produce energy for the
reactions that are about to occur, and a high-energy thioester bond is formed between a
cysteine of Els active site and the C-terminus of a ubiquitin molecule, which becomes
"active".
2) E2-Activated ubiquitin is then passed from Els on to E2s, which are a family of
ubiquitin conjugating enzymes. The E2s then form a thioester link with ubiquitin in a
similar fashion to El. These can then in some cases interact directly with the substrate
protein and add ubiquitin directly to the side chain of a lysine residue, or it can go via
another protein family, the E3s.
3) E3-Ubiquitin is attached covalently to the substrate protein by ubiquitin protein
ligases (E3s).
4) E4- binds to conjugated ubiquitin moeties and working in conjunction with El, 2 and
3 can drive the addition of more ubiquitin to yield longer chains (Figure 1.5).
What is the significance of this? The preferred substrate of the 26S proteasome are
multiubiqiutinated proteins, whilst mono-, di- and tri- ubiquitinated substrates appear to
be persistent for longer within the cell and are later subject to degradation by different
degradation pathways (Kogel et al. 1999). So, there appears to be a hierarchy for
protein degradation, akin to a "green", "amber", "red" hierarchy of alert states for
protein removal, where multiubiquitination via E4 facilitates more rapid removal of
these proteins than shorter ubiquitin chains, which are slower acting. In contrast to E3,
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the E4 (including Ube4b) proteins do not interact directly with the substrate, but with the
ubiquitin moeties of the ubiquitin-substrate conjugates (Kogel et al. 1999). E4 is
apparently essential for cells under stress conditions, at least in yeast (Kogel et al. 1999).
When a cell under stress conditions is examined, there will be a large increase in the
percentage of aberrant proteins within the cell, with the potential to interfere with
normal cell function, and chaperones will be overwhelmed. So ubiquitination is the next
step in rapid removal of proteins tagged with a "code red" degradation signal. It has also
been speculated that ubiquitin can be used to completely coat misfolded proteins and
keep them out of circulation if the degradation pathways are overwhelmed such as in
Huntington's disease (Arrasate et al. 2004). Ubiquitinated deposits are also observed in
brains of patients with Alzheimer's disease where it accumulates in the form of neuritic
plaques. Intranuclear inclusions also appear in other polyglutamine diseases such as
Myotonic Dystrophy.
Ubiquitination to the point of recognition by the proteasome for degradation is probably
not the only function of the ubiquitination system. It may not always be necessary to
degrade misfolded or aggregated proteins. There is a large pool of de-ubiquitinating
enzymes within the cell. This may act as a means of rescuing tagged protein from
definite degradation through the proteasome. This may also be a way of reclaiming
ubiquitin back to the system for use in the event of severe stress. Imagine that there is
the formation of large aggregates within the cell, and that more protein is being
misfolded. A coating of ubiquitin to stop these aggregates from interacting with other
processes within the cell may be all that is needed. The production of misfolded protein
may be so great that the proteasome cannot keep up and there is insufficient ubiquitin to
fulfill the needs of the cell. Reclamation of ubiquitin from ubiquitin chains may be the
only way to deal with these aggregates.
Addition of ubiquitin is important. However, there are several possible steps that could
follow on from the ubiquitin tagging of substrate proteins, and which add further
complexity and flexibility to the system. One other step in this chain is VCP (valosine
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containing protein/p97/CDC48), which is a member of the AAAfamily (ATPases with
multiple cellular activities), involved in a range of different functions including
membrane fusion, nuclear envelopes, nuclear envelope reconstruction, post mitotic
Golgi reassembly and ubiquitin dependent degradation (Wojcik 2002). Interactions with
Ube4b could also indirectly affect transcriptional regulation (see chapter 4).
In mammals, Ube4b (in yeast, Udf2) is a protein needed for the addition of
multiubiquitin chains to a ubiquitinated substrate. The predicted amino acid sequence
within the Wlct gene is identical to the human Ufd2 sequence, but Conforti et al. (2000)
state that it represents an N-terminal extension of the yeast Ufd2 protein. In the presence
of active El, E2 and E3 enzymes, Ufd2 is known to be required for the
multiubiquitination of already ubiquitinated substrates in yeast. The presence of the N-
terminal 70 amino acids of Udf2 in the fusion protein was therefore of interest due to the
rise in reports of altered ubiquitination in neurological disease.
1.6.0. Gene regulation hypothesis
Both the Nmnatl/NAD and L7?e47>/ubiquitination hypotheses support the idea that either
or both of these pathways can be involved in transcriptional regulation. Once again,
given that the Wlds chimeric protein (comprising the N-70 amino acids of Ube4b and all
of Nmnatl) is localised exclusively to the nucleus, it is important to fully explore the
possibility of an indirect action through transcriptional regulation.
1.6.1. Nmnatl/NAD pathway and transcriptional regulation
Sir2 in yeast is a silencing protein believed to be a component of the heterotrimeric
Sir2/3/4 complex. This complex catalyses the formation of silent heterochromatin at
telomeres. It is also a regulator of nucleolar silencing and has also been shown to
directly stimulate transcription of rRNA by polymerase I (Anderson et al. 2002; Blander
and Guarente, 2004). Its deacetylase activity is dependent on NAD+. Sir2 are a family of
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protein deacetylases and have been shown to deacetylate and therefore inactivate p53
(Blander and Guarente 2004). Sir2 have also been implicated in the regulation of the
FOXO transcription factors, specifically F0X03a through deacetylation and therefore
repression of activity (Brunet et al. 2004, Motta et al. 2004). It has also been
demonstrated that negative control of p53 by a member of the Sir2 family (specifically
Sir2a) can promote cell survival under stress conditions (Luo et al. 2001) by specifically
repressing the p53-dependent apoptotic response. In yeast Sir2 is the only protein
exclusively localised to nuclei whose activity is of great importance for both gene
silencing and extension of yeast life span. Sir2a and its human orthologue SIRT1 are the
closest homologous to yeast Sir2 and both of them are exclusively localised to nuclei.
Sirtl has also been shown to regulate the transcriptional activity of NF-kappaB. Sirtl
has been demonstrated to interact directly with the RelA/p65 subunit of NF-kappaB and
therefore inhibit transcription by deacetylating this subunit. As stated previously, Sirtl
activity can affect apoptosis. Yeung et al. (2004) suggest that one pathway for this
control may be in response to TNFalpha deacetylation inhibiting the transactivation
potential of the RelA/p65 protein (Yeung et al. 2004).
1.6.2. £/&g4fc/ubiquitination pathway and transcriptional regulation
The very fact that there is a threshold mechanism for recognition by the ubiquitin
proteasome system means that degradation mediated by ubiquitin proteasome system is
not an all or nothing system. At first glance, gene transcription and ubiquitin-mediated
proteolysis are two processes that do not appear to have anything in common. However,
ubiquitylation of RNA polymerase II itself is an important step in transcription coupled
DNA repair, in which the presence of DNA damage in a transcribed gene stops
transcription and allows for the co-ordinated entry of the DNA repair machinery
(Muratani and Tansey, 2003). More recent research by Muratani et al. (2005) has
added significantly to our knowledge of transcriptional regulation, as can be affected by
ubiquitination. As already mentioned, polyubiquitination targets a protein for
degradation, but monoubiquitination, although it can lead to destruction, can also simply
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alter the function of the "tagged" protein without signaling its destruction. There is
support for the idea that the ubiquitination system should be considered as versatile a
signaling mechanism as phosphorylation. Gal4, which is a transcriptional activator in
yeast, is known to bind to specific regulatory sites in the regulatory regions of the GAL
genes. It can activate transcription to a high level when the yeast S.cerviciae is grown
with galactose as a carbon source, i.e. under activating conditions. Gal4 ubiquitination,
and in this case subsequent destruction, are required for activation by Gal4 (Muratani et
al. 2005). Gal4 is not unique in having an overlap of activation and "destruction"
domains. It has now been shown that this is a more general phenomenon that occurs in
unstable transcription factors with a close correlation between the ability of an acidic
activation domain to activate transcription as well as signaling proteolysis. Salghetti et
al. (2000) showed that this is the case for Myc and in doing so, may have been the first
to hypothesise that transcription factors could be "destroyed" because of their ability to
activate transcription.
There are other examples where ubiquitination is important in transcriptional regulation,
for example, monoubiquitination of histone H2B is known to be associated with
activation of transcription and transcriptional activation. (Xiao et al. 2005, Laribee et al.
2005). The role of ubiquitination in transcriptional regulation has been suspected for
many years now. A review published in 1998 (Hershko and Ciechanover) makes the
case specifically for the role of ubiquitination in the NF-kB (Nuclear Factor kB) system.
NF-kB is a transcription factor involved in many processes including immune, stress,
inflammatory and developmental processes. NF-kB is a collective name for inducible
dimeric transcription factors that are made of members of the Rel family of DNA
binding proteins (Jesenberger and Jentsch, 2002). There are five Rel proteins in
mammals; NF-kB1 (p50 and its precursor pl05), NF-kB2 (p52 and its precursor plOO),
c-Rel, RelA (p65) and RelB. The latent form of NF-kB 1 is located within the cytoplasm
through association with inhibitory molecules termed IkBs (inhibitors of kB which mask
nuclear localisation signal and inhibit DNA binding ability of NF-kBs). When the cell is
stressed, IkBs are degraded and the active heterodimers are transported to nuclei to
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affect transcriptional regulation. It has been demonstrated that through phosphorylation
at serine residues 32 and 36, is strongly recognised by the ubiquitin conjugation
machinery at lysine 21 and 22, followed by degradation by the proteasome (Hershko and
Ciechanover, 1998). Mutations in TAF250 that inhibits its ubiquitination activity cause
defects in transcriptional activation in Drosophila embryos, indicating that TAF250
dependent HI ubiquitination may control gene expression (Hicke, 2001). There are
many other proteins in transcriptional systems which can be affected by ubiquitination,
including; Mdm2, c-Jun (but not v-Jun), P-Catenin (better known for its involvement in
the "wingless" pathway) and the EF2 family of transcription factors.
VCP (VCP/p97/Cdc48p AAA chaperone) as mentioned earlier is a link in the
ubiquitination pathway (in some cases directly interacting with UFD2 in yeast) which
may, indirectly, be able to effect transcription. It has been demonstrated that VCP can
interact with HDACs to alter acetylation and therefore other processes within the cells
(Seigneurin-Berny et al. 2001). This is therefore a link between the ubiquitination and
acetylation pathways, adding another level of complexity to the ubiquitination system.
Class I HDACs are homologous to yeast RPD3, class II HDACs are related to HDA1
and class III members are related to yeast SIR2 deacetylases. The interaction of VCP
with class III HDACs (SIR2 homologous) may not appear significant at first glance.
However, when this information is take in context with the earlier description of the
Nmnatl portion of the Wlct gene and its possible interactions, this information becomes
more interesting. Another interesting point is that a number of proteins show an
association with HDACs, and within this group of HDAC associated proteins are
mammalian homologues of the yeast UFD pathway (Seigneurin-Berny et al. 2001).
HDACs are involved in transcriptional regulation, and HDACs 4, 5, 6 and 7 have been
shown to shuttle between the nucleus and the cytoplasm.
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1.7. Protein aggregates in neurodegenerative disease
Taking into account that the Wlds chimeric protein is localised exclusively to neuronal
nuclei (Fang et al. 2005, Wishart et al. submitted) it is perhaps important to know
whether inclusions observed in neurodegenerative diseases are pathogenic, incidental or
even beneficial? Opinions are divided into two camps; 1. Those adherent to the view
that the formation of a protein aggregate is pathogenic, as the aggregates have the ability
to absorb other important cellular proteins. 2. Those who think that the formation of
aggregates in disease models represent an attempt to protect the cell by sequestering
mutant/abnormal proteins, reducing interference with vital cell processes.
A number of neurodegenerative diseases feature progressive cell loss in specific sub
populations of cells that appear to have some level of susceptibility to the formation of
certain protein aggregates. There are a number of processes that induce
neurodegeneration and may lead to abnormal protein aggregation. For example, unusual
protein interactions leading to altered degradation and aggregation (i.e. through the
UPS), oxidative stress and free radical formation leading to altered chaperone activity,
and altered bioenergetics (as may be the case with Nmnatl in Wlds). A recent study by
Arrasate et al. (2004) suggests that the formation of protein inclusions in models of
neurodegenerative diseases may actually be protective for the cell involved. Through
following neurones transfected with GFP tagged mutant protein, they were able to
demonstrate that those cells which formed neuronal inclusions were at a "significantly"
reduced risk of dying.
Ubiquitin is detectable in a number of human neurodegenerative diseases whose most
distinctive traits are the formation of protein aggregates. It has most frequently, been
assumed that these inclusions and the presence of ubiquitin may be the consequence of
failure to remove these abnormal protein structures by the cell. However, there is the
possibility that the presence of ubiquitin may serve a protective function to the cell. That
is, a surface coating of ubiquitin may 1) prevent further growth of the aggregate, 2)
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prevent interaction of this aggregate from interfering with normal cell processes and 3)
conceal the aggregate from detection mechanisms which may, ultimately lead to the
destruction of the cell (Gray, 2001).
VCP has previously been demonstrated to suppress the formation of polyQ aggregates in
a C.elegans system and as such it has been suggested that VCP/p97/Cdc48p homologues
(AAA chaperones) may have a protective role in polyQ aggregation (Yamanaka et al.
2004). It has also been demonstrated that mutations in VCP can lead to inclusion body
myopathy, which is associated with Paget disease of bone and frontotemporal dementia
(IBMPFD). The identification of VCP mutations as being important in IBMPFD could
be an important step in the understanding of common ubiquitin based disease pathways
(Watts et al. 2004, Schroder et al. 2005). A large protein deposit within the nucleus may
not appear to be a good thing, however, if it is coated with ubiquitin, it may be
preferable to, say, expanded polyglutamine tracts, potentially interfering with
transcriptional machinery or other potential cell functions (Grey, 2001).
So, alterations in ubiquitin pathways overall play an important role in axon
degeneration. Synaptic changes in neuromuscular synaptic form and function are known
to be altered in Drosophila mutants which display up or down regulated deubiquitinating
proteases or ubiquitin ligases (Gillingwater et al. 2002). Coleman and Perry (2002) in
their review suggest that all available evidence for the mechanism of protection in Wlif
leans towards ubiquitination-proteasome pathway being involved for three reasons:
First, that the basal level of NAD is unaltered in the unlesioned Wlds nervous system,
although that does not necessarily negate the possibility that the situation will not
undergo rapid alterations in a lesioned system. Secondly, that transgenic expression of
Nmnatl, when fused to a shorter Ube4b sequence does not delay Wallerian
degeneration, indicating that the Ube4b fragment is necessary for slow Wallerian
degeneration. Thirdly, that mutations in other ubiquitin-proteasome pathways have been
shown to alter neuronal degeneration, for example in recessive juvenile Parkinson's
disease and gad (gracile axonal dystrophy) mice. Gad mice carry a mutation in UCH-L1,
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which is associated with inclusions in a variety of neurodegenerative disorders, and
which was recently shown to have the ability to shorten ubiquitin chains on specific
substrates (Grey, 2001). This suggests that gad mice may be predisposed to the
formation of inclusions/aggregates through the depletion of monomeric ubiquitin pools.
1.8. Neurodegenerative diseases shown to be affected by Wlds
Crossbreeding Wlcf mice with models of neurodegenerative diseases has given cause for
optimism that there may be some functional use for the application of knowledge gained
from the study of Wld" (Figure 1.6). For example, in the treatment of neurodegenerative
disorders including; myelin related neuropathy (Samsam et al. 2003), motor neurone
disease (Ferri et al. 2003), Parkinsons disease (Sajadi et al. 2004) and Gracile axonal
dystrophy (Beirowski et al. 2005) it has been shown that the Wlds gene leads to
attenuation of symptoms and extension of life span in the models studied. This suggests
the plausible hypothesis that these diseases converge on one or more pathways that are
also impacted upon by Wld\ This also suggests that by testing to determine which
disease and other conditions i.e. stroke (Gillingwater et al. 2004) are affected by Wld\ it
should then be possible to determine common pathways which may be affected.
Several groups worldwide are currently using this strategy. It is therefore important to
identify the genetic status of mice crossbred with Wldx mutants especially in order to be
certain that the crossbreeding has proceeded to a homozygous Wlds state. As previously
mentioned, only homozygous animals show the Wlcf synaptic phenotype. Heterozygous
animals show neither any overt constitutive phenotype that would allow identification
without a neurological examination, nor any identifiable polymorphisms that may lead
to their genotyping by conventional methods. Genotype cannot be resolved by
conventional PCR, and southern blots are too insensitive to allow a confident
identification of genotype. The current method for genotyping Wlds mice is accurate and
reliable, based on pulse field gel electrophoresis (Mi et al. 2002). However, this method
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is time consuming and technically difficult to perform. A more rapid, reliable method for
genotyping the mutation would be highly desirable for genotyping multiple crosses.
1.9. Aims
The aim of this thesis is to advance our understanding of the mechanisms controlling
nerve degeneration, by examining the molecular interactions of the Wlct gene and its
chimeric protein product. Given the extent of knowledge currently available on the
mechanism by which the Wlct mutation provides a neuroprotective phenotype, the
objectives of this thesis were three fold;
1. To develop a rapid and cost effective method for genotyping using quantitative real
time PCR on genomic DNA from the spontaneous Wlct mutant mouse and transgenic
lines. This method should allow the determination of Wlct copy number (specifically a
region of the t\l()-Ube4b portion of the Wlct gene) for genotyping and calculating
insertion number in transgenic lines.
2. To advance knowledge of the localization of the Wlds protein product throughout the
nervous system through immunohistological mapping. Available to me was a highly
specific antibody generated against the Wld-18 peptide, which has previously been used
to confirm that the Wlct protein product is localised to neuronal nuclei in the PNS. I will
use this antibody to determine the location of the Wlds protein product in various regions
of the Wlct nervous system. I also used the antibody to compare protein levels in some
key areas. Colocalisation studies were also carried out to determine possible interacting
partners.
3. To test the hypothesis that the Wlct protective phenotype is an indirect effect and that
it is acting through affecting expression of other genes. This was carried out through the
use of microarray analysis and quantitative real time PCR of genes whose expression is
£altered by Wld . I will also demonstrate through the generation of various constructs
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Figure 1.1. Compartmentalisation of the neurone.
A. Schematic diagram of the early stages of Wallerian degeneration showing granular
disintegration of the cytoskeleton, axon and synapse fragmentation and myelin
breakdown.The WIcP mutant mouse was instrumental in working out that a neurone has
separate comparments with regards to degeneration, and that the slowed degeneration
exhibited by neurones in the H/7cF mutant mouse allows visualisation of these events. B.
Wallerian degeneration and its delay by the Wlds in peripheral nerves and NMJ of YFP-H
and YFP-16 transgenic mice, visualized directly by fluorescence microscopy. The middle
panels show an uncut nerve and the left and right panels show axons and synapses 3 to
5 days post lesion. In the wild type animal both the axons and synapses have
degenerated, but the corresponding Wlds animal shows intact axons with occupied
endplates as show by bungarotoxin labelling (Red). Adapted from Coleman and
Ribchester (2004).
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Figure 1.2. The W/cF mutation comprises an 85Kb tandem triplication of a region
already present in the wild-type animal.
The triplicated region contains the genes for Nmnat, Rbp7 and Ube4b. The boundaries of
this triplication result in the formation of a chimeric gene consisting of the N-70 amino acids
of Ube4b and the c-terminal 303 amino acids of Nmnat. This chimeric gene has been shown
to be sufficient to provide the Wlds protective phenotype through the generation of transgenic
mice and rats using the transgene shown above. The chimeric gene is expressed with the
noncoding region of exon 1 of (S-actin under the control of the human p-actin promoter. The
protein product of the fusion gene contains 18 amino acids that are not normally expressed
because they are part of the 5' untranslated region of Ube4b. This allowed the generation of
a highly specific antibody which can be used to identify the protein through
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Figure 1.3. Dose-dependence of axon protection by the Wlds protein.
A. Western blot probed for NF-200 shows the extent of 200-kD neurofilament protein
degradation in distal sciatic nerve 3 days after transection (5 days for 4836 and WIcP
homozygotes). Complete preservation of NF-200 in uncut contralateral nerve (lane 1)
indicated degradation occurred only in vivo. Although preservation of NF200 protein
can be seen there is also a "smearing" below this band which may be degraded
neurofilament. Western blot For Wlds protein shows the expression level of the Wlds
protein in brain homogenates (detected by N70 antiserum). Western blot probed with
control monoclonal antibody p-tub 2.1 against p-tubulin demonstrates that the lanes
have been correctly loaded. B. The graph shows axon preservation as a function of
the expression level of Wlds protein. Axon preservation after 3 (black circle), 5 (white
square) and 14 (cross) days as measured using light microscopy; means ± s.e.m.
where n > 1. Wlds protein expression level is the signal quantified from Gel 2
standardized against p-tubulin and expressed as a percentage of the expression in
Wlds homozygotes. This figure was adapted from Mack et al (2001).
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Figure 1.4 . The NAD biosynthesis pathways from nicotinamide in yeast and
mammals.
A, NAD biosynthesis from nicotinamide in S. cerevisiae. Pnc1, Npt1, Nma1, Nma2, and
Qns1 are nicotinamidase, nicotinic acid phosphoribosyltransferase, nicotinic acid
mononucleotide adenylyltransferase 1 and 2, and NAD synthetase, respectively. This
pathway is also conserved in C. elegans, Drosophila, and other invertebrates. B, NAD
biosynthesis from nicotinamide and nicotinic acid in mammals is shown. These pathways
are also conserved throughout vertebrates. Nicotinamide is the main precursor for NAD
biosynthesis in mammals. Npt, Nampt, and Nmnat are nicotinic acid
phosphoribosyltransferase, nicotinamide phosphoribosyltransferase, and
nicotinamide/nicotinic acid mononucleotide adenylyltransferase, respectively. Several
enzymes break down NAD into nicotinamide, but only Sir2 is shown. Sir2 is also
implicated in deacetylation of p53 and affecting FOXO transcription factors. NaMN,














Figure 1.5. UFD2 Protein family and ubiquitination pathways.
Multiubiquitination of proteins proceeds via variations of ubiquitin-enzyme thioester
cascade. E1 (yellow) is always required, forms a thioester -linked complex (S) with
ubiquitin, and transfers activated ubiquitin onto E2s (blue). In some reactions, E2s can
directly multiubiquitinate substrates, whereas others involve E3s (different shades of
green). In contrast to some E3s (APC, SCF, CBC, etc), a subfamily of E3s (hect) can
form thioester-linked complexed with ubiquitin, similar to E1 and E2. At least one E1,
E2, E3-thioester cascade involves an additional E4 (red) activity for efficient substrate
multiubiquitination. Protein is finally tagged either for degradation or regulation of other
processes. Adapted from Kogel et a/.(1999).
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Figure 1.6. Axon degeneration mechanisms may converge at a Wld3 sensitive point.
The WIcP mutation is able to delay axon degeneration not only after injury, but following a
wide range of degenerative insults. It follows that all degeneration mechanisms shown
must converge on a pathway that is delayed by WIcF. Therefore, understanding the
mechanism of injury-induced Wallerian degeneration is highly relevant to axon





2.1.1, Cerebellar granule cell preparations;
Rat:
Cultures of cerebellar granule cells were obtained via a dissociative method described
previously by Courtney et al., 1990 and Gallo et al., 1989 with some modifications.
Seven day old Wistar rat pups were killed by cervical dislocation and decapitated in
accordance with Home Office rules. The cerebellum was aseptically removed, and cut at
375|im intervals orthogonally on a nylon disc using a motorised Mclllwain tissue
chopper.
Mouse:
A variation of the technique used to culture rat cerebellar granule cells was used as
described previously (Buckmaster et al. 1995). The optimal age of mice used was P4
(C57/B16 or C57/Wlds). Four day old C57B1/6J or C57B1/Wlds mice were killed by
cervical dislocation and decapitated in accordance with Home Office rules. The
cerebellum was aseptically removed by the "flip top" method, and cut at 375p.m
intervals orthogonally on a nylon disc using a motorised Mclllwain tissue chopper.
Rat and Mouse continued:
Following crude dissociation with a Mclllwain tissue chopper, Cells were separated in
dissociation solution (O.lmM glucose, 0.3% fatty acid free BSA, 15nM MgS04.7H20
and 1 tablet of PBS (5mM Phosphate buffer, 1.4mM Potassium chloride, 50mM Sodium
Chloride, pH 7.4) and 0.685mM EDTA, all made up to 100ml with fresh milli Q water).
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The cells in solution were placed in a water bath for 40 minutes at 37°C and gently
agitated every 5 minutes. During this time three sterile, 9 ml glass pipettes were flame
polished. Each pipette was heated gently until its bore was half that of the last. After
incubation for 20 minutes the tube was removed from the water bath and this was then
taken and centrifuged at about lOOOg for one minute. The supernatant was then
removed, and the pellet re-suspended in up to 3ml dissociation of solution using the
wide bore pipette. Following this the small bore pipettes were used to thoroughly
triturate the cell suspension. After trituration, the suspension of cells were layered on top
of 10ml of EBSS solution (EBSS from GIBCO with 4% BSA and 3mM MgSCE) and
centrifuged for 10 minutes at 1500g. The purpose of the EBSS was to remove debris
caused by the trituration. The resulting pellet was re-suspended in up to three ml of
culture medium as detailed by Buckmaster et al. 1995 (containing DMEM with 32mM
KC1, 30mM glucose, 10pg/ml insulin, 10% FCS, 5ml/500ml Penicillin/streptomycin and
0.15g/500ml L-Glutamine). lOpl of this solution, diluted with 90ml of the culture
medium was then used to measure cell density with a haemocytometer. The cells
counted within a four by four square are used in the following calculation:
Cell number x volume (/xl, i.e. up to 3000/d) x 100 (conversion number for grid system) = total
yield of cells from preparation.
400 000 cells in suspension were then added to coated cover slips or about 2 000 000
cells per 35mm dish to give high density. The cover slips or dishes were put back into an
incubator for between 30 and 60 minutes and following this, 2 ml of the culture medium
were added to the cells and then replaced in the incubator. The following day the
medium was changed to medium containing Ara-C (cytosine arabinosidase to inhibit
proliferation of astrocytes. The medium used was as detailed above, but with 10|iM Ara-
C from lOmM aliquots added and filtered through a syringe filter), usually 2ml. Six days
post plating the cells were-fed again with medium containing Ara-C.
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Cells were plated out on Cellstar dishes (Greiner), which have built in rings designed to
hold four 10mm diameter glass coverslips These protected the cells from detachment or
damage during re-feeding. The rings were coated with Poly-D-Lysine two days before
pre-preparation, and left in the incubator at 37°C until one hour pre-preparation, at
which time any excess poly-D-lysine was leinoved and the rings were coated with
laminin (200ml of 50pg/ml frozen stock, thawed at 4°C and made up to one ml with
EBSS). At the time of plating the excess laminin was removed and cells were plated
directly into the rings. Mouse cerebellar granule cells from the C57/B6J background
will not grow on glass. CellStar wells with the required number of cells were placed in
the incubator for 30 minutes, then flooded with culture media. The medium was then
changed at 24 hours and again at six days with culture media containing 10pM Ara-C.
The table below details the dissociation solution as detailed by (Van Vliet et al. 1989,




MgS04 (from 1.5mM stock) lml (15nM)
PBS tablet (contents as detailed above) 1 unit
EDTA 26mg (0.685mM)
Autoclaved milliQ water 100ml
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2.1.2. Withdrawal of serum and potassium from cerebellar granule cell cultures.
I used a low serum and potassium challenge to test phenotype in vitro. It is possible to
induce neurite degeneration by removing serum and potassium from the culture media.
At 7 days in culture, the neurons were re-fed with medium containing a normal
potassium concentration (5mM) and no serum to initiate neuronal degeneration, as
previously described (Gallo et al. 1987). It is of interest to note that to begin with, the
cells are cultured in media containing 25mM potassium which is a non-physiological
concentration. The cells then become dependent on this level of potassium, and upon
returning the cells to physiological concentrations (5mM) wild-type cultures begin to
degenerate. The table below shows the contents of the culture medium (Buckmaster
media) and the media used as a challenge to the cells (low serum and potassium).
Reagent Buckmaster media Low serum and potassium media
DMEM 250ml 30ml
Insulin^Omgmr1 stock) 50|B (1.8/xM) 6|il (1.8/jM)
Pen/Strep 2.5ml (0.1%) 0.3ml (0.1%)
L-Glutamine 0.7g (19mM) 0.08g (19mM)
Glucose 1.3513g (30mM) 0.1622g (30mM)
FCS 25ml (10%) 0.75ml (2%)
KC1 (1M stock) 6.675ml (25mM) 0.15ml (5mM)
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2.1.3. Quantification of the Neurite degeneration in Cerebellar granule cell cultures
Following serum/potassium withdrawal, one wild type and one Wlds culture dish per day
were fixed in 4% paraformaldehyde with 4% sucrose, stored in PBS and imaged on an a
Nikon microscope with Hoffman optics. Up to 20 random pictures were taken per dish
at 40 X magnification. Total neurite length was assessed by measuring the length of
every neurite in the visual field using an image processing and analysis software
package, Scion image (www.scioncorp.com). Neurite lengths were summed to reach a
total neurite length for each image (Buttner et al. 2002). Mean neurite length was then
calculated for each experiment.
2.1.4, HEK 293 Cells
HEK cells were cultured in DMEM supplemented with 10% FBS and 1%
penicillin/streptomycin (Invitrogen) at 37°C in 5% C02. Cultures were split every 3-4
days.
Transfection of HEK293 cells was done using the calcium phosphate method (see
below) one day post split. Wlds-eGFP construct was used at 5|ag per well. Cells were
incubated at 2.5% CO2 for 4 hours. The cells were then washed twice with fresh filtered
PBS, and then returned to fresh media and incubated at 5% C02 until required. Control
cells were treated the same way as transfected cells.
When experiments required the incubation of cells in various reagents, they were
incubated for 4 days in HEK293 media containing combinations of the following
reagents:
NAD (Sigma, product number N-1511) at ImM.
Sirtinol (Calbiochem, product number 566320) at 100p,M made up in DMSO.
Vincristine (Sigma, product number V-8879) at 0.5pM.
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Control cells were incubated for the same period of time in HEK293 media containing
the same volume of the vector used in the experimental sample (i.e. DMSO).
2.2.0. Sectioning
2.2.1. Vibratome Sectioning
High magnesium ACSF (artificial cerebrospinal fluid) was prepared and cooled in
freezer to the point of becoming slush. Animals were sacrificed by decapitation
according to Home Office rules and regulations (Project license 60/3277). The brain was
removed and dropped into the cold oxygenated high Mg2+ ACSF to maintain the
integrity of the brain and increase firmness for cutting. Brains were mounted by
supergluing a block of agar (21ong x ldeep x lhigh cm) onto the cutting dish to provide
a firm flat surface into which the blade would slice. The brain was then mounted for
slicing (saggital/coronal) by gluing to the cutting surface and resting against the agar
block. The cutting chamber was filled with cold oxygenated high Mg2+ ACSF and sliced
are cut to desired thickness (100-150pm). Slices were cut using a Vibratome 1000 plus
sectioning system. Cut slices were removed with a large ended pasture pipette and
dropped into fixative (4% paraformaldehyde& 4% sucrose). Slices were then removed





NaCl 125mM 58.4 (molecular weight) 7.3g
NaHC03 26mM 84 (molecular weight) 2-lg
Glucose 25mM 180.2 (molecular weight) 4.5g
KC1 2.5mM 74.6 (molecular weight) 0.186g
NaH2P04(.2H20) 1.25mM 119.98 (molecular weight) 0.150g
CaCl2 ImM 1M Solution lml
MgCl2 4mM 1M Solution 4ml
2.2.2. Cryostat
Tissue was mounted on a rotatable chuck on OCT (optimal cutting temperature) gel in
the cryostat at an ambient temperature of -16°C. OCT was allowed to solidify for at least
5 minutes. The tissue was mounted and sections were cut utilising the anti-roll plate at
lO/im thickness. Cut sections were then collected onto poly-l-lysine coated slides and
stored at -20°C until used.
2.3.0. Immunocvtochemistrv
Appropriate controls were always carried out for every immunocytochemical
experiment. For example, wild type samples were always processed alongside
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experimental samples (data not shown unless otherwise stated), and secondary antibody
controls were always undertaken.
2.3.1. Fluorescent Immunocytochemical staining
2.3.1.1. Fixation
Tissue was washed with oxygenated PBS (phosphate buffered saline) and fixed with 4%
paraformaldehyde (containing 4% sucrose) for up to 60 minutes. The cells were then
washed with PBS for 30 minutes, then again with PBS containing 0.1M glycine for 30
minutes. The final wash was PBS for 30 minutes. Tissue was permeabilised and
antigenic recognition sites were masked with blocker (PBS, 4% BSA, 0.5% Triton X
[Sigma]) overnight, on a rotating tantibodyle top in the cold room.
2.3.1.2. Primary antibodies
Primary antibodies were made up in blocker and applied overnight on a rotating table
top at 4°C.
Staining for the protein product of the Wlct gene was accomplished using a primary
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antibody we refer to as Wld , which was raised in a rabbit and very kindly supplied to
us by Dr M.P.Coleman. The antibody binds to 18 amino acids of Nmnatl which are not
normally expressed in the wild type animal, but which are expressed in the Wlds mice.
The primary antibody was used at dilutions ranging from 1 in 4000 to 1 in 2000.
Staining for astrocytes in culture was achieved using GFAP (Chemicon). The primary
antibody was raised in mice and was used at a dilution of 1 in 20.
Staining for ubiquitin was carried out using FK2 (Santa Cruz) mouse primary antibody
at a concentration of 1 in 200 which was used to stain monoubiquitinated proteins, a
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Ubiquitin (Sigma) rabbit primary antibody which is specific for polyubiquitinated
proteins.
Staining for neurofilament was carried out using NF2H3 (Developmental Studies
Hybridoma Bank, University of Ioah) mouse antibody which recognises the 165KDa
form, normally at a dilution of 1 in 200.
2.3.1.3. Secondary antibodies
After primary antibody incubation, the cells were typically washed for up to six hours in
blocker before the addition of the secondary antibodies. The secondary antibodies
FITC/TRITC anti-mouse/rabbit (Dako) were typically made up in blocker, but
sometimes in PBS.
Secondary antibodies were used at a dilution of between 1 in 40 and 1 in 20, and left
overnight on a rotating table top 4°C. The samples must be kept away from light as
fluorescent secondary antibodies photo-bleach.
2.3.1.4. Mounting
After overnight incubation with secondary antibodies cells were washed for at least six
hours in a combination of blocker and PBS. CellStar culture dish wells were filled with
MoOil, and 13mm diameter glass coverslips are placed over the top of the wells. The
dishes were then left overnight to set. When mounting slices on slides a single drop of




T0PR03 is a distinct one step nuclear stain which may be added to cells during their
final wash with PBS before mounting. It was typically used at a dilution of 1 in 1000
and left on the sample for 5 minutes before washing again with PBS and mounting.
However, T0PR03 photo-bleaches much faster than the secondary antibodies. It emits
in the far red (excitation 644nm & emission 657nm), and as I typically used a red label
for the Wlds protein, confocal images shown with T0PR03 were typically
pseudocoloured blue.
2,3.2. DAB immunocvtochemistrv
If necessary (for example following paraffin embedding) tissue was rehydrated as
follows, 60°C for 30 minutes, Xylene for 10 minutes, 100% alchol for 10 minutes and
then 5 minutes. Endogenous peroxidase was blocked by incubating in 0.5% H2O2 in
methanol for 30 minutes. Tissue was then washed in running tap water for 10 minutes,
washed with PBS and then blocked with blocking solution for 1 hour (PBS with 3% fish
1 o
skin gelatine [or 1ml goat serum and 0.5ml BSA] and 0.5% Triton-X). Wld antibody
was used at a dilution of 1:500 overnight in blocker. Following this tissue was washed in
PBS twice for 10 minutes, then incubated in secondary antibody (biatinylated anti-
rabbit) 1:100 in PBS for 1 hour. The tissue was washed with PBS twice for 10 minutes.
And then the Vectastain elite kit was used as per manufacturers instructions (solution
made 30 minutes prior to use). Tissue was washed twice with PBS for 10 minutes. The
DAB was prepared and applied for 2 to 5 minutes then washed in running tap water and
Haematoxylin stained (10 to 15 seconds) followed by another wash in tap water. Acid
alcohol was used for 10 seconds and tissue washed in Scots tapwater substitute for 10
minutes followed by a final wash with water. If desired tissue could then be dehydrate as
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follows: 70% 2 minutes, 90% 2 minutes, 100% 2x5 minutes, xylene 10 minutes.
Finally, tissue was mounted in DPX.
2.4.0. Microscopy
2.4.1. Confocal microscopy
Immunostained preparations were viewed using a Radiance 2000 confocal microscope
(Biorad) via a Nikon Eclipse E600 microscope equipped with a 60x Oil immersion
objective. Images were captured using Lasersharp 2000 software running on a Dell
Poweredge 1400 computer. Tiff files were exported into Adobe Photoshop and/or Scion
Image for assessment/analysis.
Wlds protein mapping values in chapter 4 were obtained by confocal microscopy as
detailed above at 2x zoom and with a step size of 0.3/xm. Images were captured to
include 2 cell layers in the desired area. For example, cerebellar granule cell layer
images were 25/xm thick and a 3D rotation was compiled and incomplete cells were
excluded from the TOPR03/Wlds percentage count. Averages were calculated from
multiple images per brain (N=4).
2.4.2. Transmission Microscopy
Images were captured on an inverted Nikon microscope with Hoffman modulation
contrast optics. Images were captured with a chilled 3CCD camera (Hamamatsu





2.5.1.1. High efficiency transformation using calcium phosphate-DNA precipitate
formed in BES
A transfection solution was made up of 12.5pl CaCl2, 5|ig DNA (mini prep, is clean
enough), made up to 125pl with water. 125 pi BES solution (2.5M CaCD, TE buffer
pH7.4, 2 x N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES) buffered
solution and filtered PBS) was added and mixed by pippetting briefly and added
dropwise immediately to cerebellar granule cells, or a precipitate was allowed to form
for 5 minutes before adding to HEK 293 cells dropwise.
The cells were incubated at 2.5% CO2 for 1 hour (cerebellar granule cells) or 4 hours
(HEK 293 cells), washed twice with PBS and the media replaced and the cells incubated
again at 5% CO2. Transfection had no overt effect on the survival or morphology of
either the transfected or non-transfected sub-population of HEK293 cells.
2.5.1.2. Nucleofector kit.
Efficient gene delivery into primary culture is difficult to achieve. Viral transfer is
probably the most effective way of getting a high transfection rate. Construction of viral
vectors is often time consuming and limits the size of DNA to be inserted. Viral
infections can also interfere with the host cells metabolic processes such as hijacking the
cells protein synthesis machinery. Other methods of transfection also include calcium
phosphate, cationc lipids, micro injection or ballistics (i.e. gene gun). These methods can
often be toxic to neurones and are unlikely to give a rate of greater than 20% (Berry et
al. 2001). However, these methods are not as efficient or simple as the Nucleofector kit.
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This kit works around the principal of electroporation, but utilises a "super secret
expensive special" solution.
Cells were transfected using the commercially available Rat Neuron Nucleofector kit
according to manufacturer's instructions (Amaxa Biosystems). Briefly, a maximum of 6
million cerebellar granule cells (counted by haemocytometer) were centrifuged at
900rpm for five minutes. They were then resuspended in IOOjllI of Nucleofector solution
for primary neurones, and mixed with a maximum of 3)Ug of construct before transfer to
cuvettes provided (Dityateva et al. 2003). The cuvettes were then placed within the
Nucleofector electroporator and treated using programme G-014. 500|ul of media was
added to cells and they were then plated out onto poly-D-lysine (Sigma) coated
coverslips in a multiwell plate using the disposable pipettes provided. Cells were then
placed in an incubator for one hour thirty minutes before flooding each well with media.
Media was then changed one and six days later.
2.5.3. Extraction of genomic DNA
Tail biopsies or ear punches were taken from mice of ages P4 to adult. Genomic DNA
was extracted using a modified proteinase K digestion/isopropanol precipitation protocol
(Laird et al. 1991). Tissue was incubated in tail lysis buffer (lOOmM Tris-HCl, pH 8.5,
5mM EDTA, 0.2% SDS, 200mM NaCl, 100/xg/ml Proteinase K). Samples were
incubated overnight at 55°C. Lysed tissue was vortexed for 1 minute and spun at 15800
g for 10 minutes to remove hair and bone. The supernatant was decanted into a new tube
and isopropanol was added (equal volume to the tail lysis buffer used earlier). The
solutions were inverted until a white precipitate can be seen. The solution was
centrifuged and the pelleted DNA is washed with 70% ethanol and air dried before it
was resuspended in an appropriate volume of 1 x TE buffer.
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2.5.4. Extraction of RNA
RNA extraction was carried out using tri-reagent (Sigma) as per manufacturers
instructions. Tissue was rapidly plunged into liquid nitrogen for 1 minute, then placed in
lml of tri-reagent (Sigma) on dry ice. Tissue was homogenised in tri-reagent and left for
15 minutes on ice. 0.2ml CHCI3 was added and left to stand for 10 minutes at room
temperature before centrifuging for 15 minutes at 13000rpm at 4°C. The aqueous layer
was removed and 0.5ml of isopropanol was added before re-centrifugation for 15
minutes at 13000rpm at 4°C. The RNA pellet was washed with 200/ds of 70% ethanol
before re-centrifugation for 5 minutes at 13000rpm at 4°C. Pellets were re-suspended in
DEPC-treated water and stored at -80°C. Quality was checked by assaying levels using a
spectrophotometer and running on a gel to check integrity.
2.5.5. Microarrays
Total RNA was prepared from the cerebellum for microarray analysis (initially by Dr
P.Chen, and subsequently by me) as follows.
RNA quality was initially assessed using formaldehyde gels and by measurement of
absorbance at 260/280nm following standard procedures (by me). A further assessment of
RNA quality was then undertaken using an Agilent Bioanalyser (Agilent Technologies,
GmBH, by K.Robertson). Samples (lOjtxg) were labelled, hybridised to Affymetrix MOE-
430A GeneChip arrays and scanned according to standard Affymetrix protocols
(K.Robertson). All analyses were undertaken in Affymetrix Microarray Suite 5.1 software
as follows: arrays were scaled (normalised) to an overall target intensity of 100 prior to
comparison and notable differences in gene expression were identified by pair-wise
comparison of appropriate samples. Differentially expressed genes were annotated using
the Affymetrix online analysis resource 'NetAffx' (www.affymetrix.com/analysis).
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2.5.6. Reverse-transcriptase (RT) and real time-RT (ORT) PCR
Reverse transcriptase PCR (RT-PCR) was carried out in 'ready-to-go' RT-PCR tubes
(Amersham Biosciences) using a T-Personal PCR machine (Biometra). Beta-tubulin was
used as a loading control for all RT-PCR experiments. Quantitative real-time PCR
(QRT-PCR) was carried out using a Sybr-Green '1 step QRT-PCR kit' (Invitrogen) on a
Model 7700 instrument (Applied Biosystems). For all QRT-PCR experiments, actin was
used as a control gene. Where possible, primers were designed to span an intron
eliminating the possibility of any genomic DNA contamination. For all genes, PCR
bands were removed from gels and the product extracted using a Q-gel extraction kit
(Qiagen). The bands were sequenced to confirm product identity. We were unable to
obtain human Dap3 primers that worked well enough to quantify transcriptional changes
in HEK293 cells, thus Dap3 analysis was not included in any transfection or NAD
experiments. Primers used, and the full names for all genes, are shown below.
Conventional RT-PCR products were analysed in a 2% agarose gel containing ethidium
bromide in 1 x TAE buffer run at 120mV for 40 minutes. The primer sequences are
listed below.
Microarray validation RT and QRT primer list














































2.5.7. Quantitative real time-PCR on genomic DNA for genotvping Wlct mice
The primers and probes (TaqMan Probes) were designed using Primer Express software
as described in the ABI Primer Express Eiser Bulletin (P/N 4317594). Wlds primers were
based on Genbank entry AF260927 and recognise a region of exon 1. The Wlds probe
was tagged with a FAM flurophore and a TAMRA quencher producing a 75bp
amplicon. Tubulin primers were based on Genbank entry M28739. The probe was
tagged with a VIC flurophore and a TAMRA quencher producing an 81bp amplicon.
The sequences used are detailed below.









The optimal primer concentrations used were 900nM and the optimal probe
concentrations were found to be 250nM. The PCR mix was made up to manufacturer's
instructions. DNA was used at a concentration of 1:200 dilution of the original sample.
The machine used was an ABI Prism 7000 sequence detection system. Standard PCR
cycles were used as designated in the ABI user guide.
2,5.8. Assaying DNA concentration
There are 2 main ways of assaying DNA concentration, a crude method and a more
accurate method.
The crude method: A 1 in 200 dilution of the resuspended DNA in ddEbO was made.
Using a quartz cuvette and a spectrophotometer the absorbance of this dilution at 260
and 280nm was measured. The value obtained for the absorbance at 260nm, multiplied
by 10 gave the concentration of DNA in the undiluted sample in jLig/ptl. The ratio given
on dividing the absorbance at 260nm by the absorbance at 280nm gave an indication of
the possible level of contamination of the sample with RNA.
The more accurate method: As a cheaper alternative to Pico Green, DNA was assayed
accurately using Hoechst 33258, excited at 365nm, emission at 460nm. Standards were
made up using 20 pi of a lmg/ml stock calf thymus DNA diluted in lOOOpl of TE buffer
giving a solution of 20pg/ml. This solution was then be serially diluted 1:1 with TE
buffer giving concentrations of 20, 10, 5, 2.5, 1.25, 0.625 & 0.312 pg/ml. TE buffer was
used for a reference solution. Typically 2pl of sample containing 20 - lOOOOng DNA
was added to TE for dilutions in a flurometer. Standard cuvette assay is linear from lOng
to over 5000ng/ml DNA. The non-specific fluorescence should be less than 1% of the
fluorescence that can be attributed to the DNA-dye complex. The Hoechst 33258 dye
was dissolved at 2pg/ml per sample. (Teare, J.M. et al. 1997)
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2.5.9. Assaying RNA concentration
A 1 in 250 dilution of the resuspended RNA in DEPC treated H2O was made. Using a
quartz cuvette and a spectrophotometer the absorbance of this dilution at 260 and 280nm
was made. The value obtained for the absorbance at 260nm, multiplied by 10 gave the
concentration of RNA in the undiluted sample in pg/p.1. The ratio given on dividing the
absorbance at 260nm by the absorbance at 280nm gave an indication of the possible
level of contaminants in the sample.
2.5.10. RNA gel electrophoresis
A 60ml 0.8% agarose SeaKem GTG (Flowgen) RNA denaturing gel was made with the
following components:
Component Volume
5 x MOPS (0.1M MOPS-BDH-Merck, pH 7.0, 40mM NaAc, 5mM EDTA,
pH 8.0) buffer 12ml
40% formaldehyde (Gibco) 11ml
0.48g agarose SeaKem GTG (Flowgen) DEPC-water 37ml
The agarose was dissolved in water before the 5 x MOPS buffer and the formaldehyde
was added. RNA samples were loaded in the following way. Sample buffer (for each
1.0/xl RNA) was composed of 1.5/rl 5 x MOPS buffer, 2.6/xl formaldehyde and 7.5/xl
formamide. Loading buffer contained 2.0jiil Ficoll loading buffer and 0.5/xl lmg/ml
ethidium bromide. Both buffers and RNA sample were heated to 65°C for 2 minutes
before 11/jlI sample buffer and 2.5/d loading buffer was mixed with the RNA sample.
The mixture was loaded onto the gel immediately. The gel was run at a speed of 15/V in
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1 x MOPS buffer for 1 hour. A 4/jlI sample of RNA marker (1 yu.g//xl Promega) was run
with the sample to identify the molecular size of the RNA sample.
2.5.11. Western blot
Western blots were performed as described previously (Mack et al., 2001). Briefly,
tissue or cells were extracted and homogenised. Protein was homogenized using a fine
bore syringe and the solublised protein extracted in RIPA buffer with 10 % protease
inhibitor cocktail (Sigma) through centrifugation at greater than 10 OOOg. Protein
concentration was determined through the use of a MicroBCA assay kit (Pierce
Biosciences) as per manufacturers instructions. Protein was separated by
SDS/Polyacrylamide gel electrophoresis on a 4 - 20% pre-cast gradient gel (Invitrogen)
and then transferred to PVDF membrane overnight at 25 volts in CAPS buffer (pH
11.5). After blocking with 10% milk the membrane was incubated in the presence of
either Wld-18 (1:2000 dilution) primary antibody and/or VAP-A primary antibody
(rabbit 1:4000 dilution; gift from Dr P.Skehel, University of Edinburgh) for 1 hour. The
PVDF membrane was further processed using horseradish peroxidase conjugated
secondary antibody and a chemiluminescence system (Amersham) and exposed to film.
2.5.12. Southern Blotting and radiolabeled probe hybridization
DNA for Wlct genotyping was extracted from spleen and digested for 3 to 4 hours at
37°C and then run in 0.6% agarose TBE gel at 1.75V/cm overnight. Gels were then
denatured (1.5M NaCl, 0.5M NaOH) for up to two hours for genomic DNA and then
neutralized (1.5M NaCl, 0.5M Tris-HCL pH 7.2, ImM EDTA) for 30 minutes with
gentle shaking. Gels were rinsed in MilliQ-water to remove excess neutralization
solution. Genomic blots were transferred overnight via capillary transfer in 10 x SSPE
(20 x SSPE stock- 3M NaCl, 200mM Na2PO4*H20, 20mM EDTA, pH 7.4). After
blotting, nylon membranes (Hybond-N, Amersham Pharmacia Biotech) were
crosslinked in a Stratalinker® UV crosslinker 2400 (exposure = 120000 /xJ) (Stratagene)
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and then prehybridised (10ml 2 x hybridization solution-(12 x SSPE, 10 x Denhardt's
reagent and lOOjirg/ml yeart tRNA), 10ml formamide and 1ml 10% SDS) for overnight
at 42°C. Additionally 150/tl lOmg/ml fragmented single-stranded salmon sperm DNA
(Sigma) was added to further reduce non-specific binding. DNA fragments used for
probe making were digested with restriction enzymes and run at 2V/cm in a low-melting
point 0.7% agarose gel. The appropriate fragment was excised and water was added
according to the ratio 3ml of water to lg gel slice (under the guidance of Dr
M.Coleman). Radioactive probes were generated using the Primer-It© labeling kit
(Stratagene) and incorporated the radioisotope (a-32P)-dATP (Specific activity:3000
Ci/mmol) (Amersham Pharmacia Biotech). Probes were hybridized to membranes (in a
smaller volume of prehybridisation solution, by Dr M.Coleman) overnight at 42°C and
these were washed the next day in 5 x SSPE, 0.1% SDS for 30 minutes at 65°C and
twice in 0.3 x SSPE, 0.1% SDS for 10 minutes at 65°C. Blots were exposed overnight to
X-ray film (X-OMAT/AR, Kodak) at -80°C.
2.6.0. General Cloning
2.6.1. Bacterial strains
For transformations the DH5a E.coli strain from Invitrogen was used with the following
genotype:
supEAA Alac U169 (cp80/acZAM15) hsdR.ll recAl endAl gyrA96 thi-1 re 1A1
2.6.2. Restriction Enzymes
All restriction enzymes were obtained from either Boehringer Mannheim or New
England Biolabs. Enzymes were used with buffers provided according to the
manufacturers instructions.
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2.6.3. Bacterial medium and preparation of electrocompetent cells
TB (Terrific Broth) medium - 11.8g SELECT peptone 140, 23.6g Yeast extract, 9.4g
Dipotassium hydrogen sulphate, 2.2g Potassium dihydrogen phosphate (Gibco, 47g/L).
LB (Lennox Broth) medium - lOg bactotryptone, 5g bactoyeast extract, 5g NaCl
(Sigma, 25g/L).
LB Agar - (Gibco, 32g/L).
All transformations were carried out using frozen stocks, which were prepared according
to the technique described by Dower et al 1998. Bacteria were streaked (from a glycerol
stock kept at -80°C) on an LB-agar plate and incubated overnight at 37°C. This was used
to start a large scale culture using 500ml LB-medium. Cells were grown up until the
density reached OD600 = 0.5-1.0. Cells were then centrifuged at +4°C for 15 minutes at
4000g and the medium removed. The pellet was resuspended carefully in 500ml ice-cold
Milli-Q water and centrifuged again at 4000g. This process was repeated twice, again in
ice cold Milli-Q water and then in 20ml 10% glycerol. Linally the cell pellet was
resuspended in 10% glycerol in a 1:1 (cells: 10% glycerol) ratio. The cells were aliquoted
and stored at -80°C. Electrocompetence was tested by transforming lOpg SKII-Bluscript
circular vector (Stratagene), using the protocol described later. Cells usually gave 1-2 x
10 colonies on an LB agar plate supplemented with 200jtig/ml ampicillin.
2.6.4. Digestion reactions
A typical analytical digestion reaction was made of the following components:
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Component Volume
1 Ox restriction enzyme buffer 1.0/xl
Mini/maxi-prep DNA 1.0/xl (approx. 0.5/xg)
(lOx Bovine Serum Albumin) 1.0/xl if required
Restriction enzyme 0.5/xl (approx 5U)
(2nd restriction enzyme) 0.5/xl if required
Milli-Q water made up to 10/xl final volume
Preperative digestion reactions of DNA contained lx restriction enzyme buffer
backbone/insert, 0.5/xl restriction enzyme at a concentration of 5U//xl
NewEnglandBiolabs/BoehringerMannheim) and Milli-Q water (Millipore) making a
final volume of 10/xl. Reactions were carried out usually at 37°C for 1 hour unless
otherwise stated. For preparative digests, fragments were separated by gel
electrophoresis in a 0.8% SeaKem GTG agarose (Flowgen) gel made in lx TAE buffer
(40mM Tris-acetate, ImM EDTA (pH8.0)). This was carried out in an electrophoresis
tank (Flowgen) filled with lx TAE buffer. Voltage was provided by a Power pac 300
power supply (Biorad) at a speed of 2.5-5V/cm. To estimate the size of the DNA bands
1.0/xg ^-bacteriophage (Pharmcia Biotech) digested with Sty I, was added in an adjacent
well. To visualise the DNA under UV Light (wavelength 302nm) 3/xl lOmg/ml
ethidium bromide was added to 100ml liquid agarose. The DNA band of appropriate
size was excised from the gel and extracted using the Qiagen gel extraction kit (Qiagen)
according to manufacturers instructions. The isolated DNA fragment was then
resuspended in 20/xl lx TE buffer for ligation reactions.
(NewEnglandBiolabs/BoehringerMannheim), 1-5/xl mini/maxi-prep DNA
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For analytical digestions, DNA was analysed by gel electrophoresis in a 0.8% SeaKem
LE agarose gel (Flowgen) made in lx TAE buffer. 10% Ficoll loading buffer was added
to all DNA reactions prior to loading (15% Ficoll, 0.25% Xylencyanol FF, 0.25%
Bromophenol blue dissolved in water).
2.6.5. Constructs
cDNA sequence encoding full-length Wld protein, Nmnat-1 or Ube4b amino acids 1-70
(N70) was PCR amplified from the Wlds transgene template (Mack et al., 2001) using
the high fidelity enzyme Pfii (Stratagene) and appropriate combinations of the following
primers (1+2, 4+2 and 1+3 respectively) . 5' restriction enzyme tags, added for cloning
purposes, are shown in bold and the first or last three bases of sequence derived from the
Wlds gene are underlined. A single base change to repress the stop codon of Wlds Rev
and allow read through of the C-terminal EGFP is double underlined. The restriction
o
enzymes required to make the full-length Wld , Nmnat-1 or Ube4b amino acids 1-70
(N70) fragments were:
Fragment Enzymes
Full-length Wlds Hindlll and BamHI
Nmnat-1 Nhel and BamHl
Ube4b amino acids 1-70 (N70) Hindlll and Sacll










Fragments were the ligated into the pEGFPNl vector from Clontech.
2.6.6. Ligation reactions
Ligation reactions contained lx T4 ligase buffer (Boehringer Mannheim), the
appropriate concentrations of backbone/insert DNA for efficient ligation, 0.5jul T4 ligase
(5U//xl) (Boehringer Mannheim) and Milli-Q water to make the final volume up to 10/xl.
Reactions were left overnight at 14°C.
2.6.7. Electroporesis of bacteria
l-2[i\ of a ligation reaction was added to a 1mm gap BTX disposable electroporation
cuvette on ice (BTX inc.) 40/xl of electrocompotent DH5a E.coli was added to the
cuvette and mixed on ice. Bacteria was transformed in a BTX electro-cell manipulator®-
600 with a resistance of 1290hms and a voltage of 1.6kV. Immediately after, 600/xl of
pre-warmed SOC medium (2.0% w/v bacto-tryptone, 0.5% w/v bacto-yeast extract,
8.5mM NaCl, 0.25mM KC1, lOmM MgCB, 20mM glucose) was added to the cuvette
and the cells allowed to recover for 15-20 minutes at 37°C in a shaking incubator
(250rpm). Cells were then spread on LB-agar plates supplemented with 50jUg/ml
Kanamycin (Sigma) unless otherwise stated.
2.6.8. Small scale preparation of plasmid DNA from bacterial cultures (Mini-prep)
Single well isolated antibiotic resistant colonies appeared after 12-16 hours incubation at
37°C Individual colonies were picked with a sterile toothpick and grown as a small scale
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culture at 37°C and shaken at 250rpm. Cells from overnight small scale cultures (3ml)
were centrifuged (8000g) in a benchtop centrifuge-5415C (Eppendorf) and the medium
aspirated. The pelleted bacteria were the used for plasmid extraction. Small scale mini-
preparations of plasmid DNA was carried out using Qiagen Mini-prep kits as per
manufacturers instructions.
2.6.9. Large scale preparation of plasmid DNA from bacterial cultures (Maxi prep)
The protocol for a Maxi-prep (Qiagen) is the same as that for the Mini-prep except that
the small scale culture is then used to start a large scale culture (50ml) before
centrifuging at 4000g for 15 minutes. This pellet was then used to extract plasmid DNA
with a Maxi-prep kit (Qiagen) as per manufacturers instructions.
2.6.10. Conformation of positive clones
Clones were confirmed by analytical restriction enzyme digests and automated dye
sequencing (Dye-Deoxy-Terminator Cycle sequencing kit). PCR reactions were carried
out and the product was sent to SBS Sequencing Service (Ashworth Laboratories,
University of Edinburgh). Returned sequences were checked using the programme
Sequencher 4.2 (demo version) for the PC. Clones were sequenced along the entire
length of the PCR segment inserted into the DNA construct. Sequencing was carried out
in both sense and anti-sense directions.
The primers used for sequencing Nmnatl were:





The primers used for sequencing N70-Ube4b were:









The neuroprotective effects of the Wlds gene have been shown to be gene-dose
dependent. That is, the greater the amount of Wlds protein expressed, the greater the
level of axonal and synaptic protection conferred after nerve injury (Mack et al., 2001;
Gillingwater et al., 2002). Moreover, the Wldt mouse has been cross-bred with several
mouse models of neurodegenerative diseases, and shown to mitigate the onset and
progression of disease in these models, including the P0 demylinating neuropathy
(Samsam, M. et al. 2003.), and the PMN model of motor neurone disease (Ferri, A. et al.
2003). In addition, Wld" mutant and transgenic mice have been crossbred with lines
expressing neuronal markers such as derivatives of Green Fluorescent Protein (Feng et
al., 2000; Gillingwater et al., 2002; Beirowski et al., 2004). Since the extent of
protection in these models is also likely to be Wlds -gene dose-dependent, it is important
to have reliable methods for genotyping Wlds -expressing mice and/or determining the
c
extant Wld gene copy numbers.
c
The Wld mutation is a triplication of a region already present in the wild-type animal
(see General Introduction), therefore the only quantifiable measures of the number of
£
mutant Wld' alleles are: 1. by the strength of the neuroprotective phenotype. 2. Copy
number of the mutation. The principal disadvantages of the first are ethical and
temporal: an invasive procedure (nerve injury or biopsy) is required to test for strength
of neuroprotection over a period of several days. Thus, the second is more appealing.
Initially, attempts to PCR across the chimeric boundary were unsuccessful because of
the very high GC content at that point in the sequence. Conventional PCR of any other
intron-exon boundary in the triplicated region is insufficient to distinguish the different
genotypes (figure 3.2). Some success was found through the use of Southern blots in
identifying homozygous animals from heterozygous animals as it can be used to some
extent to distinguish the genotype by band strength. However, Southern blotting is not
recommended for genotyping animals where important experiments are to be carried
out, as the results can be affected by inefficient digestions, blotting efficiency, time and
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other factors that affect the quantifiable intensity of blots and their signal-noise ratio.
The most accurate published method for genotyping Wlds - expressing mice to date, has
been the method reported by Mi et al (2002) based on Pulse Field Gel Electrophoresis
(PFGE). The PFGE method is based on fragment size rather than band intensity.
The current methods for assaying Wlds DNA include; 1. conventional PCR, 2. southern
blots and 3. pulse field gel electrophoresis. By contrast, the use of quantitative real time
PCR (QRT-PCR) to assay DNA has been relatively neglected. In this Chapter, I report
the development of a more rapid and efficient alternative to PFGE as a method for
c
genotyping the Wld mutation. This method is based on QRT- PCR using genomic DNA.
3.1.1 Quantitative real time PCR
Quantitative reverse transcriptase (QRT) PCR was developed to fill a niche in
quantifying differences in mRNA expression. Possible methods used to analyse RNA
levels include; 1. Northern blots; 2. ribonuclease protection assays. Both of these
methods require significant amounts of RNA, frequently more than may be available.
They do not use amplification steps; they are only semi-quantitative; and they can be
very time consuming. 3. ln-situ hybridisation. This method is also more qualitative than
quantitative and can also be very time consuming to perform. 4. Conventional reverse
transcriptase (RT) PCR.
Conventional PCR and RT-PCR can be misleading with respect to actual differences in
DNA/RNA levels compared to a standard due to cycle number used i.e. it is difficult to
visualise in the linear phase (i.e. the phase of the reaction where the amount of PCR
product doubles, in theory, with every cycle) because of the amplification process and
inefficient incorporation of ethidium bromide into the product. Conventional PCR
should therefore only be used to gauge direction of change. By contrast, quantitative
(Q)-PCR requires very small amounts of RNA and after some calibration experiments
can be very quick and easy to use. The two methods of assessing the level of amplicon
being produced in real-time reactions are SYBR green and TaqMan.
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3.1.2. SYBR Green
SYBR Green becomes incorporated in new double stranded (ds) DNA, but not to single
stranded (ss) DNA. It can therefore be used to monitor the synthesis of new dsDNA in
real-time PCR reactions. Upon incorporation into dsDNA SYBR green fluoresces
brightly. The fluorescence is significantly better for visualising new DNA production
than ethidium bromide because of reduced background levels of fluorescence. The ratio
of the fluorescence produced when SYBR green is bound to dsDNA compared to
ssDNA is much higher than that of ethidium bromide.
3.1.3. TaqMan
The TaqMan system utilises a primer pair and a probe, which is located between the two
PCR primers and has a melting temperature 10°C higher than the primers. The binding
of the TaqMan probe to the region of interest before binding of primers is important
because without it, the PCR products would be produced without fluorescence and as a
result would not be detected. The TaqMan probe has two fluorescent tags attached to it.
One is a reporter dye, for example 6-carboxyfluorescein (FAM), which has its emission
spectra quenched because a second fluorescent dye or quencher, for example, 6-carboxy-
tetramethyl-rhodamine (TAMRA) is attached to the other end of the probe. The result of
this is that the probe is effectively silent in this state. TaqMan assays are therefore based
on the 5' exonuclease activity of the enzyme Taq DNA polymerase. This enzyme
cleaves the probe to release the reporter dye from the proximity and therefore, activity of
the quencher. The result is an increase in fluorescence which is proportional to the
amount of new PCR product formed.
3.1.4. Multiplex PCR
This utilises the ability of ABI TaqMan Sequence Detection System (SDS) to
distinguish between two different flurophores. It is therefore possible to use two separate
66
primer pairs, each interacting with its own probe linked to different reporter and
quencher dyes, to monitor two different reactions taking place in the same tube. The
implications of this kind of reaction are quite exciting. Given that the dual fluorescence
SDS is a more advanced version of a sequencer, it should be possible in the future to
detect the progress of up to four reactions taking place in the same tube. The logistics of
this would be quite complicated and the calibration required to set up such a reaction
would be no mean task, but it should be possible. However, the use of two flurophores is
enough for the present purpose. The implication is that it is possible to monitor an
internal control gene versus a gene of interest, for example /?-tubulin versus Wldt.
Because both reactions take place in the same tube and my interest was in calculating the
Wlcf copy number, it was not necessary to add exact amounts of template to the tube. It
was sufficient simply to add very dilute template and then calculate the ratio between /?-
tubulin versus Wlcf of product formed within that tube through the comparative C|
method. Because two independent reactions are monitored within the same tube, the
calibration steps must be performed first in individual reactions and then together. This
involves determining; 1. Abundance of reference and target genes. Through testing
primers as separate reactions it is possible to adjust the primer concentrations so that
accurate threshold cycles (Ct) are obtained for both species. By doing so it is possible to
stop the amplification of the majority species before it can limit the availability of the
common reactants to the minority species. 2. Optimal primer and probe concentrations,
which give the maximum ARn and the lowest ACt values. 3. Linear dynamic range, is the
range of initial template concentration that accurate Ct values can be gained. The lower
the amount of template required the more sensitive the assay becomes.
3.1.5. Selecting optimal amplicon sites
According to guidelines set out by ABI, primers can be designed as close as possible to
each other provided that they do not overlap. Generally, the smaller the amplicon the
more efficient the amplification. However, the smaller the amplicon the greater the risk
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of amplification of a homologous region. It is therefore important to keep the GC
content as low as possible, as increased CG will raise the melting temperature of the
primers. According to the primer express software (ABI) the Tm should be kept between
58-60°C, and the 5 nucleotides at the 3' end of the primer should have no more than 2
G/C bases (Primer Express User Bulletin, P/N 4317594).
DNA:
Optimal amplicon sites will allow the amplification of DNA without amplifying any
contaminating RNA sequences. This can be achieved by designing primers to span an
intron-exon boundary, thus allowing the amplification of the target DNA without
amplifying the target genes RNA product. If however there are no introns present in the
gene of interest then amplification of RNA cannot be ruled out without adding RNAse to
the extract.
RNA:
Optimal amplicon sites will allow the amplification of RNA without amplifying any
contaminating genomic DNA sequences pseudogenes or other related genes. This can be
achieved by designing primers to span one or more introns, thus allowing the
amplification of the target RNA without amplifying the target gene DNA sequence. If
however there are no introns present in the gene of interest then amplification of
genomic DNA cannot be ruled out and for this reason no reverse transciptase (no-RT)
controls should always be carried out.
3.1.6. Efficiency of amplification
One of the main problems when comparing the level of the gene of interest to an
"internal control" gene is the effect of primer efficiency. This can be explained by
saying that if the primer pairs are running at 100% efficiency, then after 1 cycle the
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amount of product present should be double the starting amount.. However if the primer
efficiency is only 90% then after 1 cycle there would be 1.9x the amount of product and
so on (80% = 1.8x, 70% = 1.7x etc). Thus, after 10 cycles this effect would be
magnified, i.e. if the primer efficiency is 100% after 10 cycles there will be 2.010x
product, 90% will give 1.910x product and so on (80% = 1.810x, 70% = 1.710x etc). So,
the effect of comparing two primer pairs that may have slightly different efficiencies can
be minimised by setting the threshold for measurement as low as possible where the
effects of this unequal amplification will not be so apparent.
Therefore, with each set of primers it is important to carry out several checks on the
primer efficiency. It is important to calculate the optimal primer concentrations required
the dynamic range of these primers and the limiting concentrations. Checks should
include; 1. melting curves, 2. the slopes of the curves are in parallel when viewed in the
log output graph, 3. there are 4 or 5 dilution points and 4. that the correlation coefficient
is greater than 0.90.
When intending to carry out duplex real time PCR i.e. TaqMan involving the use of a
probe, those primers must first be tested in separate tubes to allow the reactions to
proceed without interference from the other primer i.e. eliminating any competition for
reagents within the tube. The optimal primer and probe concentrations will be those that
give the highest ARn and the lowest ACt values. It is important that the primers can work
with a small amount of template because the reaction will give a more sensitive assay at
lower concentrations so a linear dynamic range test involving titrations of the template
to calculate the dynamic range of the primers.
3.1.7. Contamination
"The exquisite sensitivity of the polymerase chain reaction means DNA contamination
can ruin an entire experiment. Tidiness and adherence to a strict set of protocols can
avoid disaster" (Kwok et al. 1989). Potential contamination can be introduced by
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samples with high DNA concentrations, DNA template controls or PCR carryover
contamination (Peters et al. 2004). The need to analyse product through gels or
dissociation curve for non specific product formation is therefore high.
3.1.8. Miss-priming
One way of stopping the formation of non-specific product is through the use of Applied
Biosciences Ampli-tTaq Gold which is a chemically modified version of Taq DNA
polymerase. This modification renders the enzyme inactive until a certain temperature is
reached, therefore any mispriming which may have occurred will not be enzymatically
extended and amplified. The enzyme does not become active until 48°C, which is
especially important if carrying out 1 step QRT-PCR. This is because the production of
cDNA from RNA is carried out by a primary extension step at 42-45°C.
3.1.9. False positives
Non specific amplification including primer dimers can affect the amplification data, for
this reason dissociation curves should be checked. Primer dimers are likely to be most
prevalent in no template control wells and in wells with a very low template
concentration.
Single stranded contamination can lead to false positives, provided by the ability of the
PCR process to amplify single strands (Higuchi et al. 1989). This can be controlled for
through the incorporation of dUTP instead of dTTP into new product via the PCR mix
(SYBR). Subsequent treatment of PCR reactions with uracil-N-glycosylase (UNG) prior
to amplification will lead to the degradation of miss-primed, non-specific products that
may have been produced before specific amplifications. It will not however degrade the
native nucleic templates.
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Fluorescent contaminants can also lead to false positives, so it is wise to use no-
amplification control tubes (sample but no enzyme). Following the PCR reaction, if the
no-amplification tube has greater fluorescence than the no-template control tube there is
likely to be a fluorescent contaminant, either in the sample or in the heat block of the
cycler.
3.1.10. Relative quantitation of gene expression
Amplification of an endogenous control may be used to standardise the amount of
sample RNA or DNA added to a reaction. The two main methods for calculating RNA
levels are the standard curve method and the delta Ct (change in cycle number at set
threshold) method.
3.1.11. The delta CT method of relative gene quantitation
The amount of target when normalised to an endogenous reference and relative to a
calibration sample can be expressed as:
2-aacT
Derivation of the formula (ABI user bulletin number 2) through the equation that
describes the exponential amplification of a product through PCR is:
Xn= X0 x (1 + Ex)n
Where: Xn = number of target molecules at cycle n.
Xo= initial number of target molecules
Ex = efficiency of target amplification
n = number of cycles
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Threshold cycle (Cy) indicates the cycle number at which the amount of amplified target
reaches a fixed threshold:
XT= Xo x (1 + Ex)Ct'X = Kx
Where : Xt = threshold number of target molecules
Ct,x = threshold cycle for target amplification
Kx = constant
A similar equation for the endogenous reference reaction is:
«
Rt= Ro x (1 + Er)Ct r = Kr
Where: Rj = threshold number of reference molecules
Ro = initial number of reference molecules
Er = efficiency of reference amplification
Ct,r= threshold cycle for reference amplification
Kr = constant
Dividing Xt by Rt gives the following expression:
XTtRt= [Xo x (1 + Ex)Ct'x ] -r [R0 x (1 + Er)Ct'r ] = Kx- Kr = K
The exact values of Xt by Rt depend on a variety of factors including; 1. the reporter
dye used, 2. the effects of the amplified sequence on the fluorescent properties of the
reporter, 3. the efficiency of reporter incorporation (SYBR green) or cleavage of the
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probe (Taq Man), and 4. the purity of the reporter/probe and the setting of the
fluorescence threshold. For these reasons the constant K does not necessarily need to be
equal to one. However, if we assume that the efficiencies of the target and reference
amplification are the same:
Ex = Er = E,
X0 + R0 x (1+E) Ct'x " Ct>r = K
Or, XNx (1+E) act = K
Where: Xn = Xo 4- Ro, the normalised amount of target
ACT = Ct,x - Ct,r , the difference in threshold cycles for target and reference.
This can be rearranged to give:
XN = K x (1+E)'aCt
Finally XN can be divided for any sample q by XN for the calibrator (cb):
XN,q 4- XN,cb = [K x (l+E)-ACx'q ] + [K x (l+E)-AGr'cb] = (1+E)-aaCt
Where: AACT = ACT,q - ACT>Cb
So, if the efficiency is close to 1, the amount of target normalised to an endogenous
reference and relative to a calibrator is:
2-aaCt
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The use of the comparative Cj method can be preferable to the standard curve method
for several reasons, including increased throughput due to less reagents being used to
construct a standard curve, elimination of any adverse effects introduced through
dilution errors when making a standard curve and decreased sample preparation time.
3.1.12, Limitations of the delta Or method
The first limitation of the delta CT method is that it assumes that the efficiency of
amplification is 100% i.e. 2~AA T. However, this can be corrected for by adjusting the
equation to compensate for a large variance in efficiency. If the efficiency was only 90%
the equation would be 1.90~AA T. The second limitation of the delta CT method is that it
assumes that as the samples are diluted, the amplification of the gene of interest relative
to the internal control gene may not be consistent. Example, two genes A and B; B is
slightly less abundant than A. However, the primers for gene A are only 90% efficient
when compared to the primers for B. The more the samples are diluted the more the
amplification levels of B will begin to reach the amplification levels of A at higher cycle
numbers. This is another reason why it is important to set the threshold at as low a level
as possible. This is due to the fact that this possible difference in the efficiency of
amplification may not affect the results at lower threshold levels. The error will become
more obvious as the reaction progresses.. It is also another reason that multiple repeats





3.2.1. Efficiency of amplification
Serial dilution of genomic DNA from wild-type C57B1/6J mice was used as a template
for PCR to test the efficiency of amplification of the two primer pairs. The genomic
DNA was diluted 1 in 10 each time and correlation coefficients were obtained for each
primer pair (figure 3.3). Primers against a region of Wlct and p- tubulin gave correlation
coefficients of 0.9982 and 0.9928 respectively, with slopes of -3.3647 for /?-tubulin and -
3.3867 for Wlct. The reactions were found to proceed similarly when primers were used
both separately and together, indicating that the two separate primer pairs are not
interacting with each other.
3.2.2. Change in cycle number (ACt)
Amplification plots for wild-type, heterozygous-W<T and homozygous-Wlct show clear
differences for the ACt between each group (figure 3.4). The difference between /?-
tubulin and Wlct amplicon product at the set threshold can be used to determine Wlct
genotype. A difference giving less Wlct than /?-tubulin product is a wild-type animal, a
difference of 1 cycle more Wlct than P-tubulin product is a heterozygous Wlct, and a
difference of 2 cycles more Wlct than P-tubulin product is a homozygous Wlct (figure
3.3). The product of a PCR for the Wlct amplicon alone run on ethidium bromide gel
does not allow for determination of genotype (figure 3.2).
Plotting the cycle difference result for animals of known genotype in a box and whisker
plot (n=36) allows the illustration of 95% confidence limits for each genotype. When
genotyping animals it should be good practice to repeat the genotyping if the sample of
interest falls outwith the 95% confidence limits for all of the plotted genotypes (figure
3.5). However, plotting on the same axis a scatter of the results for animals of unknown
genotype (n=91) there is a trend towards banding into the 3 genotypes as demonstrated
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previously by the box and whisker plot (figure 3.5). A representative set of unknown
genotype whose identity was determined by real time PCR, were also confirmed via
southern blot (Dr M.P.Coleman, personal communication).
3.2.3. Determining copy number in transgenic animals
Transgenic animals have been generated which express the Wlct chimeric gene
(Adalbert et al. 2005). These animals show a strong neuroprotective phenotype. It has
previously been shown that Wlct neuroprotective phenotype is dose dependent on the
level of Wlds protein product being expressed (Mack et al. 2001). It is therefore of
benefit to determine the number of copies which have been integrated into the genome
of these transgenic animals. In this case there are 2 rat models of Wlct, the transgenic
line 23 and line 79 (Adalbert et al. 2005). Through the use of real time PCR on genomic
DNA it is possible to calculate the copy number of insertions into the rat genome. The
results examining the number of inserts in two of the Witt transgenic lines can be seen in
Figure 3.6. This is not an exact determination as the primers are designed against a short
sequence of Ube4b and may also amplify any endogenous rat Ube4b that may or may
not be present. There is also some variability in the amplification process at higher copy
number as previously described (Ballester et al. 2004).
As previously mentioned, wild-type animals are expected to have 2 copies,
Heterozygous Wlct are expected to have 4 copies and homozygous Wlct should have 6
copies. Analysis of the data detailed in figure 3.6 show that wild-type mice have
1.15±0.68 (mean±SEM) copies (n=13), heterozygous Wlct 3.87±0.36 copies (n=7),






I have described here a new method for genotyping Wlds mice. PFGE has hitherto been
the only method reliable enough to distinguish homozygotes from heterozygotes of this
genotype.
It is not possible to generate a Wlct-specific product suitable for conventional PCR: the
nature of the mutation means the product would also appear in samples from wild-type
animals. Conventional PCR does not produce bands of significantly different intensity
for each genotype, when run on an agarose gel (See figure 3.2). A Southern blotting
method relies on the strength of the Wl<£ specific band to distinguish between homo-
/hetero-zygous animals which can lead to ambiguity. The most recent method employing
PFGE, is based on altered fragment size rather than a difference in fragment intensity
and as such is a more reliable assay. However, this method is itself fallible: there can be
problems, for example with incomplete digestion of the sample in question. The tissue
normally required for extraction of DNA for PFGE is the spleen, the genotyping is
effectively carried out post mortem, and therefore if the animal was homozygous it is no
longer available for breeding. It also means that substantial sums are spent on animal
husbandry and breeding only to determine the genotype of the animals being generated
post mortem.
Through the use of real time PCR, animals can be genotyped using DNA extracted from
small pieces of tissue, e.g. ear punch. This is a regulated procedure often used to mark
animals within a breeding programme. This means that the genotype of the subject in
question can be tested before an experiment, and checked during or after use in breeding
or experiments. The main benefits of this method over others are; 1. The time scale in
which it can be performed. Samples can be digested overnight, the DNA extracted the
next morning, quantity assessed if desired and PCR performed the same afternoon. 2.
The animals can still be available for breeding and use once the genotype has been
determined which would not be the case after pulse field. 3. Real time PCR is very cost
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effective. By sourcing other suppliers in this case Sigma, primers and probe can be
acquired for about 30% of the cost from ABI. 4. This method is much more convenient
when mass screening for genotype. For example, each plate has 96 wells, excluding a
few wells for controls it would be possible to genotype (in triplicate) up to 30 animals at
once. Given that the time consuming part of the genotyping is the DNA extraction, but
that the PCR itself only takes about 90 minutes, which is a theoretical turnover of 30
animals every 90 minutes.
Initial experiments with SYBR green were promising but ultimately proved unreliable,
reflected in a series of conflicting data. Because only one flurophore (SYBR Green)
could be used it was not possible to run the control gene and the gene of interest in the
same tube. Pippetting errors are a significant potential source of such inconsistencies.
For example, if the reaction requires the addition of lp.1 of sample per tube, then 0.25pl
on the outside of the pipette tip will make a considerable difference to the contents of the
reaction. This is especially true when seeking a very small change in copy number i.e. 2
copy difference between wild-type and heterozygous Wlds. A standard curve must also
be run for both genes against which the samples can be compared. The need for a
standard curve for comparison means that an accurate way to assay the DNA samples is
required. The samples must all fall within the range of concentration set out by the
standard curve. This requires the use of a method to accurately assay DNA. Initially
thought was given to using Pico Green to assay the DNA, but the cost of this system was
prohibitive. Instead an assay system was set up based on the use of Hoechst 33258
(Lopukhov et al. 2002). This method, though more cost effective and based on the PCR
results, more accurate than measurement via spectrophotometry, is also time consuming.
The need for this therefore results in an increased in expense and in the amount of time
required for set up.
TaqMan Real time PCR was the best solution to the genotyping problem. Because the
comparative Ct is being used, as long as both primer pairs are running with the same
efficiency (see figure 3.3) standard curves are not required. It also means that there is no
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need to accurately assay the concentration of the DNA as each sample will be referenced
to its own control gene within the same tube. The samples, although much quicker to
assay by examining the curves produced (see figure 3.4), can also be assayed by cycle
number difference between the Wlds amplicon and the [1-tubulin control product at the
set threshold (see figure 3.5). 95% confidence limits based on samples of known
genotype assayed suggest that the number of fi-tubulin cycles minus the number of Wlct
cycles gives a reliable indication of when a result should be accepted or when it should
be re-genotyped for definite conformation. Genotyping of unknown samples with
representative samples checked for genotype by Southern blot, show that the samples do
in-fact fall within certain patterns consistent with the three genotypes.
Transgenics
The determination of copy number in transgenics is important to establish if, as in the
case of Wld\ the effect of the mutation is gene dose dependent. However, it is the level
of protein expression rather than the number of copies of the transgene incorporated in
the transgenic that leads to the "level" of protection. As previously mentioned, the
accuracy of real time PCR varies with increasing copy number (Ballester et al. 2004).
Figure 3.6 shows that the estimate of copy number is consistent with that of PFGE at
lower copy numbers. The discrepancy in results between animals from the same line at
higher copy number has been described in detail before (Ballester et al. 2004). They
showed that standard deviation of copy number between animals of the same transgenic
line increases as the number of copies increases. Ballester et al. also showed that the
discrepancies became most obvious in their line which had 18-20 copies, and that when
40 copies are reached the change in cycle number becomes unreadable in the linear
range of quantification. I suggest that this may be corrected by diluting samples of high
copy number to a greater extent before assay to obtain a more accurate measure of copy
number at a lower threshold. This however, may become a problem itself if the
endogenous reference used has a low copy number. The method of estimating insertion
copy number is therefore adequate providing the factors already mentioned are taken
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into account. This method will still not provide an indication of area/orientation of
insertion and whether or not those copies are all functional.
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Figures
Figure 3.1. Primer annealing sites on the WIcF mutation and transgene.
The spontaneous mutation discovered in the WIcF mouse and the transgene
used to make the various transgenic Wlds animals including Tg4836 mouse,
Tg23 and 79 rat lines. The above diagram is not to scale but gives an
indication of where the primer annealing sites (purple arrows) are located.
Primers were designed against a region of exon 1 in the Genbank sequence
AF260927 for the chimeric WIcP product. See methods (section 2.5.7) for
more detail.
Figure 3.2. Conventional PCR on genomic DNA does not
allow for differentiation between the 3 genotypes.
The product of a conventional PCR using the Wld primers
displayed on an agarose gel (2%) containing ethidium bromide.














y = -3.3647x + 20.772
R2 = 0.9928
Wld
y = -3.455x + 20.488
R2 = 0.9989
2 3 4
-log (pg of DNA)
■5
Figure 3.3. Primers for WIcF and p-tubulin have very similar R2
values.
Standard curves for the Wlcf and /3-tubulin gene in serially diluted
(1 in 10) template genomic DNA sample from wild-type (C57BI/6J)
mice from Harlan-Olac. Very efficient amplification was obtained as
demonstrated by the slopes of linear regression of the standard
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Figure 3.4. Real time data shows differences between wild-type,
heterozygous and homozygous animals.
Screen grabs from ABI software. The curves show the difference in
cycle number (ACt) between tubulin (red) and Wlds (green) for each






















Figure 3.5. Real time PCR on genomic DNA shows clear difference
in ACt for the 3 genotypes.
The above is a graphical representation of AC, between the tubulin and
Wld amplicons, for animals of known genotype (n=36, box and whisker)
and animals of unknown genotype (n=91, scatter). The areas shown in
blue represent the 95% confidence limits for each particular genotype as
determined from the box and whisker plots. There is a clear trend for
each particular genotype. If however the animal of interest falls out-with







WT Het-Wld Hom-Wld Tg23 Tg79
Figure 3.6. Real time PCR can be used to determine copy
number in transgenic animals.
Real time PCR carried out on pre-determined samples of genomic
DNA can be used to determine copy number of an insert in rat
transgenic lines (Tg) 23 and 79. This does not show functionality or
orientation of insertion. Although there is some fluctuation in the
determined copy number, wild-type (WT) animals are expected to
have 2 copies Heterozygous Wlcf (Het-Wld) are expected to have 4
copies and homozygous Wlds (Hom-Wld) should have 6 copies.
Analysis of the above data show WT 1.15±0.68 (mean±SEM) copies
(n=13), Het-Wld 3.87 ± 0.36 copies (n=7), Hom-Wld 6.10 ± 0.53
copies (n=7), Tg23 12.34 ± 2.05 (n=10) and Tg79 19.49 ± 1.52
(n=14).
Chapter 4:
Mapping the Distribution of Wlds Protein in the Brain
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4.1.0. Introduction
Although the Wlds mutation (Figure 3.1) itself has now been quite well characterised
(Conforti et al. 2001) the mechanism by which it provides its neuroprotective effect is
still unknown. As stated previously, the chimeric Wlds protein (see chapter 3, figure 3.1)
is sufficient for its protective effect: transgenic lines that express the chimeric gene show
a strong neuroprotective phenotype (Adalbert et al. 2005). One feature that the
transgenic animals and the spontaneous Wldt mutant all share is localisation of Wlds
protein to nuclei (Mack et al. 2001, Adalbert et al. 2005). A recent report shows that
Wlds protein is absent from the cytoplasm of neurones (Fang et al. 2005). It is therefore
logical to hypothesise that the neuroprotective effect of Wlct is not caused by the protein
directly, but rather by some cascade of interactions that are a function of Wlds protein
concentration within nuclei.
The expression of Wlds protein and its localisation within nuclei in the peripheral
nervous system has already been described, but until recently has not been extensively
studied within the central nervous system. I have made use of an antibody "Wld-18"
which targets an eighteen amino acid peptide. This peptide is coded by DNA normally
contained within the 5' untranslated region of Nmnatl, but which is expressed between
the Ube4b and Nmnat portions of the Wlct chimeric gene because of the resultant in
frame insertion and continuous read through from the Ube4b portion of the gene (Figure
4.1). This antibody is both very specific and versatile, as it allows the visualisation of the
Wlds protein through either Western blot or immunocytochemistry.
A search for conserved interactive domains using the Wlds protein sequence was carried
out using Prosite (http://kr.expasy.org/tools/scanprosite/). This search revealed possible
casein kinase II phosphorylation, N-myristoylation, protein kinase C phosphorylation,
amidation and N-glycosylation sites (Figure 4.2).
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Western blots on whole brain lysate have previously shown strong WlcT protein
expression in the brains of Wlds mice and transgenic equivalents (Mack et al. 2001).
Thus a reasonable hypothesis is that the protein should be evenly distributed throughout
neuronal nuclei in the brains of these mice, as seen previously in motor neurone nuclei
(Mack et al. 2001). Evaluation of this hypothesis will be described in this chapter. I
present evidence that:
1) Wlds protein is not uniformly distributed in CNS neurones, either in the
spontaneous mutant or the transgenic equivalents.
2) Intra-nuclear distribution of Wlds varies considerably between and within cell
types. Some neurones show intense, diffuse staining. Other neurones show fine
speckling, while some display large nuclear inclusions that can vary in shape
from spheres to more irregular structures.
3) The various patterns of Wlds protein distribution develop postnatally in vivo and
in vitro in isolated neurones.
4) Wlds protein aggregates co-localise with other proteins involved in ubiquitination
and transcriptional regulation.
5) Redistribution of the Wlds protein occurs following stressful or damaging stimuli
to the cells in which it is expressed.
Therefore, the protection of axons which has previously been demonstrated in neurones






4.2.1. Western Blot analysis of Wld protein expression in the Brain
c
Previous analysis of Wld protein expression by Western blot was limited to protein
s
extracts made from whole brain. I first refined this analysis by examining Wld protein
levels in different regions of Wlds mouse brain, specifically cerebral cortex,
c
hippocampus and cerebellum. All these regions appeared to contain Wld protein in
both immature postnatal mice and in adults. However, expression appears greater in the
c
cerebellum, where it increased with the age of the Wld mutant mice (Figure 4.3). Thus,
c
the adult cerebellum showed increased levels of Wld compared to either P6 cerebellum
o
or adult hippocampus and cerebral cortex. Levels of Wld protein in the immature
hippocampus and cortex were not discernibly different compared to adult mice.
However, the expression pattern in the hippocampal and cortical neurones appear to be
very different (Figure 4.4). The levels of VAP-33 (a synaptic protein which does not
alter during postnatal development) were constant across all these brain regions, and did
not change with age. The increase in Wlds expression in cerebellum with age, can be
also be detected immunocytochemically, both in vivo and in vitro (Figure 4.3, 4.6 &
4.7).
4.2.2. Distribution of Wlds protein in the Wlds mouse brain is not uniform
Through the use of the Wld-18 antibody in immunocytochemistry I confirmed that Wlds
protein is expressed in the central nervous system of the adult Wlds mouse when
visualised using fluorescent secondary antibodies or DAB immunohistochemistry. Both
methods show Wlds confined to the nucleus (Mack et al. 2001, Sajadi et al. 2004 &
Fang et al. 2005). However, I found that the expression pattern is not uniform, which has
not been reported in the previous studies (Figure 4.4). A comparison of the two immuno-
labelling techniques demonstrated that although DAB immunocytochemistry has been
assumed to be more sensitive than fluorescent labelling, I could not discern any
difference in protein labelling between the two techniques (Figure 4.5). However,
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fluorescence imaging provides a more fine grained resolution of Wlds puncta
distribution within nuclei of cells in different regions of the nervous system (Figure 4.4,
Table 4.1 & 4.2). There was both regional variation and inter-cellular variation within
regions. To analyse the expression patterns observed with confocal microscopy I
grouped the cells into four categories;
1) large inclusions in the nucleus (dots),
2) numerous small nuclear inclusions (speckles),
3) strong diffuse nuclear expression (diffuse),
4) very weak diffuse/no staining in the nucleus (weak).
The number of cells in each category were counted through the use of low power
confocal microscopy (Figure 4.4). The nuclei containing Wlds positive inclusions were
expressed as a percentage of the total number of visible TOPRO-3 positive nuclei. This
would also include TOPRO-3 positive non-neuronal cells. Therefore, the numbers are
c
probably an underestimate of the percentage of neurones expressing Wld protein (Table
4.1 and 4.2). Attempts were made to count only neurons using Neu-N a neuronal
marker, but this proved too difficult to accurately quantify in the more neuronal dense
regions (data not shown). Some cells fell into more than one category (e.g. large
inclusions plus strong diffuse staining were evident in some layers of cortex (Figure 4.3,
Table 4.1). Table 4.1 and 4.2 lists the percentages of cells in each category within each
of the major brain regions analysed.
Cerebellum
The cerebellum showed a very striking distribution pattern; 90% of cerebellar granule
cells and 82% of cells in the molecular layer. Flowever, Purkinje cells showed no
nuclear Wlds protein (Figure 4.4, Table 4.1 and 4.2).
Hippocampus
In contrast, where I have shown there is Wlds protein present by Western blot, the
hippocampus has no discernable Wlds protein within nuclei of either dentate gyrus
granule cells or CA1 neurones. However, most CA3 neurones show nuclear speckling.
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This variability in distribution patterns is in contrast to spinal motor neurones, where
there is a uniform strong diffuse nuclear staining pattern (Mack et al. 2001).
Ganglia
On the other hand, Wla expression in peripheral (autonomic and sensory) ganglia
showed similar diverse staining patterns. No discernible nuclear staining was seen in
Wlcf mouse superior cervical ganglion (SCG), which is reported to show a strong
protective axonal phenotype in vitro. There were large, clear nuclear inclusions in the
nuclei of small neurofilament positive neurones in the dorsal root ganglion (DRG).
Some DRG neurones contained unusual shaped inclusions. These neurones showed a
reproducible array of unusual shapes including; large circular structures, smaller tight
ring shaped structures and strings of protein (Figure 4.4). Without deconvolution
software it is not easy to determine whether these are hollow structures, i.e. a coating of
protein around an internal core, or whether they represent "solid" aggregates of Wlds
protein. In order to simplify classification, these structures were grouped together and
termed "tubes" (Table 4.1 and 4.2). There were also examples where inclusions appear
to be joined by threads of Wld protein. Interestingly, these complex nuclear inclusions
were not observed in the large neurones in the DRG which display a more diffuse, rather
faint staining pattern. Although these patterns were not seen elsewhere in the regions of
the spontaneous mutant I examined, they were present in certain areas in the transgenic
animals (see below). Interestingly, these structures and faint diffuse Wlds staining have
not been mentioned in any other studies, and yet the DRG have a very strong
neuroprotective phenotype in the majority of fibres following axotomy (Mack et al.
2001).
4.2.3. Changes in protein distribution during development
A comparison of neonatal and adult brain revealed developmental changes in Wlds
protein expression (Figure 4.6, 4.7, Table 4.1 and 4.2). These were particularly striking
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in the cerebellum. Only 3% of cerebellar granule cells from P6 animals showed
discernable levels of Wlds protein in the nucleus, compared with over 90% in the adult
(Table 4.1). Figure 4.6 illustrates the formation of the characteristic large nuclear
inclusions in cerebellar granule cells in vivo. Very little Wlds protein was visible at P6.
This was followed by an increase in the number of cells with a "speckling" of protein
(Panel B, Figure 4.6) which appear to aggregate and form the nuclear inclusions
characteristic of the adult cerebellar granule cell. It appears as though there is an
increase in the amount of speckling and strong diffuse protein which may aggregate to
form the large inclusions seen in the adult.
Cultures of dissociated cerebellar granule were prepared from neonatal P4 mice. I
anticipated that Wld protein would initially be undetectable in vitro. When dissociated
s s
granule cells from Wld mice were fixed and stained for Wld protein immediately
following plating and adhesion, no Wld protein expression was observed (Figure 4.7,
Panel A). However, after 7 days in culture, Wlds-containing inclusions could clearly be
seen in the cultured cell nuclei (Figure 4.7, Panel B). This suggests that cerebellar
granule cell neurones mature in culture. The observation that these inclusions reach a
maximum size by seven days is interesting because a previous study by Buckmaster et
al. (1995) showed that the Wlcf protective phenotype developed over seven days. It is
also possible to demonstrate that Wlds positive inclusions can be formed in rat cerebellar
granule cell dissociated cultures following transfection with a Wlds-eGFP construct
(Figure 4.7). These reached a maximum size approximately 9 days after transfection and
look similar in both appearance and size to cerebellar granule cell inclusions in the Wlds
mutant mouse (Figure 4.7). Interestingly, in the adult cerebellum Figure 4.8 shows a
size calculation for the size of the nuclear Wlds protein aggregates in cerebellar granule
a
cells. The average aggregate size is 1.12±0.36 (Mean±SD, n=10) p,m~. If we assume
there are 10lo-10" granule cells per cerebellum (Llinas, 1975) there is about 1.12xl010(-
1011) (im3 of visible Wlds protein aggregate in the cerebellar granule cell layer.
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There was also an interesting developmental change in the pattern of staining visualised
in the primary-, secondary- motor cortex and the somatosensory cortex. At P6 when
Wlds protein expression was seen, it was mostly in the form of small speckles. As the
animals matured, Wlds expression appeared as a strong diffuse pattern, suggesting that
the strong staining may possibly represent a myriad of tiny inclusions that it is
impossible to fully resolve at the confocal/light microscope level (Table 4.1). Thought
was given to a more detailed examination using immuno-electron microscopy, but it was
beyond the scope of the current study.
c
4.2.4. Wld expression in transgenic mouse and rat brains
Dr M.P.Coleman provided brains from transgenic Wlds animals, made by non-targeted
insertion of the chimeric Wlct gene under the control of the [3-actin promoter. Although
the mouse line 4836 and rat line 23 both show a strong neuroprotective phenotype in
axotomy of peripheral nerve (Mack et al. 2001, Adalbert et al. 2005), the expression
s s
pattern of Wld protein in the Wld transgenic mouse is markedly different from the
spontaneous Wlds mutant.
Surprisingly, for example, cerebellar granule cells show no Wld , in either the transgenic
mouse or rat (Figure 4.9, 4.10 & Table 4.3). Instead, there was clear Wlds protein
expression in a subset of neurones at the interface between the granule cell layer and
molecular layer in both of the transgenic lines. The transgenic rat shows large inclusions
in what appeared to be basket cells. The transgenic mouse had very unusual inclusions,
resembling 'tubes' of Wld protein, in the nucleus of what may be Golgi cells.
Similarly, in the hippocampus the transgenic expression patterns were unlike the
c
spontaneous Wld mouse; dentate gyrus granule cells and CA1 cells of the hippocampus,
regions mostly devoid of Wlds protein in the Wlds mouse (Table 4.1), show strong Wlds
expression in the transgenic mouse. However, these regions showed very little evidence
of Wlds staining in the line 23 transgenic rat (Table 4.3).
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4.2.5. Where in the nucleus is the Wlds protein?
Currently it may be easier to say where the protein is not. Wlds protein does not co-
localise with either Cajal (or coiled) bodies, PML bodies or the splicing factor SC35
(M.P.Coleman personal communication). Dr Haley and I have also shown that Wlds
does not co-localise with SMN, ConA or mono-ubiquitin or poly-ubiquitin (data not
shown). However, the fact that we have not seen the Wlds protein in these areas may
simply be due to our inability to adequately detect it given the limitations of the current
protocols.
Perhaps not surprisingly given that native Ube4b (in yeast) is known to interact with
VCP (Berny et al. 2001), a pull down assay revealed an interaction between Wlds and
VCP, through interaction at a specific binding site located on the N70-portion of Ube4b,
contained within the chimeric protein (Laser et al. 2005, Submitted). I therefore
examined cerebellar granule cells, which I found to be a rich source of Wlds protein, for
evidence of co-localisation with VCP.
4.2,6. Colocalisation of Wlds protein with VCP
Valosin containing protein (VCP; p97/Cdc48) is a protein with diverse cellular roles
including an important involvement with the ubiquitin proteasome system. A recent
study by Laser et al. (2005, unpublished but submitted at the time of writing) shows that
c
Wld lacking its N-terminal 16 amino acids (N16) does not bind or redistribute VCP, but
the Wlds protein will still form nuclear aggregates. This means that the binding site for
VCP on the Wlds chimeric gene is in the N-terminal 16 amino acids, which are part of
Ube4b. Laser et al. also state that wild-type Ube4b also requires N16 for binding to
VCP, even though the yeast homologue has its binding site towards its C-terminus.
Figure 4.11 demonstrates colocalisation of Wlds protein with VCP in cerebellar granule
cells and Wlds positive cells within the cerebellar molecular layer. Figure 4.12 shows
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colocalisation in the DRG. In the DRG the co-localisation is not absolute. That is, not
every Wlds positive inclusion is VCP positive. VCP staining on wild-type tissue shows
that it normally does not aggregate in nuclei (Figure 4.13). Not all Wlds inclusions
showed evidence of VCP co-localisation, suggesting that aggregation of Wlds protein
does not require interactions with VCP, but that VCP does require Wlds.
VCP is known to interact with histone deacetylases (HDACs, Berny et al. 2001). A
recent publication by Araki et al. (2004, explained in more detail later) suggested that
the Wlds phenotype is mediated through the NAD pathway in a Sirtl dependent fashion,
and it is known that Sirtl is a member of the histone deacetylation family (NAD
dependent deacetylases, Kyrylenko et al. 2003). Following a fruitful discussion with Dr
Hardingham (Edinburgh University) it became apparent that a subset of HDACs and
another pathway related protein, silencing mediator for retinoic acid and thyroid
hormone receptors (SMRT), show a similar distribution to Wlds protein within neurones.
For these reasons I decided to test for co-localisation of Wlds with SMRT and HDAC5.
4.2.7. Colocalisation of Wlds protein with SMRT & HDAC5
The silencing mediator for retinoic acid and thyroid hormone receptors (SMRT)
mediates transcriptional repression by recruiting histone deacetylases (HDACs) to DNA
bound receptor complexes. SMRT contains an N-terminal sequence that is highly
conserved in the nuclear co-repressor N-CoR. It has previously been demonstrated that
SMRT aggregates in cell nuclei and forms nuclear speckles. This can lead to recruitment
of HDAC4 & 5 to these speckles. HDAC4 is primarily diffuse in the cytoplasm, and
HDAC5 has a primarily diffuse localisation within the nucleoplasm. SMRT movement
is followed by translocation of these into discreet nuclear foci (Wu et al. 2001).
Figure 4.14 shows some evidence of colocalisation of Wlds protein with SMRT in
transfected cortical cells. A colocalisation "map" (Figure 4.14 panels D and H) shows
colocalisation in a low power and higher power confocal micrograph. The co-
localisation is not complete. In some cells there was no evidence of colocalisation. The
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results were similar when either cortical cells or HEK 293 cells were cotransfected with
Wlds-eGFP and SMRT-Flag.
However, Figure 5.15 shows co-transfection of cortical cells with Wlds-eGFP and
HDAC5-Myc. In this case all the cells examined appear to show complete co-
localisation with HDAC5. This co-localisation is strongly evident in both dissociated
cortical cells and HEK293 cells when transfected with either Wlds-eGFP and HDAC-
Myc or Wlds-RFP and HDAC-GFP. This apparent preference for co-localisation of Wlds
with HDAC5 over SMRT could perhaps be related to an interaction between HDACs
and VCP (see discussion).
4.2.8. Wlds protein may move in response to stress
At this point I would like to report observations I have made in relation to some
preliminary experiments undertaken initially to test whether Wlds localisation may be
related to electrical activity of neurones that express it. These observations may be of
general interest, although I feel that to cover them in detail would distract the reader
from the overall direction of this thesis. Further information can be found in appendix
4.1.
Could the formation of connections in the CNS could be the reason for the change in
localisation of Wlds protein during development? I have already shown that Wlds protein
accumulates into inclusions over a period of more than a couple of weeks in vivo, but
rapidly accumulate in culture reaching a maximum size at about 7 days in vitro, which
would correspond in time with the formation of a complete network of connections in
dissociated cerebellar granule cell cultures.
Electrical activity has previously been shown to affect the localisation of HDACs
(Chawla et al. 2003, Fin et al. 2005). It has been demonstrated that spontaneous
electrical activity is sufficient to drive nuclear export of HDAC4 but not of HDAC5 in
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cultured hippocampal neurones, and that HDAC5 translocation to the cytoplasm can be
induced, following stimulation of calcium flux through synaptic NMDA receptors or L-
type calcium channels (Chawla et al. 2003). In order to test the possibility that electrical
activity may involved in the localisation of the Wlds protein (as it can affect the
localisation of HDACs), whole brain vibratome cut slices were incubated in oxygenated
ACSF with either PTX (picrotoxin, blocks the gamm-aminobutyric acid activated
chloride channels) or TTX (tetrodotoxin, specifically blocking voltage-gated sodium
channels) over a time period of 4 hours. This caused an interesting change in distribution
of the Wlds protein within the nuclei of neurones. In the cerebellar granule cells protein
became localised towards the edges of the nuclei. However, this visual effect was no
different between treatments with PTX, TTX or if the slices were just maintained in
oxygenated ACSF. An example of the protein redistribution seen in cerebellar granule
cells is given in Figure 4.16. It was initially thought that the reason for this lack of
difference between treatments could be that the tissue, following slicing and incubation
in ACSF are reacting to the severing of synaptic connections that must have occurred
during the process. It is not the case that the cells are simply dead because incubation
with the dying-cell marker, propridium iodide, showed very few cells with uptake at 4
hours (data not shown).
The images shown in Figure 4.16 give an impression that there is an increase in the
visible amount of protein. To confirm overall protein levels a Western blot was carried
out on protein extracted from different brain region of slices, which have undergone
incubation in ACSF for 0 and 4 hours. However, the Western blot in Figure 4.17





s sWld protein is localised to nuclei of neurones in both the PNS and the CNS of the Wld
mouse (Figure 4.4 and Table 4.1; Mack et al. 2001). The data presented here show,
however, that the distribution of the Wlds protein throughout the nervous system is not
uniform from region to region. There are also intra region variations. For example,
although there is as much protein within the hippocampus as there is in the cortex as
estimated by Western blot (Figure 4.3), the distribution of visible protein is very
different both between and within the two regions, and varies greatly within the
hippocampus itself (Table 4.1). Almost 50% of cortical cells are Wlds positive, ranging
from large inclusions to speckling, to strong diffuse immunostaining, whilst the
hippocampus shows no discernable Wlds immunostaining in the dentate gyrus, with only
10% of cells in the CA1 and over 80% of cells in the CA3 with speckled
immunostaining. This variation suggests that there is cytoplasmic Wlds protein, which is
so diffuse that we cannot visualise it either by DAB or fluorescence immuno-
cytochemistry, or that there are two pools of Wlds protein both with different
configurations, one which allows visualisation with the Wld-18 antibody, and another
which does not. However, due to the fact that transfection with an eGFP tagged Wlds
construct shows a similar pattern as visualised by immunocytochemistry on the Wlds
mouse, I am tempted to assume that the protein is just diffuse, and therefore below
detection levels. Fang et al. (2005) also appear unable to detect any Wlds protein within
the cytoplasm of neurones, and although their publication has validated the methods
used in this study, they were unable to show co-localisation of Wlds with any possible
candidate downstream factors and have not provided any form of quantification of
expression profiles throughout the nervous system.
The formation of visible aggregates also appears to develop postnatally (Figure 4.6). In
the regions examined by Western blot (Figure 4.3), all the areas appear to have the same
levels of protein at P6 and P70 except the cerebellum, which shows an increase. Large
nuclear Wlds protein aggregates within every cerebellar granule cell were not evident
until after PI7.
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It therefore becomes important to ask if these inclusions serve any function; for
example, does the phenotype vary with pattern of nuclear aggregates of Wlds protein?
In particular, the inclusions must contain very high local concentrations of Nmnatl,
reported to be the active component of the Wlds protein (Araki et al. 2004). This
increased local Nmnatl content within the nucleus may be important in activating local
downstream effector pathways and subsequently causing the Wlct neuroprotective effect
through a cascade of events.
The formation of these inclusions could have implications for neuroprotection, both in
vivo and in vitro. Experimentally, neurones are cultured normally from very young
tissue, and if it can be determined that the formation of inclusions within nuclei are
important for phenotype, then when neurones are first cultured there may be no
c
protection. In cerebellar granule cell cultures from Wld mice, although there is no
c
obvious nuclear Wld protein at postnatal day 4 when the cultures are prepared,
inclusions do develop in vitro over 7 days by which point the distribution of protein
resembles that of the adult in vivo. This timescale is accelerated compared to the in vivo
development of inclusions but correlates well with the time course of development of an
in vitro neuroprotective phenotype in DRG, SCG and cerebellar granule cells from Wlds
mice where maximal protection of neurites was observed only after the cells had been in
culture for 7 days (Buckmaster et al. 1995). This slow development of the phenotype in
vitro suggests that perhaps the development of nuclear inclusions is necessary for the
protective phenotype. Other studies have utilised dissociated cells and/or explants of the
SCG to demonstrate and assay the axoprotective Wld'' phenotype (Deckwerth and
Johnson, 1994; Buckmaster et al. 1995). The fact that cerebellar granule cells look like
adult tissue after 7 days in vitro (i.e. chronologically PI 1) reinforces the idea that tissue
from the developing animal can subsequently be treated as adult tissue.
s s
Thus, it has become critical to ask whether nuclear localised Wld and/or nuclear Wld
inclusions are required for the full axonal protection phenotype. If they are essential,
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then not all neurones in the CNS or PNS of the Wlds mouse or transgenic mouse/rat
would exhibit axonal protection. This issue might be addressed by comparing the
strength of the neuroprotection observed in the spontaneous Wld mouse with that seen
in comparable neurones in the transgenic equivalents. The mosaic expression pattern of
Wlds protein makes this feasible. Regardless, it is clear that Wlds neurones are able to
survive and develop normally despite the presence of large inclusions of abnormal
protein within the nucleus. Recent evidence suggests that some neurones survive by
accumulating aggregates of abnormal protein (Arrasate et al. 2004). Although the
aggregates themselves are probably not directly effecting survival, they are more likely
acting through some cascade of events initiated in the nucleus.
It is difficult to correlate Wlds inclusions with the strength of the neuroprotective
phenotype since there is a wide variety of expression patterns, even within a particular
cell type. However, there are some cell types where there is a more homogeneous
distribution of Wld protein and it may be possible to draw some conclusions from these:
c
1) Motor neurones have very strong diffuse nuclear Wld protein (which could be
numerous small inclusions that it is not possible to resolve) and there is clear
neuroprotection of motor neurone axons following axotomy (Gillingwater & Ribchester.
2001 & 2003, Coleman & Ribchester. 2004).
2) The majority of cortical cells in the adult have strong diffuse nuclear staining similar
to that seen in motor neurones. Dr T.Gillingwater has recently provided evidence that
these cells exhibit protection of synapses following cortical ablation (Gillingwater et al.
Submitted).
s s
3) 90% of cerebellar granule cells from Wld mice have single large inclusions of Wld
protein (Figure 4.4 and Table 4.1) and clear neuroprotection is observed in vitro
following removal of serum and potassium (Explained in more detail in chapter 5,
Figure 5.1, Buckmaster et al. 1995, Haley et al. submitted).
c
4) Small DRG neurones contain very large and unusually shaped inclusions of Wld
protein (Figure 4.4) and sensory axons are protected following axotomy in vivo and in
vitro and vincristine toxicity (Perry et al. 1990, Buckmaster et al. 1995, Wang et al.
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2001 & Araki et al. 2004). However, large DRG neurones appear to have only faint,
diffuse Wld staining and yet they are also protected following axotomy.
5) Superior cervical ganglion neurones are also protected in vitro after 5-7 days of
culture (Deckworth and Johnson 1994, Buckmaster et al. 1995), but there is only faint
sWld staining in these neurones in vivo. I have not seen strong nuclear expression of
sWld in adult SCGs in situ. This could be a function of the growth factors present in the
culture medium, inducing SCG neurones to express Wlds in vitro.
6) Recent electrophysiological studies by Dr Haley demonstrate that the axons of
hippocampal CA3 cells, which do have visible Wlds protein inclusions are protected
against axotomy, whilst those axons from CA1 cells, which do not have visible
aggregates are not protected (Dr J.Haley, unpublished data, Appendix 4.2).
s sThe diverse pattern of Wld protein expression in the Wld mouse is also reflected in the
transgenic mouse and transgenic rat (which express the Wlds gene) although the actual
a
patterns of expression differ from each other and from the Wld mouse (Figure 4.9, 4.10
and Table 4.3). A possible reason for the different expression patterns in the transgenic
lines, relative to the spontaneous mutant is that both transgenics are driven by a P-actin
promoter, whilst in the spontaneous mutant, transcription is regulated by the native
promoter for Ube4b (Conforti el al. 2000). I might predict that Wld' protein distribution
between neuronal subsets in the Wlds mouse would parallel the distribution pattern of
Ube4b expression. This is not the case. In the mouse cerebellum, Ube4b is expressed
c
predominately in Purkinje cells (Kaneko et al. 2003) whereas nuclear Wld expression is
very weak in these neurones. However, the p-actin promoter used in the transgenic lines
c
is almost ubiquitously expressed in neurones and yet Wld protein also has a very varied
distribution pattern in these animals. The differences between the expression in the
transgenic lines, could also be due to the fact that the lines are generated by a non-
targeted insertion. This means that the constructs have probably inserted in different
regions of the genome and are probably being affected by local factors. Referring back
to Figure 3.6, I have already demonstrated that the transgenic lines have a different
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number of insertions, although as stated previously, this does not mean that all of the
inserts are functional.
c
Whatever underlies the inter-cellular distribution pattern of Wld , the intra-cellular
localisation of this protein to the nucleus appears to result from the full-length Nmnatl
present in the protein. Recently, Araki et al. (2004) provided evidence that elevated
NAD synthesis by Nmnatl is sufficient to confer neuroprotection. They suggested that
this would need to occur locally in the nucleus since overall NAD levels are not altered
c
in the Wld mouse (Mack et al. 2001). Nmnatl is known to have a nuclear localisation
signal as part of its structure (Figure 4.1, Schweiger et al. 2001). This portion is required
o
for the nuclear localisation of Wld protein in cell lines since the removal of the Nmnatl
region results in the cytoplasmic localisation of Wld protein (Explained further in
chapter 5, Figure 5.11, Araki et al. 2004). In contrast, the ubiquitin ligase Ube4b is
normally cytoplasmically located (Figure 5.11, Kaneko et al. 2003), or possibly shuttled
between cytoplasm and nucleus. Thus, the truncated N70 portion of Ube4b (which
constitutes part of the Wlds protein), might be inappropriately located in the WW5 mouse
and is sequestered away from its normal cytoplasmic location, into the nucleus by the
attached Nmnatl region.
Whether this relocation of the truncated Ube4b has any consequence for the
neuroprotective phenotype remains to be demonstrated, but it may be required for the
formation of inclusions. In HEK293 and COS-7 cells, only the full length WIds
construct produced inclusions in addition to nuclear expression of the protein (Figure
5.11, Laser et al. submitted).
I have also demonstrated that Wlds co-localises with VCP and HDAC5. HDAC5 is a
class II HDAC, and the class II members are related to yeast SIR2 deacetylase. The
possible significance of this will become apparent in the next chapter. As previously
described, class II HDACs, which include HDAC 4,5,6 & 7 are capable of shuttling
between the cytoplasm and the nucleoplasm, and their localisation is highly regulated by
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a number of factors (Chawla et al. 2003), including electrical activity and cell stress.
Through immunoprecipitation in yeast, HDAC6 associated proteins have been shown to
have high homology to proteins involved in the regulation of ubiquitination. These
homologous proteins include UFD3 (phospholipase A2 activating protein) and Cdc48p
AAA ATPase (i.e. VCP). It has been demonstrated that Ube4b (the mammalian
homologue of Ufd2) has a binding site for VCP (Laser et al. 2005), and also that
HDAC6 can interact with VCP (Seigneurin-Berny et al. 2001). It is known that HDACs
can act as transcriptional regulators, but only when they have translocated to the nucleus.
I have shown that VCP is distributed diffusely and does not aggregate in a wild type
mouse, but in the presence of Wlds protein, VCP does form aggregates. This may be
because VCP binds Wlds protein at an identified binging site on N70-Ube4b and is
"dragged" into the nucleus due to the nuclear localisation signal incorporated in the
sequence of Nmnatl. I have also shown co-localisation of Wlds with HDAC5 (another
class II HDAC), and it could be that class II HDACs in general interact with VCP,
resulting in its movement to the nucleus, and in its new position exert transcriptional
regulatory effects. This suggests a possible mechanism by which Wlds protein localised
to nuclei may effect protection of axons and synapses, following separation from the cell
body. However, this is just untested speculation.
Furthermore, it remains to be determined what intranuclear structures house both the
c
inclusions and the extraordinary loop structures highlighted by the Wld protein.
Further characterisation of these structures could provide insight into the mechanism of
c
Wld -conferred neuroprotection.
To summarise, I have mapped the Wlds protein in various different regions within the
nervous system, and have never found it outwith the nucleus. A pressing question
remains: how can a protein localised to the nucleus protect axons and synapses from
degeneration when separated from the cell body by a cut or a crush injury? The easiest
hypothesis is that through its nuclear localisation, and now proven interaction with
members of the ubiquitin proteasome system and possible regulators of transcription, it
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Figure 4.1. Wlds protein sequence.
The protein product of the WIcF mutation showing the location of the
N70 amino acids of Ube4b (black). The 18 amino acids normally located
in the 5' un-translated region of Nmnatl but which are expressed in the
chimeric protein (red) allowing the generation of the highly specific Wld-
18 antibody. The C-terminal 303 amino acids of Nmnatl (the whole
coding region in blue), including a constitutively expressed nuclear
localisation signal (green). This sequence was obtained from PubMed:
AF260924.
Hits for all PROSITE (release 18.48) motifs on sequence USERSEQ1






hits by patterns with a high probability of occurrence or by user-defined patterns:
[14 hits (by 5 distinct patterns) on 1 sequence]
PS00006 CK2_PHOSPHO_SITE Casein kinase II phosphorylation site :
5-8: SadE
345-348: TesE
PS00008 MYRISTYL N-myristoylation site :
19-24: GGqtSQ
68 - 73: GAadNI
77 - 82: GLhvGQ
147 -152: GLipAH
PS00005 PKC_PHOSPHO_SITE Protein kinase C phosphorylation site :
91 - 93: SsK




324 - 326: SiR
PS00009 AMIDATION Amidation site :
211-214: PGRK
PS00001 ASN_GLYCOSYLATION N-glycosylation site :
369 - 372: NHST
Figure 4.2. Scan Prosite Results Viewer.
This view shows ScanProsite results together with rule-based
predicted features inside (profile) matches. For further information visit:
http://kr.expasy.org/tools/scanprosite/
Cereb. Hippo. Cereb. Cortex
Figure 4.3. Western blot analysis confirms the absence of Wlds protein
in wild type mice.
Levels in P6 mice are detectable and similar in hippocampus (hippo ),
cerebellum (cereb.) and cortex as well as adult hippocampus and cortex
(P>0.13; N=3, 2 tailed T-test welch corrected from band density analysis).
There is a clear increase (P<0.03), in the level of Wlds protein (43KDa)
present in the adult cerebellum compared to the neonate. However, protein
levels are consistent between the hippocampus and cortex. Similar levels of
protein were loaded in each lane, as demonstrated by the uniform VAP-33
(33KDa) staining in all lanes.
cerebellum I caudate I DRG
Figure 4.4 Wlds protein staining in the Adult WIcF mouse is not
uniform in its distribution.
Confocal micrographs illustrating that the expression of Wlds protein
(red) in various regions of brain slices from Wlcf mice, plus dorsal root
ganglion (DRG) and retinal ganglion cells. Slices were counterstained
with TOPRO-3 (blue) to show nuclei. Distribution patterns have a wide
range including; clear strong diffuse staining in the nucleus of retinal
ganglion cells and motor cortex layer 2 cells (D & E), to large or small
punctuate inclusions in hippocampal CA3 neurones, cerebellum and
caudate (C,G &H) and no obvious staining in dentate gyrus and
hippocampal CA1 neurones (A & B). Staining in the small neurones of
the DRG was unusual with circles and tubular structures occurring
within the nuclei (I). Scale bar = 10pm.
Figure 4.5. DAB immunocytochemistry does not appear to reveal
any Wlds protein that fluorescent immunocytochemistry may not
detect.
DAB (A & C) and fluorescence (B & D) immunocytochemistry on Wlcf
primary motor cortex at P6 (A & B) and P70 (C & D). Using both DAB
and fluorescence it is possible to see strong nuclear staining with large
inclusions in the adult cortex (C & D), and nuclear speckling of Wlds
protein in developing cortex (A & B). The 2 main disadvantages of DAB
are 1. That the length of the staining protocol can affect the
appearance of the DAB and 2. That with Wlds protein
immunocytochemistry the use of a nuclear marker can obscure the





































Figure 4.6. Wlds distribution in vivo alters during the first few
weeks of postnatal life.
Confocal micrographs of WIcF cerebellar granule cells
immunocyochemically labelling Wlds protein in red and the nuclear
marker TOPRO-3 in blue. Very few nuclear inclusions are present in
the cerebellar granule cells at P6 (A) while about 90% of granule
cells have large nuclear inclusions by 2 months (C). Panel B shows
an intermediate stage of inclusion formation. (D). Graphical
representation of nuclear inclusion type in cerebellar granule cells
during development shown in panels A-C. Scale bar = 10pm (A-C )
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Figure 4.7. Wlds protein inclusions develop in vitro at an
accelerated rate.
Confocal micrographs show dissociated cerebellar granule cells
cultured from P6 Wlcf mice have no obvious Wlds protein expression
when initially plated (A). Nuclear Wlds protein inclusions develop in
culture reaching an apparent maximum size after 7 days in culture (B).
Inclusions also develop in dissociated cerebellar granule cell cultures
from P7 Rats, 9 days after transfection with a Wlds-eGFP construct (C
& D). Scale bars = 5pm (A-D).
A
Figure 4.8. Wlds protein inclusions in adult cerebellar granule cells
make up less than 0.5% of their nuclear volume.
Panel A shows an example of an adult cerebellar granule cell nucleus and
its Wlds protein inclusion taken from a confocal micrograph. Images like this
were analysed using Scion image. Panel B details volume calculations for
10 example cerebellar granule cell nuclei and their Wlds protein inclusions,
as calculated with Scion image.
B
Nucleus Inclusion
93.80 11.51 Diameter in Pixels
9.38 1.151 Approx. diameter pm
476.24 1.12 Approx. volume pm3
0.23 % nuclear volume
tubes |inclusions| speckles diffuse weak/none
1 1 ,>V-v mmm
<7 * mM ES
Caudate 0 55 0 0 45
Cerebellum: granule cells 0 90 10 0 0
Cerebellum: Purkinje cells 0 0 0 0 100
Cerebellum: molecular layer 0 82 0 0 18
Cortex: primary motor, layer2/3 0 20 5 75 25
Cortex: primary motor, Iayer4 0 5 40 50 50
Cortex: primary motor, layer 5 0 10 50 60 40
Cortex: somatosensory, layer2/3 0 0 24 50 50
Cortex: somatosensory, Iayer4 0 3 82 85 14
Cortex: somatosensory, Iayer5 0 2 29 63 37
Dentate 0 0 <10 0 100
DRG 5 1 12 16 70
Hippocampus: CA1 0 0 10 0 100
Hippocampus: CA3 0 0 84 0 100
Medial Habenulla 0 0 79 94 6
Retina: ganglion cells 0 11 13 86 12
SCG 0 1 11 2 88
Thalamus 0 0 21 0 100
P6 caudate 0 0 0 25 75
P6 cerebellum: midlayer 0 0 3 0 97
P6 cortex: primary motor, layer 5 0 0 14 0 86
P6 cortex: somatosensory, layer 5 0 0 1 0 99
Table 4.1. Quantification of Wlds protein distribution profile in the
WIcF mouse nervous system.
The percentage of cells in each region displaying a particular nuclear
Wlds protein distribution pattern was assessed from low power confocal
pictures. Percentages are calculated as a percentage of TOPRO-3
labelled nuclei. The distribution pattern was divided into large inclusions,
multiple small inclusions (speckles), strong diffuse and weak diffuse/no
obvious staining. A cell could therefore fall into more than one category
(e.g. a cell with a large inclusion which also showed strong diffuse
staining) and would be counted twice.
% % strong % weak
speckles diffuse diffuse/none
J El■IH
Anterior commissue 0 0 5 0 95
Corpus callosum 0 0 0 0 100
Cortex: cingulate 0 8 62 38 30
Cortex: secondary motor, layer2/3 0 20 0 36 64
Cortex: secondary motor, Iayer4 0 17 4 38 62
Cortex: secondary motor, layer 5 0 0 11 35 65
Geniculate nucleus 0 0 9 0 91
Retina: bipolar cells 0 0 9 7 93
Retina: innerplex 0 0 0 0 100
Retina: rods 0 0 27 73 28
PVP 0 0 70 97 3
P6 cerebellum: inner layer 0 0 12 0 88
P6 cerebellum: outer layer 0 0 0 0 100
P6 corpus callosum 0 0 0 0 100
P6 cortex: cingulate 0 0 23 0 77
P6 cortex: primary motor, layer 2/3 0 0 0 0 100
PS cortex: primary motor, layer 4 0 0 6 0 94
PS cortex: secondary motor, layer 2/ 0 0 19 0 81
P6 cortex: secondary motor, layer 4 0 0 80 0 20
P6 cortex: secondary motor, layer 5 0 0 85 0 15
P6 cortex: somatosensory, layer 2/3 0 0 0 0 100
P6 cortex: somatosensory, layer 4 0 0 0 0 100
Table 4.2. Quantification of Wlds protein distribution profile in the
W/cF mouse nervous system.
This table details other areas that were not included in table 4.1. The
percentage of cells in each region displaying a particular nuclear Wlds
protein distribution pattern was assessed from low power confocal
pictures. Percentages were calculated as a percentage of TOPRO-3
labelled nuclei. The distribution pattern was divided into large inclusions,
multiple small inclusions (speckles), strong diffuse and weak diffuse/no
obvious staining. A cell could therefore fall into more than one category
(e.g. a cell with a large inclusion which also showed strong diffuse
staining) and would be counted twice.
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Figure 4.9. The transgenic line 4836 mouse has a different
expression pattern of Wlds protein to that of the spontanious WIcF
mouse.
Expression of Wlds protein (red) in various regions of brain slices from
transgenic mouse expressing the Wlds gene. Slices were
counterstained with topro-3 (blue) to highlight the nuclei. The distribution
patterns differed from that seen in the Wlcf mouse but also varied
between cell types. Speckled inclusions can be seen in CA1 (A)
neurones but there is no obvious expression in CA3 (B), whereas in the
caudate there are single nuclear inclusions (E) and in the cerebellum
there are tubes of Wlds protein in a subset of neurones similar in shape




Figure 4.10. The transgenic line 23 rat has a different expression
pattern of Wlds protein to that of the transgenic line 4836 mouse
and spontanious WIcF mouse.
Expression of Wlds protein (red) in various regions of brain slices from
transgenic mouse expressing the Wlds gene. Slices were
counterstained with topro-3 (blue) to highlight the nuclei. Wlds protein
expression differed from that seen in either the transgenic mouse or
WIcF mouse. There is little staining in the CA1 (A) and dentate (D) but
very large inclusions in the basket cells of the cerebellum (C) and tubes
of Wlds protein in the dorsal brainstem (B) similar in shape to those
seen in the Wlcf mouse DRG and transgenic line 4836 mouse
cerebellum. Scale bar = 10pm.
% % large % % strong % weak
tubes inclusions speckles diffuse diffuse/none
El H
Transgenic Mouse
Caudate 0 55 0 0 55
Cerebellum: granule cells 0 2 0 0 98
Cerebellum: Purkinje cells 0 0 0 0 100
Cerebellum: molecular layer 6 2 0 0 94
Cortex: layer 4 0 8 8 73 27
Cortex: layer 6 0 8 0 72 28
Dentate 0 7 15 0 85
Hippocampus: CA1 0 1 65 20 35
Hippocampus: CA3 0 0 3 0 97
DRG 0 0 4 0 96
motorneurone 0 0 0 100 0
Transgenic rat
Caudate 0 3 15 0 85
Cerebellum: granule cells 0 2 0 0 98
Cerebellum: Purkinje cells 0 0 0 0 100
Cerebellum: molecular layer 0 17 0 17 83
Cortex: layer 4 0 0 2 15 85
Cortex: layer 6 0 5 0 27 73
Dentate 0 4 6 0 94
Dorsal Brainstem 4 18 10 12 82
DRG 0 0 18 19 81
Hippocampus: CA1 0 6 50 0 50
Hippocampus: CA3 0 7 4 4 93
motorneurone 0 0 0 100 0
Table 4.3. Distribution profile of Wlds protein in the transgenic
mouse line 4836 and rat line 23.
The percentage of cells in each region displaying a particular Wlds
protein nuclear distribution pattern was assessed from low power
confocal pictures. The distribution pattern was divided into large
inclusions, multiple small inclusions (speckles), strong diffuse and weak
diffuse/no obvious staining. A cell could fall into more than one category
(e.g. a large inclusion with strong diffuse staining as well) and would
therefore be counted twice.
Figure 4.11. Co-localisation of Wlds protein and VCP.
Confocal micrographs show immunolabellirig of Wlds protein
(green) and VCP (red) in cerebellar slices from WIcP mouse. Slices
were counterstained with topro-3 (blue) to highlight the nuclei
(merged C). A-D show cerebellum with evidence of Wlds protein in
granule cell and molecular layers (arrow) (A), and VCP inclusions in
the same regions, with diffuse VCP staining in purkinjie cells (arrow
head) (B). There are some examples of cells with VCP but no Wlds
protein (C). Image J allows areas of co-localisation to be marked on



















Figure 4.12. Co-localisation of Wlds protein and VCP (2).
Confocal micrographs show immunolabelling of Wlds protein
(green) and VCP (red) in DRG slices from Wlds mouse. Slices were
counterstained with topro-3 (blue) to highlight the nuclei (merged
C). A-D. Show DRG cells with evidence of Wlds inclusions both
with, and without corresponding VCP aggregates (arrow head), and
other cells with complete co-localisation (arrow). Image J allows
areas of co-localisation to be marked on an overlay image using
white pixels (D). Scale bar = 10pm.
A B
C D
Figure 4.13. Co-localisation of Wlds protein and VCP (3).
Confocal micrographs show immunolabelling of Wlds protein (green
A) and VCP (red B) in cerebellar slices from wild-type mouse.
Slices were counterstained with topro-3 (blue) to highlight the nuclei
(merged C). A-C. Show immunostaining in a non-l/Wd5 control
cerebellum. There is no visible Wlds protein (A) with visible diffuse
VCP in the purkinjie cells (B) and no VCP puncta elsewhere in the
section. Image J allows areas of co-localisation to be marked on an





























Figure 4.14. Co-localisation of Wlds protein and SMRT.
Cortical cells in dissociated culture co-transfected with Wlds-
eGFP and SMRT (Myc or Flag tagged). A-D. Green Wlds (A)
and Red SMRT (B) shows some evidence of co-localisation (C)
at low power magnification. E-H. High power confocal
micrographs of some cells show very little/no co-localisation of
SMRT and Wlds. Image J allows areas of co-localisation to be
marked on an overlay image using white pixels (D, H). Scale



















Figure 4.15. Co-localisation of Wlds protein and HDAC.
Cortical cells in dissociated culture co-transfected with Wlds-
eGFP and HADC (Myc or Flag tagged). A-D. Green Wlds and
red HDAC show some evidence of co-localisation at low power.
E-H. Wlds and HDAC show co-localisation at high power.
Image J allows areas of co-localisation to be marked on an






Figure 4.16. Movement of Wlds protein following slicing and
incubation in oxygenated ACSF.
Tissue was vibratome cut and incubated in oxygenated ACSF for
various time intervals before fixation and immunohistochemistry for
Wld (red) and T0PR0-3 (blue). Propridium iodide staining showed that
all cells imaged were still viable (not shown). A. Cerebellar granule
cells following section, 0 hours incubation. B. Cerebellar granule cells
following section and 1 hour incubation in ACSF. C. Cerebellar granule
cells following section and 4 hours incubation in ACSF. Scale bar =
12pm.
Cereb. Caudate Hippo.
0 Hrs 4 Hrs 0 Hrs 4 Hrs 0 Hrs 4 Hrs
Wlds protein
VAP-33
Figure 4.17. Western blot analysis demonstrates that Wlds
protein levels are not changed after incubation in ACSF.
Levels are detectable and similar in hippocampus (hippo.),
cerebellum (cereb.) and caudate at the two time points. There is
a clearly more protein in the cerebellum compared to the other
regions as shown previously in Figure 4.3. Similar levels of
protein were loaded in each lane, as demonstrated by the
uniform VAP-33 staining in all lanes.
Appendix 4.1
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Appendix 4.1. Wlds protein appears to move in response to stress
I have already shown that there is Wlds protein present in areas such as the hippocampus
where there are no visible aggregates (Table 4.1, Figure 4.3). There are examples of
other nuclear proteins (BARD1 and BRCA1) that are known to form nuclear aggregates,
and are present and obvious on Western blots, but are not visible as protein aggregates
with immunocytochemistry until a set point in the cell cycle is reached (Jin et al. 1997).
Jin et al. suggest that BARD1 polypeptides are distributed diffusely within nuclei of
cells at concentrations too low for antibody detection, but that at certain cell cycle points
are accumulated into inclusions and therefore raising their local concentration at that
position in the nucleus allowing detection. This accumulation of protein into aggregates
may be what is happening in response to stress in the CA1, where there are more cells
showing nuclear Wlds inclusions following slicing and 4 hours incubation in ACSF.
"Nuclear dots" belong to a heterogeneous group of nuclear bodies and do not co-localise
with any other known nuclear structures (Sternsdorf et al. 1999). Their localisation can
change in response to stress as a result of hyper-SUMOylation (i.e. modification by
SUMO-1). This could be viewed as an indicator as one of the initial events of apoptotic
induction in leukemic cells (Sternsdorf et al. 1999).
An analysis of the fluorescence levels in the slices at set time points allowed the
generation of a graphical representation of protein "levels" (Appendix figure 4.1.1). An
analysis of the areas under the curves given at each time point in the experiment show
that the overall levels of fluorescence have not changed, suggesting that this is a
redistribution of existing protein and not simply new protein synthesis. Incubation of
slices in puromycin, an inhibitor of new protein synthesis, also failed to stop this
redistribution of Wlds protein (Appendix figure 4.1.2).
Apoptosis has been interpreted as a failure to correctly re-enter the cell cycle. Will an
inhibitor of a component of the cell cycle regulatory mechanism (the CDKs) alter the
redistribution of Wlds protein observed following slicing and incubation in ACSF?
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Incubation with the CDK inhibitor roscovitine shows that it does not affect the
redistribution of the Wlds protein (Appendix figure 4.1.2).
It is also know that HDACs can shuttle and in response to staurospaurine (as a trigger
for cell stress) move from the nucleus into the cytoplasm. The redistribution seen in
cerebellar granule cells following vibratome sectioning may be attributed to a stress
response, and the formation of the "halo" like shapes (Figure 4.16) could be an
accumulation of the protein at the edge of the nucleus. If the movement of the Wlds
protein is linked to the possible movement of HDACs, the Wlds protein may be unable
to leave the nucleus due the constitutive nuclear localisation signal contained within the
protein (Figure 4.1).
Could the change in Wlds protein localisation simply be a reversion to a localisation seen
during development? Appendix figure 4.1.3 illustrates the change in localisation of Wlds
protein in the cerebellum and cortex following incubation in ACSF for 4 hours, and what
the localisation is like in those areas at P6. Could this suggest that the protein is moving
in response to changes in connectivity following sectioning?
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A.
Fluorescence Values (256 max)
B.
ACSF Time course 0 Hours 1 Hour 4 Hours
Baseline 0 0 0
Total peak area 458328 457418 458052
Number of peaks 1 1 1
Appendix 4.1.1. Redistribution of Wlds protein in cerebellum
following slicing and incubation in oxygenated ACSF.
A. Graphical representation of protein movement. Pixel intensity for
Wlds protein immunostaining was measured and plotted for each
time point, with 256 as the maximum fluorescence intensity. B: Area
under each curve was measured and all the curves match at each
time point suggesting that this phenomenon is the result of
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Appendix 4.1.2 Redistribution of Wlds protein in cerebellum
following slicing and incubation in oxygenated ACSF.
Graphical representations of protein movement. Pixel intensity for Wlds
protein immunostaining was measured and plotted for each time point,
with 256 as the maximum fluorescence intensity. A. Incubation in TTX
(500nM ) and PTX (50pM). B. Incubation in Puramycin (500pM). C.
Incubation in Roscovitine (10pM) .
Cerebellum : Cortex
P70 H P70
P70 & 4Hrs ACSF U P70 & 4Hrs ACSF
P6 n P6
Appendix 4.1.3. The Wlds protein redistributing is reminiscent of
a previous developmental localisation.
Confocal micrographs showing Wlds protein (red) and the nuclear
marker TOPRO-3 (blue). Protein is redistributed to give patterns
similar to that seen at P6 in the cerebellar granule cells and cortex.
Scale bar = 10pm
Appendix 4.2
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Appendix 4.2. Nuclear Wlds protein is required for axonal protection in the hippocampus
The work detailed in this appendix was all carried out by Dr Jane Haley and is identified
here in order that I may refer to the experiment in discussion.
Hippocampal slices were cut and stored in O2/CO2 bubbled artificial cerebrospinal fluid
(ACSF) containing elevated Mg2+. Slices were recorded on the day of slicing (acute), 24
and 48 hours later. Extracellular field recordings were made in stratum radiatum of CA1
(stimulating the CA3 Schaffer-collateral pathway) and from stratum radiatum of CA3
(stimulating the mossy fibre pathway). At the time of slicing, half the slices had the
Schaffer-collateral pathway axotomised and half had the mossy fibre pathway
axotomised.
The fibre volley on Wild type mice was not present 48 hours after slicing/axotomy of
Schaffer-collateral pathway. In Wlcf mice stimulation of this pathway revealed a clear
fibre volley still present after 48 hours (appendix figure 4.2.1.). In contrast, the mossy
fibre pathway did not show protection and the fibre volley was not present after 48 hours
in Wlcf mice.
The axons that constitute the mossy fibre pathway originate in the dentate gyrus, which
does not exhibit nuclear Wlds protein aggregates (Figure 4.4). By contrast, the Schaffer-
collateral pathway originates from CA3 neurones, which do show nuclear Wlds protein
aggregates. This region specific protection suggests that the formation of nuclear Wlds
protein aggregates may be important for the Wlcf neuroprotective phenotype, adding
value to mapping data presented in this thesis. It may also have wider implications for
others who are testing the ability of Wldt to protect against neurodegenerative disorders
through cross breeding. The ability to protect may be linked to whether the affected cells
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Appendix 4.2.1. Nuclear Wlds protein is required for axonal
protection in the hippocampus.
Extracellular field recordings were made in stratum radiatum of CA1
(stimulating the CA3 Schaffer-collateral (SC) pathway) and from stratum
radiatum of CA3 (stimulating the mossy fibre (MF) pathway). The fibre
volly (arrows in A & B) in Wild-type mice was not present 48hrs post
slicing of the SC (C). Wlcf mice revealed a clear fibre volly at this time
point (C). In contrast, the MF pathway did not show protection and the
fibre volly was absent in Wlcf at 48hrs.
o-
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Chapter 5:




Transgenic expression of the chimeric Ube4b/Nmnatl gene alone has previously been
shown to be sufficient to confer the neuroprotective phenotype (Mack et ah, 2001). As
detailed in the previous chapter, the Wlds protein product localises to neuronal nuclei.
How can the protein product of a gene, known to affect axon and synapse survival
following injury, act when the cell body is severed from those compartments by a cut or
a crush? I have already shown that the Wlds protein can co-localise in nuclei with VCP
and HDAC5. These factors could affect other processes in the cell, for example through
ubiquitination and acetylation pathways. The hypothesis addressed in this chapter is
therefore that the Wlct chimeric gene exerts its neuroprotective effect indirectly, through
a cascade of downstream events. More specifically, I address the hypothesis that the
Wlds protein regulates expression of other genes, one or more of which may be more
directly responsible for the Wldt phenotype. A priori analysis of this hypothesis leads me
to focus attention on the Ube4b and Nmnatl components of the Wlds chimeric gene.
5.1.1. Ube4b
The incorporation of an E4 ubiquitination factor in the Wlds gene has previously led to
speculation that protein tagging and degradation via the ubiquitin-proteasome system
may be altered in these mutant mice (Coleman & Ribchester, 2004). The yeast
homologue of Ube4b, (Ufd2) gives clues to the function of Ube4b in mammals. An
alignment of Yeast Ufd2 and mammalian Ube4b show that the N-terminal portion of
Ube4b is absent from Ufd2 (NCBI blast alignment). This suggests that the ability of
Ube4b to multi-ubiquitinate target protein is a function of the C-terminal region of the
gene as Ufd2 homologues display the same functionality as Ube4b. If the Ube4b portion
of the gene is responsible for the Wlds phenotype then it is probably not through multi-
ubiquitination as only the N-terminal 70 amino acids of Ube4b (N70-Ube4b) are
included in the Wlds chimeric gene. What are the remaining possibilities for its action?
One could be a dominant negative effect on other functions of Ube4b. For example,
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Ube4b incorporated in the Wlds mutant protein could bind native Ube4b and therefore
interfere with VCP interactions. This hypothesis is supported by data from studies
showing that the ubiquitin-proteasome system can regulate synaptic and axonal
degeneration in a variety of systems (Zhai et al., 2003; Korhonen & Lindholm, 2004).
Zhai et al. (2003) showed that axon degeneration can be prevented through the use of
protease inhibitors, but is protected only by pre-treatment with these inhibitors. The
proteasome inhibitors were unable to prevent the earliest signs of Wallerian
degeneration. Proteasome inhibitors did not retard microtubule fragmentation which is
one of the earliest signs of axon degeneration and is UPS dependent. Proteasome
inhibitors can block the degradation of neurofilaments, but Zhai et al considered this to
be a secondary effect to the UPS activating a subset of E3s, causing degradation of a
subset of proteins which themselves trigger a secondary phase of degeneration. This
suggests the involvement of the ubiquitin proteasome system only at the early stages of
Wallerian degeneration. Zhai et al. also suggested that the UPS inhibitors were unable to
counteract Wallerian degeneration instigated by microtubule destabilising agents such as
vincristine. However, it has also been shown that Wlct mice neurones are resistant to
vincristine neuro-toxicity (Wang et al. 2001). Therefore, Wlct must act via some
mechanism other than that employed by general protease inhibitors which cannot
prevent microtubule degradation. Gad mice show spheroid body formation and dying
back axon degeneration through a mutation in the Uch-Il gene. This mutation highlights
the importance of the UPS in axon integrity and maintenance. The Gad
neurodegenerative phenotype can be partially rescued by crossing with Wlct (Mi et al.
2005) suggesting that it can protect against UPS disorders. This suggests that if Wlds
does act by UPS dominant negative inhibition of Ube4b that it is not the whole story.
Another possibility is that the Ube4b portion of the chimera could affect the UPS
through its interactions with VCP or other nuclear proteins such as HDAC (see chapter
4). One possible chain of events could be that N70-Ube4b interacts directly with VCP
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and that this then interacts with HDAC to alter acetylation and therefore other processes
within the cells (Wu et al.2001).
5.1.2. Nmnatl
Many studies in yeast have been carried out in order to identify cellular factors which
could be required for transcriptional silencing, and among proteins identified are those
encoded by yeast SIR genes. These genes are responsible for silencing at repeated DNA
sequences in yeast mating type loci, telomeres and rDNA. SIR2 is required for silencing
in the rDNA, causing closed regions of chromatin structure making it inaccessible
(Blander and Guarente, 2004). This silencing requires lysine residues in the N-terminal
tail of histones H3 and H4, which are acetylated in active chromatin and deacetylated in
inactive/silenced chromatin. SIR2 is the yeast homologue of a mammalian protein, Sirtl.
Sirtl is a forkhead transcriptional regulator which can also regulate the activity of p53
through deacetylation at Lysl82 (Blander and Guarente, 2004). The Sir2 family of
conserved proteins require NAD to upregulate deacetylase activity and as such, can
regulate a variety of processes including aging, metabolism and stress response. Nmnatl
codes for the enzyme responsible for the production of NAD. NAD and its derivatives
have previously been implicated in transcriptional regulation through various pathways
(Revollo et al. 2004).
A recent study by Milbrandt and colleagues suggested that the Wlds phenotype is caused,
at least in part, by increased nuclear NAD biosynthesis, mediated by the Nmnat-1
component of the Wlds gene (Araki et al., 2004). These authors also reported that
increased nuclear NAD acts through the nuclear transcriptional regulator Sirtl,
suggesting that modification of gene expression patterns is required to produce NAD-
dependent neuroprotection.
In this chapter I set out to test whether the Wlcf gene regulates mRNA levels of other
genes. I show that 11 non-associated genes are altered in the mouse cerebellum in vivo. I
also reproduced and quantified this response in a human (HEK293) cell line following
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transfection with an eGFP-tagged Wlcf construct. In addition, I show that some of the
transcriptional changes induced by Wlds expression are regulated via NAD-/Sirtl-
dependent pathways, whereas others are NAD-/Sirtl-independent. Following the
observation that some genes are NAD dependent and others are independent. I
demonstrate that the different components of the Wlds mutation independently regulate





5.2.1. Microarrav analysis of RNA from Wlct mouse cerebellum
In order to identify potential candidate genes whose expression may be regulated by
Wld\ preliminary microarray experiments were performed comparing RNA levels in
Wldt and wild-type (C57B16) mouse cerebellum. The intial experiments were instigated
by Dr T.H.Gillingwater and the microarray analysis carried out by Kevin Robertson at
the Scottish Centre for Genomic Technology and Informatics (University of Edinburgh).
The cerebellum was chosen as an ideal preparation for several reasons. First, it is
composed predominately of large numbers of cerebellar granule cells (1010-10n),
resulting in an almost homogenous cell population (Flinas, 1975). Cellular heterogeneity
as is present in most other anatomically distinct brain regions such as the hippocampus,
hampers gene expression profiling due to large region-specific divergence in expression
patterns (Datson et ah, 2004). Second, as I showed in chapter 4, the vast majority
(>90%) of cerebellar granule cells strongly express Wlds protein (Figure 5.1; Wishart et
ah, submitted). Third, the Wlds neuroprotective phenotype can be shown through neurite
survival assays in cerebellar granule cell dissociated culture following a death stimulus
(Figure 5.2). Four days following withdrawal of serum and potassium from the culture
medium, wild-type cultures are reduced to 13.73±3.70% of neurites remaining (see
figure 5.2), while the Wlds cultures still have 74.77±2.38% of neurites remaining.
Finally, the cerebellum is a discrete anatomical unit, suitable for precise and rapid
removal before subsequent RNA extraction. Thus, the cerebellum is perhaps the most
unique, identifiable structure in the brain, but fortuitously also shows exceptionally
strong expression of Wlds protein in Wlds mice.
Patterns of RNA expression were compared in cerebella from 3 independent microarray
experiments, each pairing a Wlds and wild-type mouse. The arrays highlighted 11 out of
-23,000 genes whose expression patterns were consistently altered across all 3 runs by,
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on average, more than a factor of 2 (Table 5.1). As expected, Rpb7 (contained within the
triplicated Wlds region, but previously discounted as contributing to phenotype; Mack et
al., 2001) was also up-regulated (Figure 5.3). A small number of candidate genes were
identified, including both up-regulated and down-regulated examples (Table 5.1). These
findings suggest that the Wlds gene may be directly targeting specific down-stream
genes, and is not acting as a non-specific, broad-spectrum repressor/instigator of gene
expression. All of the candidate genes are known, with the exception of 1427820_at and
1427055_at. A BLAST (NCBI) search using the sequence for the Affymetrix EST
1427820_at a BLAST sequence comparison showed a 91% homology to a genbank
sequence submitted by Strausberg et al. (2002) (Erdl; public ID NM_133362). I will
therefore refer to this EST as "erythroid differentiation regulator 1-like" (Edrl-L-EST).
However, our novel transcript is unlikely to be an exact match for this gene as levels of
erythroid differentiation regulator 1 transcripts were below the detectable threshold in all
experiments and were not altered on any of our microarray chips (Affymetrix
1439200_x_at; data not shown). Biochemical analysis of this novel transcript and its
possible products is beyond the scope of the current study, so I have therefore named
this transcript Edrl-L-EST for the purposes of this paper. This gene consistently showed
the greatest up-regulation on the Wlds cerebellar microarray, about 3.4 fold higher than
in wild type mice.
A similar BLAST search for Affymetrix EST 1427055_at yielded no overt homology
and hence its identity remains unknown, and I therefore simply refer to this gene as
"EST'. Of the 11 identified genes, the most significantly down-regulated candidate was
pituitary tumour transforming gene 1 (Pttgl), whose expression was virtually silenced.
The most significantly over-expressed candidate, was the sequence coding for Erythroid
differentiation regulator 1-like EST (Edrl-L-EST). A preliminary assessment of
potential functional genetic linkages was undertaken using Pathway Assist software
(Ariadne Genomics). However, no specific pathway in which two or more of the
candidate genes were a significant component could be identified (data not shown).
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5.2.2. Validation of provisional microarray screen on Wlct cerebellar RNA
I confirmed provisional modifications in RNA expression for those genes which were
consistently altered across all 3 microarray runs semi-quantitatively using triplicate RT-
PCR analysis. All 11 genes were confirmed to be up- or down-regulated, as indicated by
the microarray data (Figure 5.4.A). Conventional RT-PCR can be quite insensitive to
small variations in RNA levels. This is due to several factors (for more information see
chapter 3). This inherent insensitivity means that some of the smaller changes as
indicated by the microarray were not so apparent when the RT-PCR product was
visualised on an agarose gel, for example myosin binding protein C3 (Mybpc3, Figure
5.4 A). I therefore used QRT-PCR to determine the change in mRNA levels of the two
most highly altered genes: Pttgl and Edrl-L-EST (Figure 5.4 B). This analysis showed
that Pttgl mRNA levels were 14.1 ±2.2 (mean±S.E.M, N=3) fold down-regulated in Wlds
mouse cerebellum compared to wild-type tissue. Edrl-L-EST mRNA, on the other hand,
was 8.6±1.4 fold up-regulated in Wlds cerebellum. Examples of raw QRT-PCR data in
the form of amplification curves can be seen in Figure 5.5.
5.2,3. Mimicry of alterations in an independent (HEK293) cell line
My QRT-PCR endorses the changes in gene expression level shown by microarray of
Wltf cerebellar RNA. It is possible however, that such changes are a result of some other
irregularity within the Wlds mouse and not as a direct result of Wlds expression.
Therefore, in order to test whether the observed in vivo changes in gene transcription
could be directly attributed to Wltf gene expression, RNA levels were measured in a
stable Human Embryonic Kidney (HEK293) cell line after transfection with a Wlds-
construct. The eGFP-Wlds construct comprised the N70 amino acids of Ube4b and the
C-terminal 303 amino acids of Nmnatl, which includes the Wldl8 region, normally in
the 5' untranslated region of Nmnatl in the wild-type (Mack et al., 2001, Figure 5.10).
The Wld' component was then inserted into the pEGFP-N 1 vector under the control of a
CMV promoter (Clontech). To confirm that Wlds expression was present in all cells
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containing GFP signal, and that all cells expressing Wlct also expressed GFP, HEK293
cultures were fixed 4 days after transfection and stained immunocytochemically for
Wlds protein (Figure 5.6). Transfection efficiency, as measured by the relative numbers
of cells showing both GFP fluorescence and Wld-18 immunostaining, was 17.9±8.7% of
total cells (mean±S.E.M, N=4). These cells localised the fluorescent Wldt gene product
to their nuclei, forming either discrete puncta of staining, or diffuse nuclear
fluorescence. A similar diversity of nuclear localisation patterns to those seen in the Wlds
mouse brains was observed (e.g. motor neurones show diffuse labelling; CGC show
punctate labelling; different cortical neurones show both types of labelling; see chapter
4). All cells expressing GFP were also positive for Wlds protein, and Wlds protein
expression without co-localisation with GFP was never seen (Figure 5.6). Transfection
had no overt effect on the survival or morphology of either the transfected or non-
transfected sub-population of HEK293 cells. The effects of transfection with Wlc? were
consistent and reproducible (Figure 5.13).
5.2.4. Alterations of mRNA levels are Wlct gene dose dependent
Semi-quantitative RT-PCR of HEK293 cells after transfection was first used to examine
expression patterns of those genes previously seen to be altered in the Wlds cerebellum
(with the exception of Dap3, see methods; data not shown). To rule out the possibility
that any changes in gene expression were due to a 'hijacking' of cellular RNA and/or
protein synthesis machinery, rather than specific expression of the Wlds gene, I
preformed a 'squelching' experiment. Under many circumstances, the presence of
abnormally large amounts of a foreign protein can result in altered gene expression
patterns (Everett and Wood, 2004). HEK293 cells were therefore transfected with 5/rg of
total construct, with varying amounts of W7<7v-eGFP in the total transfect. For example,
when the concentration of WlcC was reduced to 3/xg, the difference was made up using
2j«g of plain eGFP (Clontech).
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Figure 5.7 A-C shows an example of a conventional RT-PCR from one of these
experiments focussing on Pttgl and Edrl-L-EST. The data clearly demonstrate a Wlds-
eGFP dose-dependent response. Figure 5.7 D shows that as expected, with transfection
of more Wlct construct more Wlds protein is produced. Thus, the transcriptional changes
observed when Wlct is also present occur as a direct result of Wlct gene expression, and
are not simply due to large amounts of a foreign construct and/or protein. These findings
also underscore the gene-dose dependence of the neuroprotective phenotype conferred
by Wlct expression, as measured in different transgenic lines in vivo (Mack et al., 2001).
5.2.5. Quantification of mRNA levels in Wlct transfected HEK293 cells
Subsequently, real-time PCR (QRT-PCR) was used to confirm and quantify the changes
in response to transfection with 5/xg Wlct-e.GFP (Figure 5.8). Most genes examined (9
out of 10; Figure 5.8) showed significant changes in transcription compared to actin
controls (P<0.05 for all genes except TNFAIP3_IP, ANOVA with Tukey's Post Hoc
Test; N=3 for all genes except Pttgl and Edrl-L-EST, N=6). The other gene
TNFA1P3_IP1 was altered with a P>0.05 compared to actin, but were still clearly
responding to Wlct transfection (Figure 5.8).
The largest changes in expression detected were for the genes Pttgl and Edrl-L-EST.
Pttgl expression was down-regulated by 13.97±1.8% (mean±SEM). At the other
extreme, Edrl-L-EST expression was up-regulated by 18.55±4.8%. Importantly, it
should be noted that RNA from HEK293 cells was extracted from the entire cell culture
preparation, where -75% of cells were not transfected with Wlds (see above and Figure
5.6C). Thus, changes in expression of about 10-20% in the entire cell preparation
probably represent a 40-80% change in expression at the level of individual Wlds
positive cells. As expected, actin controls showed no change in expression following
transfection with Wlct (-1.35±0.53%). So, to calculate the changes which may be
occurring at the level of the individual cell it is necessary to compensate for the average
transfection efficiency. This calculation suggests the levels of expression for Pttgl and
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Edrl-L-EST, are downregulated by 77.6±10%, and upregulated by 103.0±10.8% per
WlcE positive cell.
5.2.6. WlcE can change some mRNA levels through the NAD/Sirtl Pathway
Araki et al (2004) provided evidence that the WlcE phenotype is due to the Nmnatl
portion of the gene alone in a Sirtl dependent fashion. I therefore tested whether
changes in gene transcription following WlcE expression might occur due to
modifications in the NAD and Sirtl pathway. Instead of DRG cultures or fibroblasts
(used by Araki et al.), I added ImM NAD to HEK293 cultures and examined mRNA
levels 5 days later using QRT-PCR. Of the 11 candidate genes regulated by WlcE
(excluding Dap3 as no reliable human primers were available) Ccl21, EST,
TNFAIP3_IP1, Mbp-C, Ssr and Edrl-L-EST all responded with less than 5% change in
expression following NAD addition (Figure 5.9 and Table 5.2). Thus, a significant
proportion of Wlds mediated changes in transcription are not regulated by NAD-
dependent pathways. However, the other 4 genes (Dll, Fabp7, Src-LA and Pttgl) did
respond with a greater than 5% altered expression pattern after 4 days of NAD
incubation (Figure 5.9 and Table 5.2). All of these changes were in the same direction as
those indicated by the microarray and after Wlds transfection. The largest change was
found for Pttgl (-14.9±2.7%; P<0.001; ANOVA with Tukey's Post Hoc Test; N=5).
However, it should be noted that the magnitude of expression changes are not directly
comparable to those seen after WlcE transfection. NAD addition to the culture medium
should affect every cell in the preparation, whereas only -25% of cells would be
exposed to the effects of WlcE following transfection (see above). Thus, the magnitude of
transcriptional modifications for Pttgl at the level of individual cells were in the order of
70-80% following transfection, yet were only in the order of 10-15% following NAD
addition. It therefore remains possible that these NAD-dependent gene changes are
potentiated by a non-NAD dependent mechanism in W7<T-expressing cells.
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Araki and colleagues demonstrated that the neuroprotective effects of NAD were
mediated through activating the deacetylase Sirt-1 (Araki et ah, 2004). Of the 4 genes
altered by the addition of NAD, only one showed a significant decrease (P<0.05) in
responsiveness following pharmacological inhibition of the Sirt-1 pathway using sirtinol
(Figure 5.9). Pttgl downregulation was reduced from (-14.9±2.7%; to -2.49+0.59%
(P<0.02; Mann-Whitney test; N=3). Interestingly, Ssr-a expression was significantly
increased above those levels observed with NAD only by the addition of sirtinol
(P<0.05, Table 5.2). This may suggest that Sirt-1 normally acts as a repressor of Ssr-a,
and that alleviation of this repression via the addition of sirtinol can increase expression
of Ssr-a.
5.2.7. Dissecting Wlct induced gene regulation
Araki et al. (2004) showed that over-expression of Nmnatl was sufficient to reproduce
the Wlcf phenotype in vitro, but that over-expression of Ube4b was not. I have
demonstrated that exogenous NAD affects the regulation of Pttgl but not Edrl-L-EST
(the two transcripts most highly altered by the presence of the full length Wlct chimeric
gene). I therefore asked whether transfection of HEK293 cells with either component of
the Wlcf gene (Figure 5.10), would produce changes in expression of the two most
strongly regulated genes. I used QRT-PCR to measure mRNA levels following
transfection of HEK293 cells with either eGFP-Nmnatl or eGFP-N70-Ube4b constructs
(Figure 5.10).
Interestingly, transfection with N10-Ube4b produced protein product diffuse throughout
the cytoplasm (Figure 5.1 IB), with no more present within the nucleus than would be
seen with transfection of just eGFP alone. N70-Ube4b does not produce any aggregates,
nuclear or otherwise. Transfection with the Nmnatl portion of the gene produced
fluorescent protein localised to nuclei in a strong diffuse pattern (Figure 5.11C), with no
visible aggregates. This suggests that to obtain aggregates the two components of the
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gene must be at least within the same cell and possibly attached (via their 18 amino acid
bridge).
Nmnatl transfection alone caused a significant down-regulation of Pttgl (Figure 5.11C,
5.12; -7.34±0.8%, (-40.77±4.44% normalised) P<0.001 compared to actin controls,
ANOVA with Tukey's Post Hoc Test, n=6). As may have been expected, since NAD
had no effect, transfection with Nmnatl did not alter the level of Edrl-L-EST mRNA (-
1.57±0.7%, (8.31±4.16% normalised) P>0.05). However, the Ube4b construct caused a
significant up-regulation of Edrl-L-EST mRNA levels (Fig 5.1 IB, 5.12; 7.84±1.3%,
(43.52±7.21% normalised) PcO.Ol). This construct had no effect on the expression level
of Pttgl mRNA (-1.71±0.9%, (9.49±4.99% normalised) P>0.05). Surprisingly,
transfection with full length Wlds construct produced greater changes in expression
levels of both Pttgl and Edrl-L-EST than either of the separate constructs (Figure 5.11
A, 5.12). Therefore, it appears that Ube4b increases the efficacy of Nmnatl as a gene
expression regulator; and similarly Nmnatl must affect the capability of N70-Ube4b to





The data presented here provide the first direct evidence that the neuroprotective Wlds
gene acts as a transcriptional regulator for a conserved set of genes in both mouse and
human cells. In addition, I have demonstrated that this transcriptional regulation is
mediated through both NAD/Sirtl-dependent and -independent pathways. Furthermore,
I have shown that transcriptional regulation by Wlds is species independent, since the
same transcriptional responses to Wlds are present in both mouse and human cells. If the
Wlds phenotype is conferred due to changes in mRNA levels of the other genes detailed
above, the findings highlight the potential transferability of the neuroprotective
phenotype to the human nervous system. This is cause for optimism that the utilisation
of Wlds induced specific pathways could be exploited for therapeutic intervention in
neurodegenerative disease. The data suggest that further examination of genetic
pathways regulated by Wlds may identify novel therapeutic targets for the treatment of
neurodegenerative diseases in humans where axonal and/or synaptic degeneration is a
major pathological event.
Remarkably, expression levels were substantially altered (greater than two fold) for only
a small number of genes, and yet for some of these, the change was as great as tenfold.
As the Wlds mutation confers a neuroprotective phenotype without affecting normal
development and function of the nervous system (e.g. Parson et al., 1997), it seems
appropriate to suggest that the chimeric fusion protein is acting on a very specific step in
the degeneration process (Coleman & Ribchester, 2004). As the Wlds neuroprotective
phenotype can be transferred to other species through the generation of transgenic lines,
it must be acting on a conserved pathway(s). Preliminary assessment of potential
functional regulatory linkages could not identify any common molecular pathways
connecting the candidate genes. The hypothesis that Wlds is targeting a specific step in
the degeneration process is supported by the fact that none of the identified genes with
altered expression levels are thought to play a major regulatory role in normal cell
development or maintenance pathways. Otherwise a non-degeneration related phenotype
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would perhaps be expected in Wlct mice. To date, no study of either mutant or
transgenic mice or rats expressing the Wlct gene has identified any overt phenotypic,
developmental or behavioural abnormality (Gillingwater & Ribchester, 2001). It is
however, unlikely that the phenotype could be recapitulated through alterations of the
product levels of one gene. An example of this is given in appendix 5.2 where a Pttgl
null mutant is examined for a neuroprotective phenotype.
The data suggest that both NAD-dependent and -independent pathways may underlie
the Wlct neuroprotective phenotype. I demonstrated that increased levels of exogenous
NAD are sufficient to alter the expression patterns of at least some of the genes modified
in Wlct neurons in vivo. However, not all genes altered by Wlct in vivo were affected by
NAD application, suggesting that transcriptional regulation is also expected by NAD-
independent pathways. None of the changes we observed following NAD application
approached the relative levels obtained via transfection with a Wlds-eGFP construct.
Thus, while NAD-dependent pathways are apparently sufficient to regulate axon
degeneration (Araki et al., 2004), it seems likely that other modifications of other
pathways may be required to generate full transcriptional changes at the level observed
in Wlct tissue in vivo. It is tempting to suggest that the ubiquitin-proteasome system,
modified by changes in Ube4b, may provide this additional regulation. This hypothesis
is supported by recent data showing that the ubiquitin-proteasome system does not act as
a general effector of protein degradation in axonal degeneration, but rather can function
in the regulation of signalling pathways that control these degeneration processes
(Maclnnis & Campenot, 2004).
None of the genes identified here have previously been shown to play a critical
regulatory role in neuronal degeneration. Nevertheless, previous research on
TNFAIP3_IP1, Dap3 and Ccl21 suggest that they may be able to directly influence
neurodegenerative pathways associated with axonal and/or synaptic degeneration.
TNFAIP3_IP1 acts on TNFAIP3, which is a component of the NF-KB/Rel signaling
pathway (Baltathakis et al., 2001). Activity of this molecular pathway has been observed
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in neurodegenerative disorders and rodent models of seizure and stroke (Mattson &
Calmandola, 2001). TNF-a has also been shown to be a pro-inflammatory cytokine,
induced during Wallerian degeneration (George et al., 2004). However, exactly how,
and to what extent, TNFAIP3_IP1 may influence these pathways remains unclear.
Interestingly, Dap3 may act on similar pathways to TNFA1P3_1P1, as it is known to be a
positive mediator of TNF-a- and Fas-induced cell death (Kissil et al., 1999), although
any potential interaction was not highlighted by our functional linkage assessment.
Ccl21 is another chemokine signalling molecule, responsible for signalling between
neurons and microglia following nerve injury (Dijkstra et al. 2004). Loss of expression
of Ccl21, on its own or in addition to altered TNF-a activity, could therefore perturb
inflammatory responses in the nervous system. However, it should be noted that changes
in expression levels for a cytokine do not necessarily indicate changes in their functional
involvement in neuronal degeneration (Shamash et al., 2002).
Several of the other identified genes have been independently implicated in regulation of
cell survival mechanisms, suggesting that they may also have the potential to directly
regulate axonal and/or synaptic degeneration pathways. The human homologue of Pttgl
(securin) has been shown to interact with p53, regulating its transcriptional and
apoptosis-inducing behaviour (Bernal et al., 2002). It also modulates cell proliferation
and FGF-2 expression in the developing human foetal brain (Boelart et al., 2003). It
should be noted that I have been unable to determine a change in Pttgl protein levels
with the currently available antibodies (Figure 5.14). Edrl is a newly characterised gene
involved in haemoglobin synthesis induction, but which is also present in brain and can
act as a stress-related survival factor (Dormer et al., 2004).
A recent publication detailing cell type specific gene expression of midbrain
dopaminergic neurones, specifically, differences between A9 and A10 neurones gave a
detailed microarray analysis. This analysis included a list of mRNA differences which
may relate to their different vulnerabilities to Parkinson's Disease. In the middle of a
large table of gene changes is an up-regulation of Edrl in A10 cells, which show
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resistance to PD (Chung et al.2005). None of the genes I have detected changes in are
typically associated with neuronal protection. As a result the authors of this particular
paper may have overlooked the possible importance of Edrl alterations and focused on
genes which are already thought to be involved in neuronal pathways. Another recent
paper carried out microarray analysis on Sodl mutants. The authors of this paper noted a
decrease in NADPH and in their published microarray table there is a decrease in levels
of EDR which was not mentioned in the text of the paper (Kirby et al .2005). This may
be significant in so much as Wlds mice have increased nuclear Nmnatl which gives rise
to the production of NAD, and I have shown an upregulation in an EDR like transcript,
as well as a possible upregulation in EDR levels as gauged by P.Dormer (Figure 5.15).
One facet of this study should remind us that we should not rule out the involvement of
one, or several, of the other genes yet to be implicated in any neuronal survival
pathways. These genes will need to be the subject of further investigation to identify any
potential role they may play in regulation of neurodegenerative pathways. Thus, it
remains possible that modifications in the expression of either a single candidate gene,
or multiple candidate genes, are required to confer phenotype, with or without changes
in other genes which we may have failed to identify in the current experiments.
This finding begs the major question, beyond the scope of the present thesis, whether
any of the genes here identified, either alone or in combination are responsible for the
Wlds phenotype. Answers to this question could have a major impact on our
understanding of neurodegenerative mechanisms and possibly for treatments for
neurodegenerative diseases as well. To address this would require the development and
implementation of a high throughput analysis where transcription of more than one gene
at a time can be controlled experimentally with a clear readout of Wlds phenotype.
In summary, the transcriptional effects of Wlds expression on conserved sub-sets of
genes in mouse and human cells suggest it may be possible to extend the neuroprotective
phenotype into large animals, including man.
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Figures
Figure 5.1. The cerebellum is an enriched source of Wlds
protein product.
(A) Confocal micrograph of cerebellar folium immuno-
cytochemically labelled for Wlds protein (red). There is strong
labelling in the cerebellar granule cell layer. (B) High power
confocal micrograph of cerebellar granule cells
immunocytochemically labelled for Wlds protein (red) and the
nuclear marker TOPRO-3 (blue). Every cerebellar granule cell has
a large nuclear Wlds protein inclusion. Scale bar = 50pm (A); 6pm
(B). W
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Figure 5.2. The WIcF cerebellum displays a neuroprotective
phenotype.
(A) Phase contrast micrographs of dissociated cerebellar granule
cell neurones in culture showing protection of neurites in
preparations from Wlds compared to wild type mice, 4 days after
withdrawal of serum and potassium. (B) Bar chart showing
quantification of neurite retention in cultures of cerebellar granule
cells from wild-type and Wlds mice up to 8 days after serum and
potassium withdrawal (mean±SEM). Scale bar = 80pm.
Figure 5.3. Microarray analysis of Wld5 cerebellar mRNA
shows both up- and down- regulated genes.
A scatter plot comparing mRNA expression in Wlcf and wild-type
cerebellum from a single (of 3) microarray experiment. The Wld5
signal (y axis) is plotted against the wild-type signal (x axis) for
each gene probe set present on the Affymetrix MOE-430A array. 3
Diagonal lines are guides, centre is line of no change, 2 outer lines
indicate a 2 fold level of up or down regulation. Transcripts for
Rbp-7, WIcF and Edr1-L are evidently up-regulated. Transcripts for
Pttgl are evidently down regulated (Graph courtesy of
T.H.Gillingwater and K.Robertson, RNA extracted by myselft and
P.E.Chen).
Affvmetrix ID Gene Title Gene Symbol Approx Fold Change
Up-requlated
1427820..at Erythroid differentiation requlator 1 - like Edrl-L 3.4
1418551. at Myosin bindinq protein C, cardiac Mybpc3 2.1
1417764. at Siqnal sequence receptor, alpha Ssrl 2.0
1450779 .at Fatty acid bindinq protein 7, brain Fabp7 1.7
1427689._a_at TNFAIP3 interactinq protein 1 Tnipl 1.5
1420819..at Homoloqous to Human/Rat Src-like adaptor Src-LA 1.5
Down-requlated
1450848._at Death associated protein 3 Dap3 -1.7
1427055._at RIKEN cDNA 4921507102 qene EST -2.0
1447146._s_at DNA seqment, Chr 11, ERATO Doi 730, expressed DllErtd730e -2.5
1419426._s_at Chemokine (C-C motif) liqand 21b (serine)
Chemokine (C-C motif) liqand 21a (leucine)





1438390._s_at Pituitary Tumor Transforminq 1 Pttql -7.1
Table 5.1. Affymetrix analysis shows mRNA levels for 11 of -23 000
genes on the chip are altered.
This table lists those genes with a change consistently greater than 1.5 fold
across the 3 affymetrix gene chip comparisons. 6 genes show a higher
presence in Wlcf mRNA and 5 genes show decreased presence in WIcF
mRNA. The table indicates the affymetrix gene identification code, the gene











































Figure 5.4. Bidirectional changes in mRNA expression in
Wlcf cerebellum. (A) RT-PCR validation of microarray data on
cerebellar mRNA. Each of these semi-quantitative experiments
was performed in at least triplicate. An example band for each is
shown. (B) QRT-PCR validation of Pttgl and Edr1-L fold
expression changes in Wlds mouse cerebellum (Mean±SEM).
A 1.0e+002
1 0e+001
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Figure 5.5. Example curves from QRT-PCR on mouse
cerebellar RNA.
Green line indicates WIcF RNA and red line indicates wild-type
RNA. Screen grabs are shown for /3-tubulin (A), Pttgl (B) and
Edr1-L-EST (C).
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Figure 5.6. WIcF can be transfected and expressed in a human
(HEK293) cell line.
(A-C) Confocal micrographs of HEK293 cells 4 days post
transfection with Wlds-eGFP. These cells shown were also
immuno-labelled for Wlds protein using the Wld-18 antibody, to
demonstrate that all of the eGFP visible is attached to Wlds
protein. Panel A shows the eGFP image alone (green), panel B
shows immuno-labelling for Wlds protein (red) and panel C shows
the overlay of (A) and (B) and labelling of nuclei with TOPRO-3
(blue). Panel C shows -25% transfection efficiency in this
particular example. (D) - A graphical representation of the
correlation between eGFP and Wld-18 antibody labelling as a
measure of fluorescence intensity (100 being the most intense).




















Figure 5.7. Transfection of HEK293 cells with Wlds-eGFP
regulates mRNA levels in a dose dependant fashion.
HEK293 cells were transfected with 5|jg of total construct. The
proportion of Wlds-eGFP and "plain" eGFP in that mix was varied
in order to demonstrate that the effects shown are not only due to
the presence of a large amount of foreign DNA. (A-C) RT-PCR.
(A) Pttgl amplicon levels decrease with increasing WIcE. (B) Edr1-
L-EST amplicon levels increase with increasing WIcF. (C) Actin
amplicon levels remain constant. (D-E) Western blot. (D) Wlds-
eGFP protein levels increase with increasing Wlds-eGFP
construct. (E) VAP-A controls remain roughly constant. (F)

































































































Figure 5.8. Alterations in mRNA levels mimicked in Wlds-eGFP
transfected HEK293 cells.
Transfection with 5|jg of construct and subsequent QRT-PCR assay of
mRNA levels for 10 of the 11 genes indicated by the initial microarray
studies show changes in the same direction as the Wlds mouse. Note
that the 2 largest changes in the HEK293 cells are Pttgl and Edr1-L as





















Figure 5.9. Changes in Pttgl mRNA levels are mimicked by
NAD in a Sirtl dependant fashion.
The bar chart shows QRT-PCR responses of Pttgl and Edr1-L-EST
mRNA levels with actin controls, 4 days post application of
exogenous NAD (1mM) or NAD (1mM) and sirtinol (100pM). Note
that only Pttgl showed a significant response to NAD application



















Actin -2.92 0.85 N/A -1.45 1.495 NS
Pttgl -14.95 6.60 P<0.001 -1.80 1.587 P<0.02
Ccl21 -4.33 0.90 NS -2.74 2.551 NS
DllErtd730 -5.32 1.49 NS -1.69 0.468 NS
EST -1.99 1.23 NS -1.03 0.411 NS
Fabp7 10.21 2.75 P<0.0001 3.42 0.453 PcO.04
Mybpc3 3.60 0.94 NS 1.53 0.288 NS
Src-LA 6.89 1.78 P<0.01 1.23 1.494 P<0.04
Ssrl 4.82 2.10 NS 13.03 1.295 P<0.05
Tnipl 2.33 1.08 NS 3.73 2.996 NS
Edrl-L-EST 2.27 0.58 P>0.05 1.27 1.035 P>0.05
Table 5.2. Changes in mRNA levels for most of the indicated genes are not
mimicked by NAD in a Sirtl dependant fashion.
The table illustrates QRT-PCR responses of mRNA levels for all the Wlcf altered
genes, 4 days post application of exogenous NAD (1mM) or NAD (1mM) and sirtinol
(100pM). Note that Fabp7 and Src-LA show "significant" changes in response to
NAD addition and that these changes can be averted when NAD and sirtinol are
added together. However, Ssr1 shows a significant increase in response to NAD
and sirtinol. This also occurs in response to sirtinol alone suggesting that Sirtl is










Figure 5.10. Constructs produced for in vitro transfection.
Diagrammatical representations of constructs used to introduce and visualise
(with an eGFP tag) (A) full length chimeric Wlcf, (B) U10-Ube4b and (C)
Nmnat-1 in vitro.
Figure 5.11. Pttgl and Edr1-L are independently regulated by
the Nmnat-1 and Ube4b portions of the WIcF chimeric gene.
Transfection with 5(jg of each construct was carried out and
followed by visualisation and QRT-PCR analysis. (A-C) Confocal
micrographs. (A) Transfection with the full length chimeric Wlds-
eGFP construct shows localisation of the protein product to the
nucleus and in this case a large single inclusion. (B) Transfection
with the N70-Ube4b-eGFP construct shows the protein product
dispersed throughout the whole cell, nucleus and cytoplasm. (C)
Transfection with the Nmnat-1-eGFP construct showing
localisation to the nucleus without the formation of inclusions.
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Figure 5.12. Pttgl and Edr1-L are independently regulated by the
Nmnat-1 and Ube4b portions of the WIcF chimeric gene.
Transfection with 5|jg of each construct was carried out and followed
by QRT-PCR analysis. (A) Raw values for gene levels following
transfection with each construct. (B) The values normalised according
to transfection efficiency. Pttgl levels are changed following
transfection with chimeric Wlds and Nmnat-1 but not N70-Ube4b. Edr1-
















"O<0 LU CO LU








LU o LU LU o LU
X z X X z X
Figure 5.13. The effect of WldP transfection were reproducible
and consistent.
Conventional RT-PCR for Pttgl on HEK293 RNA from non
transfected cells and Wlds transfected cells. It is important to note
the inconsistency between the different lanes. Although Pttgl
levels are always at lower levels in the Wlcf RNA in comparison to
non transfected controls, it is obviously only possible to note the
direction of change and not relative difference. This is the main




Figure 5.14 It is not possible to detect alteration of Pttgl
protein levels in WIcF mice.
The antibodies available for western blotting and
immunocytochemistry of Pttgl protein are poor. The western blot of
Pttgl above was carried out using antibody kindly donated by
S.Melmed (Cedars-Sinai Research Institute, UCLA).There are too
many bands at the expected size of 22KDa for the Pttgl protein to
be sure which is the correct band. Western blots were also
attempted using commercially available antibodies from Santa
Cruz, and the outcome was equivocal. Immunocytochemistry with














Figure 5.15. Edr1 levels appear to be increased in WIcF mice.
The antibodies available for western blotting and
immunocytochemistry of Edr are poor. The western blot shown in
figure A was prepared using an antibody kindly donated by P. Dormer
(GSF-Department of Experimental Hematology, Gaunting,
Germany). There is a detectable increase in the trimer (B) and dimer
(C) forms (112 and 56KDa respectively) of Edr, but not the monomer
(D, 28KDa). Immunocytochemistry carried out with this antibody was
inconclusive.
D
Appendix 5.2.1. Pttgl knock out animals do not show a
neuroprotective phenotype.
(A) Pttgl -I- mouse tibial nerve immunostained for 165kDa
neurofilaments, showing fragmentation of axon profiles 3 days after
sciatic nerve lesion. (B) Pttgl -/- mouse deep lumbrical muscle 2 days
after sciatic nerve lesion. Evidence for functional motor nerve
terminals was sought using FM1-43 (green), and motor endplates
were labelled with TRITC-conjugated alpha-bungarotoxin (red). No
functioning motor nerve terminals were found in any of the muscles
examined (n=6) 2 days after sciatic nerve lesion, whereas nearly all
terminals in contralateral unoperated muscles were stained with FM1-
43 (data not shown). (C) Micrograph of unlesioned pttgl -I- mouse
tibial nerve stained with toluidine blue. (D) Pttgl -I- mouse tibial nerve
6 days after sciatic nerve lesion. Almost all axon profiles appeared to
be undergoing degeneration. Scale bars = 50pm (A,B) 10pm (C,D).
Taken from Gillingwater et at. (2005) Under review.
Appendix 5.1
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Appendix 5.1. Colony specific strain variations can affect microarrav results
Although it detracts from the flow of this chapter I believe it is interesting to point out a
possible problem with microarray analysis. An initial list of mRNAs whose expression
was highly different between wild-type and Wlds and showed an apparent alteration in
levels during aging. That is, changes in levels between Wlct and wild-type and an
alteration in levels from young to old Wld\ but not across all 3 comparisons were also
identified. As described earlier, the Wlds shows an age related synaptic protective
phenotype, therefore an age related change in mRNA levels could be very exciting. An
example of one of these was Kcne2, a potassium channel, which registered as a down-
regulation in Wld\ Validation showed that it was down-regulated in Wlds mice
compared to wild-type. In this case the control was a C57B1/6J from Harlan-Olac, which
is also known to be a-synuclein negative. When the levels of Kcne2 are compared to a
C57B1/6J from Charles River they are very similar to that in Wld\ Therefore, the
apparent down-regulation of Kcne2 in Wlds mice could be an a- synuclein related
alteration in expression. The spontaneous loss of a-synuclein from the Harlan-Olac
C57B1/6J appears to have occurred after the spontaneous triplication forming the Wlds
mutation in that line. This assumption can be made as both the Wlds and the C57B1/6J
from Jackson Labs are a-synuclein positive (Appendix figure 5.1.1.). Whether or not the
alterations shown by the microarray are a function the presence or lack of a-synuclein,
remains to be seen. This should serve as a cautionary note to those who wish to carry
out microarray analysis. It is important to be aware of the history of the control strain
used for analysis.
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Appendix 5.1.1. Kcne2 mRNA level alterations may be a-
synuclein linked.
Conventional RT-PCR for a-syncutein (A) and Kcne2 (B) show
that a-synculein is present in Charles River C57BI/6J and Harlan
Olac C57BIAA/lds but not Harlan Olac C57BI/6J and that Kcne2 is
present at greater levels in Harlan Olac C57BI/6J.
Appendix 5.2
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Appendix 5.2. Pttsl knock out animals do not show a neuroprotective phenotype
The only available mutant for the genes of interest identified by the microarray screen
and subsequently verified was a null mutant (knockout) pttgl -/- mouse. This mutant
was located in Los Angeles. Experiments performed by Dr T.Gillingwater and Prof.
R.Ribchester showed that these mice do not show axonal or synaptic protection after
sciatic nerve injury (Appendix figure 5.2.1 and 5.2.2). This should not exclude the
possibility that an alteration of Pttgl levels may contribute to the phenotype, however,
as it may be important in conjunction with alterations in any of the other genes identified
by this study. It is also important to note that these Pttgl knock out mutants may have
redundant genes that may compensate for the low levels of Pttgl in a constitutive knock
out.
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Appendix 5.2.1. Pttgl knock out animals do not show a
neuroprotective phenotype.
(A) Pttgl -I- mouse tibial nerve immunostained for 165kDa
neurofilaments, showing fragmentation of axon profiles 3 days after
sciatic nerve lesion. (B) Pttgl -/- mouse deep lumbrical muscle 2 days
after sciatic nerve lesion. Evidence for functional motor nerve
terminals was sought using FM1-43 (green), and motor endplates
were labelled with TRITC-conjugated alpha-bungarotoxin (red). No
functioning motor nerve terminals were found in any of the muscles
examined (n=6) 2 days after sciatic nerve lesion, whereas nearly all
terminals in contralateral unoperated muscles were stained with FM1-
43 (data not shown). (C) Micrograph of unlesioned pttgl -/- mouse
tibial nerve stained with toluidine blue. (D) Pttgl -I- mouse tibial nerve
6 days after sciatic nerve lesion. Almost all axon profiles appeared to
be undergoing degeneration. Scale bars = 50pm (A,B) 10pm (C,D).
Taken from Gillingwater ef at. (2005) Under review.
No Lesion 2d Lesion 4d Lesion 6d Lesion
Appendix 5.2.2. Pttgl knock out animals do not show a
neuroprotective phenotype.
Bar chart showing quantification of axon profile preservation in the
tibial nerve of pttgl-/- (ko) and +/+ (wt) mice at 2, 3, and 6 days
post sciatic nerve lesion (mean±SD; n = 2-/- and 1 +/+ per time-
point). There was no difference in the onset or rate of
degeneration between the two experimental groups.





Before the discovery of the Wlds mutant mouse (Lunn et al. 1989), it was assumed that
one of two things were happening in response to injury by axotomy; either 1. The injury
starves the isolated distal axon of essential maintenance factors, which are normally
synthesized in neuronal cell bodies and propagated through the neuron by axonal
transport, or 2. The injury generates a signal at the site of the injury itself which triggers
a rapid necrosis in the distal stump. The delay of Wallerian degeneration in Wlds mice
suggests that Wallerian degeneration is an active, highly regulated process (Gillingwater
et al. 2005 submitted). More recently a third possible hypothesis has become apparent.
This hypothesis does not preclude either of the above hypotheses. The Wlds mutation
affects expression levels of RNAs or proteins that may be ordinarily involved in
regulating the programme of axon degeneration.
As more work is carried out in the field of cell death there appears to be increasing
overlap in some of the complex pathways involved in necrosis and apoptosis. Wallerian
degeneration was once thought to be a passive necrotic process in response to the
separation of the axon from the cell body. It appears now to a highly regulated
programme involving genes and proteins that have yet to be fully characterised, but
which is distinct from apoptosis. It is gradually becoming accepted that Wallerian
degeneration is involved in numerous neurodegenerative diseases/injuries where axons
and synapses are the primary pathological targets. This may include diseases where
aggregates are formed and/or axonal transport is blocked. It is therefore important that
the mechanism underlying Wallerian degeneration is elucidated.
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6.1. Genotyping
By crossing various neurodegenerative disease models with Wlct mice, it has become
possible to test what type of neuronal insults Wlct can help to protect against. The
development of an efficient genotyping system (as detailed in chapter 3) through QRT-
PCR should be of help to others working in this field in the future. It is also important to
note that this method should, in theory, be applicable to other mutations and transgenic
animals where there is a need to determine mutation/insert copy number.
6.2. Mapping
The mapping of Wlds protein expression to neuronal nuclei throughout the CNS was one
of the first clues that the Wlct mutation may be affecting neuroprotection by some form
of transcriptional regulation. The discovery that the pattern of protein localisation within
neuronal nuclei changes during development, but is still never seen outside the nucleus
may also be of some importance. The development of Wlds protein inclusions within
cerebellar granule cells {in vivo and in vitro) in particular, is especially important to note
when taken in context with the discovery that cerebellar granule cells in culture take
time to display the neuroprotective phenotype (Buckmaster et al. 1995).
Recent work carried out by my colleague Dr Jane Haley demonstrates
electrophysiologically that cells in the hippocampus which develop Wlds protein
inclusions (CA3) display the Wlct phenotype, but those which do not form inclusions
(CA1) are not protected (Wishart et al. submitted, appendix 4.2). All of this information
suggests that the formation of nuclear Wlds protein aggregates are important for the
neuroprotective phenotype. However, I have also demonstrated through the generation
of constructs for N70-Ube4b and Nmnatl that neither portion of the Wlct chimera is
sufficient to form aggregates alone. Both are required for the formation of nuclear
protein aggregates in vitro (Figure 5.11).
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Whether or not the pattern of Wlcf immunostaining in nuclei is functional or not, the fact
that it occurs offers the opportunity to discern which other molecules may associate with
(or be segregated from) Wlds as I have shown in the case of VCP and HDAC5. This
could provide further data on the mechanism of Wlct action.
6.3. Microarray
Mapping the Wlds protein product throughout the nervous system showed that the
richest source of Wlds protein aggregates localised to neuronal nuclei, is the cerebellum.
This tissue is an almost homogeneous cell population, due to the large number of
cerebellar granule cells. Therefore it seemed appropriate that this should be the tissue to
carry out a Microarray analysis.
Microarray analysis revealed 11 genes which were altered above the set threshold. The
two most highly changed were Pttgl and Edrl-L-EST. The scope of the present data
does not allow determination of whether the changes in transcript level are due to altered
rates of RNA synthesis, altered turnover rate for existing levels of the RNAs examined
or both of the above.
Both Pttgl and Edrl-L-EST remained the most highly altered RNAs examined following
transfection of a Human cell line (HEK293). I cannot at this point say whether any of
the genes examined are involved in the Wlds phenotype. The changes in gene expression
levels may have nothing to do with phenotype and may in fact be an unrelated but highly
reproducible response to the presence of a large amount of Wlds protein within the
nucleus of the cells examined. The response will not simply be a response to a large
amount of foreign protein within the cells (demonstrated in figure 5.7).
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6.4. The NAD link
The recent study by Araki et al. (2004) suggested that the Wlct phenotype is caused
mainly by the Nmnatl portion of the Wlct mutation, and can be mimicked through the
addition of exogenous NAD. It was also shown that the mimicry of the phenotype occurs
in a Sirtl dependent fashion.
Addition of exogenous NAD to HEK293 cultures showed that few of the genes studied
were affected by NAD addition and only Pttgl, Fabp7 and Src-LA was affected in an
NAD/Sirtl dependent fashion. The other genes shown to be altered in the micrarray and
HEK293 validation were not affectd by NAD and/or sirtinol addition. There was one
exception to this; Ssr-a levels were potentiated by the addition of sirtinol alone
suggesting that Sirtl normally acts to suppress Ssr-alevels.
With the exception of the Araki study, there have been no other publications validating
the NAD dependent protection of axons as the mechanism through which the Wlct
mutation is working, apart from a recent study by Wang et al. (2005). However,
although the study by Wang et al. agree that it may in fact be NAD dependent protection
of axons, mediated through local mechanisms, they suggest that NAD alone is not
enough and do not completely agree with the findings of Araki et al.
6.5. Dissecting the Wlct gene
However, as Pttgl and Edrl-L-EST showed the largest changes in the preliminary
Microarray and transfection experiments I focussed on these. Transfection with
separate constructs for the Nmnatl and N70-Ube4b portions of the Wlct chimeric gene
showed that Pttgl and Edrl-L-EST are differentially regulated by the two separate
portions of the chimera respectively.
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It is unlikely however, that either Pttgl or Edrl-L-EST alone, will be sufficient to induce
a neuroprotective phenotype. The reasoning for this is as follows; Nmnatl
overexpressing mice do not show delayed Wallerian degeneration in vivo.
Overexpression of Ube4b also fails to induce the phenotype (M.P.Coleman personal
communication). The only available mutant for any of the genes examined, Pttgl null
mice, do not show delayed Wallerian degeneration (Gillingwater et al. 2005 submitted,
Appendix 5.2).
6.6. How does Wlct protect?
How might the Wltf gene be affecting mRNA levels of these 11 genes? A preliminary
examination of the Wlds protein sequence did not highlight any zinc fingers or other
motifs known for transcription factor interaction. However, the protein product of the
mutation has not been the subject of much examination prior to this body of work. The
most in depth study to date on Wlds protein and its interactions was carried out recently
by Laser et al. (2005 submitted) who have built on previous work detailing that Ufd2 in
yeast is known to interact with VCP. It appears that the N70 portion of Ube4b contained
within the Wlds chimera is sufficient to interact with VCP. This protein functions as a
chaperone for ubiquitinated proteins, ER associated degradation, nuclear envelope
reconstruction, cell cycle, postmitotic Golgi reassembly and suppression of apoptosis,
and may indirectly regulate transcription (Zhang et al. 2000).
The finding that the Wlds protein aggregates co-localise with HDACs is also an
interesting discovery as HDACs are also capable of affecting transcription via activating
and repressing effects on target transcription factors, including retinoic acid receptor,
thyroid hormone receptor and centromere binding factor-1 (as discussed in chapter 4).
As previously discussed, the Wlds gene protects axons and synapses in both the central
and peripheral nervous system from physical injury (Gillingwater & Ribchester 2003),
toxic injury (Wang et al. 2001) and disease induced neurodegeneration e.g. Parkinson
137
disease (Sajadi et al. 2004) and motor neurone disease (Ferri et al. 2003). The inability
to detect a non neuroprotective phenotype coupled with the ability to perpetuate the
phenotype cross species suggests that the effect is limited to a few very specific
conserved pathways. The work carried out by the Ribchester lab and its collaborators in
combination with the work presented in this thesis could represent a significant step
forward in elucidating these pathways. I would speculate that mimicry of the down
stream effects of the Wlds mutation could be sufficient to protect injured or diseased
neuronal populations without having a detrimental effect on the surrounding non
affected neuronal tissue.
Understanding the Wlcf protective phenotype may therefore be a very productive
strategy for the development of therapies for neurodegenerative diseases or injuries
where axons and/or synapses are the primary pathological targets.
6.7. Future directions
There are several main points that need to be addressed in the future;
1. Are changes in expression of the candidate genes a conserved response in different
neuronal populations which show the Wlds neuroprotective phenotype?
Do different areas of the Wlds brain with different protein expression patterns show the
same gene changes? If they don't, do those areas show a protective phenotype? The use
of transgenic lines generated by Dr M.P.Coleman may also be of use in this respect as I
have also mapped the protein distribution in 2 of his transgenic lines which show poor
Wlds protein expression in the cerebellum.
2. Which components of the Wlds gene are required to control the expression of the
candidate genes ?
I have already shown differential regulation by the Nmnatl and N70-Ube4b portions of
the Wlds gene for the two most highly altered genes Pttgl and Edrl-L-EST as detailed
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by the initial microarrays. The main problem with analysing the smaller changes at the
moment is the transfection efficiency. This may however, have been overcome by the
generation of an enriched population of Wlds positive NSC34 immortalised
motorneurone cell line (Dr P.Skehel).
3. Which genes are the primary changes and which are downstream events?
Examination of gene expression changes by QRT-PCR in HEK293 cells and/or NSC34
cells could illuminate temporal changes in gene expression. Following transfection at 6h,
12h, 24h, 2d, 3d and 4d it may be possible to determine which genes are altered by
which time point. For example, if Pttgl and Edrl-L-EST are changed within 24 hours of
transfection but the other genes are not altered until 3-4 days later, then they may be
downstream compensatory changes which occur in response to the early changes in gene
expression.
4. What about protein?
Studying changes in transcript level is interesting, but RNA levels do not necessarily
relate to protein levels. For example, the attempt at identifying changes in Pttgl protein
levels were a failure due to poor antibody availability. Although Edrl levels are not
changed in Wit? mice, the Edrl-L-EST levels are changed. I am not suggesting that there
is definitely a protein product associated with this EST. It is a short sequence and could
very well be a natural RNAi. However, the use of an Edrl antibody (P.Dormer)
suggested an increase in 2 forms of the Edrl protein levels in Wlds cerebellum.
Depending on where about in the protein this antibody binds it may pick up the product
of the EST. It is also important to carry out a more indepth study of the Wlds protein
itself. X-ray crystallography may provide insights into potential binding sites that
conventional web based protein sequence analysis can not.
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5. Are changes in expression of these candidate genes necessary and/or sufficient to
confer the Wlds neuroprotective phenotype?
Overexpression of a candidate gene that has increased expression levels in wild type
tissue and look for a gain of phenotype. Overexpress a candidate gene that has decreased
expression levels in Wlds tissue and look for loss of phenotype. Knock down a candidate
gene that has increased expression levels in wild type tissue and look for a gain of
function. Any of these processes should help determine if any one gene is necessary
and/or sufficient to confer the Wlct neuroprotective phenotype. However, a combination
of these processes may be required to test out combinations of candidate genes.
6. What ifwe missed something?
There may be many transcripts with altered levels in the Wlds mouse but which were
either excluded from the screen as they fell below the set cut off point, of they were
classed as below detectable levels by the Microarray. Re-analysis of the Microarray
output as a bioinformatics project may throw up something we missed. More
microarrays may be required, but it will take a long time to exhaust the list of genes
currently being investigated.
7. What about synaptic phenotype?
This will probably require more microarrays on young versus old homozygous Wlds. It
may also be worth carrying out the same microarrays on heterozygous Wlcf tissue as it is
known that they have the axonal protection, but not the synaptic protection. For
example, the levels of Baspl were altered in 2 of the 3 microarrays and the change was
just below the set threshold level. However, preliminary RT-PCR showed that Baspl
appears to be upregulated in Wlds mouse cerebellum. Baspl is also known as NAP22 and
also has very high levels in the DRG, and declines with age in motor and sensory nerve
terminals. Could this be a potential factor in the synaptic protection seen in Wlds mice?
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6.8. Summary
As a result of this body of work the following has been determined:
1. The mutation can be genotyped rapidly and effectively through the use of QRT-
PCR on genomic DNA.
2. This process can also be applied to the determination of insertion copy number in
transgenic lines.
3. The protein product of this mutation localizes exclusively to neuronal nuclei.
4. The conformation of localisation of this protein changes during development.
5. The protein product is mobile under some conditions.
6. The formation of nuclear aggregates is required for axonal protection (in
conjunction with Dr Jane Haley and Dr Tom Gillingwater).
7. Wlds protein aggregates colocalise with a member of the ubiquitin proteasome
system (VCP) and histone deacetylase family (HDAC5), which can affect
transcriptional regulation amongst other processes. It also colocalises to some
extent with SMRT.
8. Expression of the Wlct chimeric gene (N70-Ube4b- Nmnat-C303) is sufficient to
give rise to altered RNA levels for at least 11 genes, in the spontaneous mutant
and HEK293 cells.
9. Alteration of one of these genes alone (Pttgl) is not sufficient to provide the Wlct
neuroprotective phenotype (Dr Richard Ribchester and Dr Tom Gillingwater).
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NUCLEAR EXPRESSION OF WLD PROTEIN IS REQUIRED FOR AXONAL
AND SYNAPTIC PROTECTION IN THE CNS OF WLDS MICE
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The Wlds mouse mutant shows a 10-fold delay in neurodegeneration after peripheral
nerve lesions or transient global ischemia (Gillingwater et al., 2004, JCBFM,
PMID.T4688617). This neuroprotection arises from a spontaneous gene triplication
yielding expression of a chimeric gene N70-Ube4b/NMNAT coding for the Wld
fusion protein. We used a specific Wld antibody to immunocytochemically map the
profile of Wld expression in the brains of Wlds mice and their transgenic equivalents
in mice and rats. Regardless of the promoter driving Wld gene expression, Wld
protein staining within the CNS was not uniform with expression in the nucleus of
some, but not all, neurons. Furthermore many different patterns of nuclear Wld
expression were observed, from intense puncta to fine spots and diffuse staining. We
tested the hypothesis that nuclear Wld protein is required for axonal and synaptic
protection in the CNS. Cerebellar granule cells, which contain single large nuclear
Wld inclusions, had protected neurites in vitro following K+/serum withdrawal: 4 days
after withdrawal only 4% of wild type neurites remained whereas 72% of Wlds
neurites were intact. Most cortical neurons express nuclear Wld and we found a high
degree of synaptic preservation in vivo in the cortico-striatal pathway 8 days
following removal of the ipsilateral cortex under deep anaesthesia. By contrast,
neurons in the hippocampal dentate gyrus appear devoid of nuclear Wld and the
mossy fibre axons show no significant protection following axotomy in
organotypically-cultured slices. We conclude first, that nuclear Wld protein
expression is crucial for the manifestation of the protective phenotype. Second, we
have provided the first direct demonstration of synaptic preservation in the CNS of
Wlds mice in vivo.
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Transcriptional regulation of pituitary tumour transforming gene-1 Search Medline for
by the neuroprotective WldS gene in mouse cerebellar granule cells
and HEK293 cell lines.
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WldS mutant mice and their transgenic equivalents show 10-fold slower axonal and synaptic
degeneration in response to either peripheral or central nerve lesions, due to overexpression
of an Ube4b/Nmnat-1 chimeric protein (Gillingwater & Ribchester, 2001; Mack et al., 2001).
The WldS protein forms dense nuclear aggregates, suggesting that the gene exerts its
neuroprotective effects indirectly (Gillingwater et al., 2004; Araki et al, 2004). Here we
examined the hypothesis that the WldS phenotype is due to transcriptional regulation of other
genes. Western analysis and immunostaining of brains isolated from WldS mice killed by
cervical dislocation (Home Office Schedule 1) established cerebellar granule cells as a rich
source of WldS protein. We therefore extracted cerebellar mRNA from three WldS and three
WT control mice and analysed gene expression using Affymetrix microarrays. Changes in the
levels of candidate genes were validated by RT-PCR on the same mRNA extracts. As
expected, there was a significant increase in Nmnat-1 expression in the WldS cerebellum, but
several other genes were more than 5-fold up- or down-regulated, the largest change being a
10-fold downregulation in mRNA for pituitary tumour transforming gene (pttg-1). To test
whether downregulation of pttg-1 was caused by WldS expression, we transfected cultures of
human embryonic kidney (HEK) 293 cell lines with a fused WldS-EGFP construct, to allow for
visual confirmation of protein expression. Semi-quantitative RT-PCR showed gene-dose
dependent downregulation of the human PTTG-1 mRNA, 4 days after WldS transfection.
Sciatic nerve section under ketamine/xylazine anaesthesia (respectively 100/10 mg/kg, IP) in
nine pttg-1 (-/-) null mutant mice showed no evidence of protection of neuromuscular synapses
by 48 hours. However, confocal microscopy revealed several intact axon fragments extending
over 1mm in length in the distal tibial nerve. We conclude that expression of the WldS gene
results in downregulation of the pttg-1 gene. However, the neuroprotective phenotype of WldS
mice is not explained by downregulation of only this gene.
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BIDIRECTIONAL REGULATION OF TRANSCRIPTION BY THE
NEUROPROTECTIVE WLDS GENE
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1. Centre for Neuroscience Research, Univ. ofEdinburgh, Edinburgh, United
Kingdom
2. The Babraham Inst., Babraham, United Kingdom
3. Burns & Allen Institute, Cedars Sinai Med. Ctr., Los Angeles, CA, USA
Axons and synapses are primary pathological targets in many neurodegenerative
diseases. The spontaneous WldS mutation blocks degeneration of axons and synapses
in mice and offers potential for therapeutic intervention in humans. The mutant gene
is a chimera, comprising complete code for the NAD-synthetic enzyme NMNAT-1,
and a truncated ubiquitination ligase UBE4B (N70-Ube4b). The WldS protein
localises to cell nuclei and its neuroprotective effects on distal axons are therefore
indirect. Here we tested the hypothesis that WldS regulates gene expression in vivo
and in vitro. Microarray analysis and quantitative PCR measurements of WldS mouse
cerebellar mRNA revealed one unrelated gene, pitutitary tumour transforming gene -1
(pttg-1), that was downregulated by a factor of 10 and another, an erythroid
differentiation regulating gene homologue (EDRl-like) upregulated by a factor of
about 5. Transfection of HEK293 cells with a GFP-tagged full-length construct
triggered WldS-dose dependent changes in mRNA expression for these two genes.
Downregulation of pttg-1, but not the EDRl-like gene, was partly mimicked by
exogenous administration of ImM NAD to the HEK293 cell culture medium and this
effect was blocked by sirtenol. Transfection with separate Nmnat-1 and N70-Ube4b
constructs produced selective downregulation of pttg-1 and upregulation of EDRl-
like respectively. Sciatic nerve section in six ketamine-xylazine anaesthetised pttg-1
null mutant mice produced no protection of distal axons and neuromuscular junctions
when examined 2-6 days later, suggesting pttg-1 downregulation alone does not
explain the WldS phenotype. Overall, the data suggest that WldS protein
bidirectionally regulates transcription: its separate components linking
downregulation of some genes with simultaneous upregulation of others.
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